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The main focus of the studies undertaken as a part of this thesis was to develop new
methods of contraception, while broadening our current understanding of the anti-
fertility potentials of two progesterone receptor modulators: antiprogesterone
compound mifepristone, and the synthetic progestin Levonorgestrel (LNG). We
suggest that LNG taken immediately before ovulation acts as an emergency
contraceptive (EC) by delaying or preventing ovulation. We have demonstrated that
the combination of a home-use fertility monitor with once a month administration of
mifepristone (especially if mifepristone is administered at the early luteal phase) is
an acceptable contraceptive option with minimal side effects. Our investigations have
explained some characteristics of non-compliant behaviour. We have shown that the
microelectronic monitoring systems provide objective information no other
monitoring technique can produce. This information offers the opportunity to make
the optimum use of potentially effective treatments while validating research
evidence. We have further illustrated, that this microelectronic system of Luteinizing
Hormone (LH) detection can replace laboratory assays in monitoring frequently
changing hormone levels in contraceptive research because it is easy to use and
provides reliable data on compliance. Finally, we conclude that mifepristone induce
endometrial-shedding & vaginal bleeding, in the mid-luteal phase by a mechanism
involving both Prostaglandin Dehydrogenase (PGDH) and Cyclo-oxygenase - 2
(COX-2) to increase local Prostaglandin (PG) levels in the endometrium. These
studies provide information which will be useful in the development of novel
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Introduction and literature review
1.1 General Introduction
The world population reached 6 billion on 12th October 1999, according to the best guess
of demographers. It has doubled in less than forty years, and if the decline in fertility
rates falters, could yet double during our lifetime (United Nations (UN) population
division 1999). The changes that occurred during the last century including the early
menarche and age of first intercourse, late marriage, with many women choosing not to
have children (mirrored by the highly significant decline in total fertility rate per woman
(UN 1999a)), mean that the women of today are burdened more than ever "from the
tyranny of excessive fertility" (Baird 1965). In order to avoid an unwanted pregnancy,
sexually active women may have to adhere with a contraceptive regimen all their
reproductive life - i.e. over a 40-year period. World Health Organization (WHO) reports
a significant change in the use of contraception in the world, but we are still failing to
meet the demand of millions of couples who want to plan their families and prevent
pregnancies. In 1994, it was estimated that approximately 300 million couples in the
world were using a method of contraception either that they are dissatisfied with or is
unacceptable to them (UN population division 1994). Fuelled by women's increased
education and awareness of the need for contraception, the customer base for
contraception is likely to expand significantly over the next decade (UN 1995). Since we
are in the era of the largest cohort of reproductive aged population in history,
consequences of even a small difference in unwanted fertility will be catastrophic.
Although the steroid hormonal regimens dominated the female methods of reversible
contraceptives over the last 40 years, side effects have severely affected their
acceptability. This provides the incentive for the pursuit of novel alternative 'non-
hormonal' methods of contraception.
Progesterone controls most, if not all, of the key events surrounding the complex
regulation of normal female reproductive function. Thus, a substance with anti-
progesterone properties should be versatile not only as a contra-gestive but also as a
contraceptive. Mifepristone binds with high affinity for progesterone receptor and
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antagonises the actions of progesterone at its receptor level (Baulieu 1989a). It has been
successfully used to induce medical termination of pregnancy in the UK, France, Sweden
and in China. Our study described herein explored the feasibility of using mifepristone
as a once-a-month contraceptivepill (Chapter 3).
Widespread use of effective emergency contraceptives (EC) is estimated to prevent
millions of abortions in the world (Glasier & Baird 1997 Review). The synthetic
progestin Levonorgestrel (LNG) was licensed in the UK early in the millennium, as a
new EC agent. It has already been used for this purpose in several other countries.
Despite this, the mechanism by which LNG acts when given in this manner is unknown.
In order to explain the post-coital contraceptive mechanism we investigated the effect of
LNG on the menstrual cycle (Chapter 2).
Non-adherence to a contraceptive method interferes with its efficacy and disrupts the
evaluation of results in a research setting (Rudd et al. 1991; Urquhart 1991). Although a
problem of great importance, the realities of patient non-compliance with contraceptives
are still poorly understood. The literature on non-compliance with the use of different
contraceptive methods is limited. If at all, very little progress is made in either accurately
detecting, or predicting non-compliance. We sought to obtain insight into the adherence
behaviour of women taking part in a contraceptive trial assessing the feasibility of
administering once a month mifepristone (Chapter 4).
The frequent and regular laboratory assays of steroid hormones in either blood or in
urine had traditionally played a major role in determining the fertile period of the cycle.
In contraceptive research these assays have been used as the standard method of timing
the ovulation. This approach is not only inconvenient for the volunteers but it is also
expensive and time consuming to collect samples for daily assays. We analysed the
practical aspects of using a microelectronic personal fertility monitor as an alternative
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to the laboratory based hormone assays, in a study that investigated the mechanism of
action ofan emergency contraceptive (Chapter 5).
Withdrawal of progesterone is the physiological trigger for menstruation. In 1988,
Johannisson et al. suggested that the menstrual bleeding which follows the
administration of mifepristone in luteal phase might be due to a direct effect on the
capillary vessels of the endometrium. Further understanding of the mechanism by which
mifepristone induces endometrial shedding may contribute in the future to the
development of novel methods of contraceptives. To investigate this issue further, we
evaluated the effects ofmid-luteal phase administration ofmifepriistone on endometrial
parameters (Chapter 6).
1.2 Progesterone
Progesterone is a natural steroid hormone that is produced by the corpus luteum in
mammals. It is fundamental for the initiation, establishment and maintenance of
pregnancy, whereas the cessation of progesterone secretion results in parturition,
lactation and menstruation. Although the primary target tissues for the actions of
progesterone are in the female reproductive tract, it also acts on the mammary gland
(lobular-alveolar development in preparation for milk secretion and suppression ofmilk
protein synthesis prior to parturition), on the central nervous system (mediating sexual
behaviour in rodents) (Mani et al. 1994 a&b) and, on the thymus (inducing thymic
involution) (Tibbetts et al. 1999). Corner and Allen were the first to isolate progesterone
from the pig corpus luteum. In 1929, they demonstrated that when injected to
overiectomised animals, progesterone can induce endometrial morphological changes
similar to those of the early pregnancy, and has an anti-abortifacient effect (Corner &
Allen 1929). Subsequently, in 1934, several independently working groups reported
isolation of the crystallised progesterone (Allen & Wintersteiner 1934; Butenandt et al.
1934; Hartmann & Wettstein 1934). In the following year, Butenandt succeeded in
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synthesising progesterone using cholesterol, and by 1938 several other synthetic
progestins were commercially available.
Since then, several other important discoveries have contributed to our current
understanding of this important hormone. These include the radio-immuno assaying
techniques that accurately quantify progesterone by Lieberman et al. (1959), the
identification of the uterine progesterone receptor by Milgrom & Baulieu (1970), the
demonstration of the role of progesterone in the establishment of and maintenance of
pregnancy by Csapo & Pulkkinen, (1978) and, the confirmation of this pivotal role of
progesterone in fertility with the progesterone receptor knock-out mouse (PRKO) by
Coneelly et al. in 2001. The pathways of progesterone action in target tissues are still not
fully understood and, in many regards, distinctions remain to be made between the direct
effects of progesterone and indirect consequences of progesterone regulation.
Furthermore, progesterone mediates its effects through the progesterone receptor (PR)
and PR is induced by oestrogen in most target tissues. Therefore, mapping out the
progesterone specific effects, as distinct from those of oestrogen, is a complicated task.
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Progesterone is a C21 steroid (Figure 1.1) that belongs to the progestin class of ovarian
hormones on the basis of its biological function. It is converted from cholesterol in the
follicular cells. The delivery of cholesterol to the inner mitochondrial membrane is the
rate-limiting step in progesterone synthesis. In corpus luteum, the steroido-genic acute
regulatory protein (StAR) mediates this process (Review by Strauss 2000 references
therein). Cytochrome P-450 enzyme system that is responsible for catalysing the
cleavage of C-20, 22 bond is located in the inner mitochondrial membranes and
pregnenelone (C22) is formed as illustrated in Figure 1.2 (Farkash et al. 1986;
Lieberman & Lin 2001). Thereafter, the 3(3-hydroxysteroid dehydrogenase: 5-4
isomerase enzyme complex functions as a single entity to further convert pregnanelone
to progesterone. Finally, the principle catabolite of progesterone, pregnanediol, is formed
in the liver (Swart et al. 1993) and is eliminated by the kidney.
Pregnenolone
Figure 1.2 Progesterone synthesis from cholesterol
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Figure 1.3 The structural organization of the Progesterone Receptor
This figure illustrates the human PR cDNA, PRA and PRb proteins.
TAF-1 & 3: Amino terminal containing a constitutional ligand-independent trans-
activation function (TAF-1 and TAF-3); DBD: central DNA-binding domain; H: the
hinge region; LBD: the ligand-binding domain. The arrows indicate the translation start
site for each receptor subtype. PRb is 933 amino acids in length and PRA lacks the N-
terminal 164 amino acids.
The gestation-promoting properties of progesterone are exerted via interacting with
specific nuclear receptor proteins that are induced by oestrogen. Conversely, in most
target tissues, the expression of PR is decreased by its own ligand, progesterone.
Progesterone displays lower affinity to PR, when compared with oestrogen binding to
oestrogen receptor (ER). At high concentrations glucocorticoids can bind to PR (Walters
& Clark 1977), whilst progesterone too can bind to both the glucocorticoid receptor
(GR) and the androgen receptor (AR) at similar high concentrations (Lippman et al.
1977; Rousseau et al. 1973). Universally, the cellular uptake of progesterone appears to
have no impediments thus, is rapid. The retention of the hormone in target cells seems to
be attributable to the presence of PR (Clark & Sutherland 1979).
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1.2.2.1 Structure ofthe Progesterone Receptor
PR belongs to a large steroid receptor super family of ligand-activated nuclear
transcription regulators. They are characterised by organisation into specific functional
domains that are relatively conserved between species and family members. The
"consensus" PR consists of 4 different domains (Kumar et al. 1987; Evans 1988;
Carson-Jurica et al. 1990; Figure 1.3).
1. The N-terminal domain contains a constitutional ligand-independent
transactivation function (TAF-1 and TAF-3), which specifies the promoter of the
target gene activation (Tora et al. 1988; Sartorius et al. 1994). This region
appears to differ between species (Conneeley & Lydon, 2000a).
2. The highly conserved central DNA-binding domain (DBD) interacts with specific
DNA sequences -the hormone regulatory elements (HRE) - in the target genes
and it also contributes to receptor dimerisation (Freedman et al. 1992; Peterson et
al. 2000).
3. Sandwiched between the DBD and the ligand-binding domain (LBD) is the hinge
region.
4. The LBD at the carboxy-terminal contains a second ligand-dependent
transactivation function (TAF-2). In addition to the obvious ligand binding
activity, this region is important for receptor dimerization, interaction with heat
shock proteins (hsp), and inter- and intra-molecular silencing (Webster et al.
1988; Fawell et al. 1990; Vegeto et al. 1992; Lanz & Rusconi 1994; Conneeley
et al. 2000b).
Since the discovery of PR (Laumas & Farooq 1966; O'Malley et al. 1969; Sherman et al.
1970; Milgrom & Baulieu 1970), two natural forms of the human PR (PRa and PRb)
have been characterised, and extensively studied. Both iso-forms bind progesterone and,
are derived from transcripts initiated from two distinct promotors within the same PR
gene (Kastner et al. 1990). Their functional properties differ in a cell type, promotor, or
ligand specific manner (Tora et al. 1988; Chalbos et al. 1994). Thus, existences of these
10
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PR isoforms may add to the complexity of progesterone action. Furthermore, the tissue
distribution of these PR isoforms, and their ratio in reproductive tissues is influenced by
developmental status (Shyamala et al. 1990), hormonal status (Duffy et al. 1997; Mangal
et al. 1997) and malignant transformations (Graham et al. 1996). The full length PRB
(114 kDa), contains an additional N-terminal transactivation region, hence in the
presence of progesterone, has a greater transcriptional efficacy than the truncated PRA
version. When expressed in the same cell in equi-molar ratios, with progesterone binding
PRa & PRb may dimerise and bind to DNA as PRA :PRA, PRA :PRb, or PRb : PRb
(Conneely et al. 2001). Although usually the progesterone activated PRB homo-dimers
bind positively acting PREs to induce gene transcription, activated PRA homo and hetero
dimers appear to repress transcription of specific genes. PRA (94 kDa) exhibit a trans-
dominant negative activity, towards other steroid receptors including PRB, ER, GR and
AR (Vegeto et al. 1993; McDonnell et al. 1994 a&b; Saatcioglu et al. 1994). Since PRA
can act as a dominant repressor of PRb (Vegeto et al. 1993; Saatcioglu et al. 1994), the
ratio of PRA to PRb expression may determine the progestin responsiveness in a
particular cell type.
Production of PR subtype knock-out mice by Conneely et al. has provided the
opportunity to test their functional roles at least in the rodent model (Conneely et al
2001). The PR null mouse (PRA & PRb knock-out) showed several reproductive
abnormalities including failure of ovulation, uterine hyperplasia and inflammation,
defective implantation, lack of sexual behaviour in response to progesterone, abnormal
morphology of the mammary gland and defective thymic immuno-adaptation to
pregnancy (Lydon et al. 1995). The suppressive function for P in uterus appears to be
due to PRa while both the isoforms are involved in ovulatory process (Conneely et al.
2001). The epithelial hyperplasia seen in PRA knockout mice may suggest that PRb
facilitates endometrial hyperplasia while PRA inhibits it, and this may have obvious
relevance to pharmacological management of endometrial dysplasias.
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1.2.2.2 Progesterone binding and cellular mechanism ofaction ofthe
progesterone receptor
Free PR forms an inactive, non-DNA-binding hetero-oligomeric 8S complex, which
upon agonist binding dissociates in to homo-dimers with DNA binding capacity. 42 C-
terminal amino acids of the LBD region are mandatory for progesterone (agonist)
binding (Carson-Jurica et al. 1990; Vegeto et al. 1992). The 8S complex includes
receptor-associated proteins such as heat shock protein hsp90 and immunophilin
FKBP59/HBI. These proteins play a role in stabilising the hetero-oligomeric receptor
complex (Baulieu et al. 1989 a, b&c; Lebeau et al. 1993). Furthermore, the multipoint
hsp90 binding to PR involves both LBD and DBD thus, obliterates the DNA binding to
the DBD (Bourgeois et al. 1984; Baulieu & Catelli 1989b). Progesterone binding
induces tran.v-conformation (Allan et al. 1992) that initiates dissociation of the heat-
shock proteins from the non-DNA binding receptor complex, homo-dimerisation (Tsai et
al. 1988), increased receptor phosporylation (Edwards et al. 1993; Weigle et al. 1993 &
1994) thus activating the receptor.
1.2.2.3 Mechanisms ofaction ofprogesterone through classic hormone
regulatory element
The activated PR binds to the progesterone regulatory element (PRE) of a target gene, a
specific DNA sequence that is located in the promoter, upstream of the coding sequence.
Consensus FIREs consist of palindromic hexanucleotide motifs separated by three-
nucleotide spacers (Beato et al. 1989 & 1996). Binding of the progesterone-PR complex
to the two halves of the same palindromic PRE results in gene transcription via the
action of RNA polymarase. How exactly the activated PR couples with the general
transcriptional machinery is not well understood. Nevertheless, recent data on PR and
other steroid receptors suggest a possible involvement of specific co-activators, co¬
mpressors, specific-DNA binding transcription factors and, general transcriptional
factors. It has been shown that co-activators (e.g. SRC family, CBP/p300, E3 ubiquitin-
protein ligases, L7/SPA, HMG-1/2 and, SRA) are recruited by the progesterone-bound
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PR and, they enhance receptor-dependent trans-activation (Rowan 2000 & references
therein). Agonist-bound PR may also induce remodelling of the chromatin structure
thereby facilitating the DBD and PRE interaction and recruiting transcription factors
(Tmss etal. 1993 & 1994).
The two transcription activation function areas (in the DNA binding domain & in the
LBD) within the PR further regulate the initiation of gene transcription (Cadepond et al.
1997). Activity of TAF-1 depends on receptor and promoter types and cell-specific
factors (Meyer et al. 1990; Vegeto et al. 1993), while only agonists are able to activate
the TAF-2 in LBD, possibly by opposing an inhibitory activity that is located at the C-
terminus of the PR (Vegeto et al. 1992). In addition, upon DNA binding PR undergoes
N-terminal mediated changes outside the DBD (Bain et al. 2000).
PR, in parallel with the other members of the steroid receptor super family, is a phospho-
protein and, agonist induced phosphorylation of the PR is associated with enhanced
specific-DNA binding which may consequently enhance the transcriptional activity
(Beck et al. 1992; Edwards et al. 1993; Weigel et al. 1993 & 1994).
In addition to the above described progesterone induced transcription activation, recent
data has proposed alternative ligand independent pathways of PR activation, which
involve altered cellular conditions due to increased intracellular kinase activity, or
stimulating intracellular phosphorylation (Conneely et al. 2000 and references therein).
Therefore, following progesterone binding, the PR undergoes a conformational change
and initiates a number of progesterone-dependent transcription processes that mediate
the genomic response to the hormone.
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1.2.2.4 Novel mechanisms ofaction through PR interaction with alternative
sequence-specific transcription factors.
Interestingly, it has been shown that progesterone-PR complex is able to either repress or
enhance transcription of different proteins that depended on the same transcription
factor. In normal mammary epithelial cells, under the same cellular conditions but
different promotor context, PR is able either repress (p-casein) or enhance (3P-HSD)
Stat5 (signal transducer and activator of transcription)-mediated gene transcription. The
3p-HSD promotor region only contains a Stat5 response element and, progesterone
induced 3P-HSD gene transcription appears to be Stat5 dependent. In the same cell type,
the liganded PR suppressed the Stat5 dependent P-casein transcription. It has been
proposed that both PR and Stat5 compete for a composite binding site in the P-casein
promotor, and that occupancy by the liganded PR prevents Stat5 transactivation function
(Edwards et al. 2000).
In breast cancer cells, PR activates the c-Src tyrosine kinase in a rapid, progesterone
dependent manner and this action is independent of gene transcription but involves the
prolin-rich motifof the N terminus ofPR (Edwards 2002).
1.2.2.5 Non-genomic actions ofprogesterone
There is now compelling evidence for the existence of progesterone effects that cannot
be explained by the classic model of steroid-target cell interaction. These effects tend to
be incompatible with mRNA and protein synthesis (rapid and can be observed in cells
that do not have trancriptional ability e.g. spermatozoa; and transcription inhibitors are
unable to block these effects) and, may not involve PR or progesterone entering the cell,
yet are highly specific and may involve surface membrane binding sites (Revelli et al.
1998). Data exist on non-genomic actions of progesterone in granulosa cells (Machelon
et al. 1996), in amphibian oocyte maturation (Sadler et al. 1985; Revelli et al. 1998 and
references therein), and in spermatozoa (Bray 1999). However, the importance of these
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non-genomic responses to progesterone in human female reproduction remains to be
determined.
1.2.3 Endometrial steroid receptors
Immuno-histochemical studies employing monoclonal antibodies have made it possible
to demonstrate the nuclear location of the steroid receptors in different endometrial
compartments (McCarty et al. 1985; Press et al. 1988). During the proliferative phase,
PR concentration increases in both epithelial and stromal compartments. Although, this
remains high in the early luteal phase (predominantly in the glands), there is a decline in
the mid- to late secretory phase (Garcia et al. 1988; Lessey et al. 1988; Berthois et al.
1991). The observed decrease in the PR expression during the latter part of the cycle is
pronounced in the glandular epithelium, when compared to the stromal compartment
(Bergeron et al. 1988; Lessey et al. 1988; Press et al. 1988; Snijders et al. 1992; Fung et
al. 1994; Moutsatsou et al. 1997). Furthermore, within the stromal compartment, PR
showed a specific localisation in the perivascular regions (Critchley et al. 1998a).
Several groups have shown that in the human endometrium, the PR expression varies
with the menstrual cycle phase, and reach a maximum during the early luteal phase
(Janne et al. 1975; Bergeron et al. 1988; Garcia et al. 1988; Lessy et al. 1988; Press et
al. 1988; Snijders et al. 1992; Fung et al. 1994; Zeimet et al. 1994; Moutsatsou et al.
1997). Oestrogen and progesterone sequentially regulate endometrial PR expression.
Oestrogen induces PR protein synthesis by mediating an increase in PR mRNA
throughout the proliferative phase (Clarke 1990) while progesterone down regulates PR
at transcriptional and posttranscriptional levels throughout the secretory phase
(Chauchereau et al. 1992). Although the smaller A-receptor remains the phenotypically
dominant iso-form in the endometrium, the PRA: PRB expression ratio is increased in the
peri-menstrual period of the cycle (Tung et al. 1993; Mangal et al. 1997). The
transdominant negative effect of PRA may produce the observed inhibitory effects of
progesterone and antiprogesterones on ER expression. Furthermore, in mid-luteal phase
endometrial glands, PRB may be the predominant PR subtype (Mote et al. 1999).
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In the secretory endometrium, AR expression had been observed predominantly in the
stroma with barely detectable AR immunoreactivity in the glandular epithelium (Slayden
et al. 2001). Immediately before menstruation in the late secretory phase, a decrease in
stromal AR immuno-staining had been reported (Slayden et al. 2001). In contrast, an up-
regulation was observed in glands as well as in stroma, following the early luteal phase
administration ofmifepristone (Slayden et al. 2001).
1.2.4 Myometrial PR
Recent evidence suggests that the non-pregnant uterus acts as a peristaltic pump during
the menstrual cycle with directed sperm transport being one of the main functions
(Lyons et al. 1991; Kunz et al. 1996; Leyendecker et al. 1996). Noe and colleagues
demonstrated a cyclical pattern ofER and PR expression in the subepithelial myometrial
cells, which parallels that of the endometrium. They went on to suggest that progesterone
might be involved in the very early processes of reproduction, by regulating the cyclical
uterine peristalsis (which is confined to the endometrium and sub-endometrial
myometrium) that assists rapid and sustained sperm transport, in addition to the action
on the endometrium. The outer myometrial layers did not exhibit a cyclical pattern of PR
expression, but the immuno staining remained strong throughout the whole cycle. This
cell-specific differential receptor regulation might be functionally significant in
suppressing the action of progesterone in the subendometrial myometrium (supressing
the cyclical uterine peristalsis) in the presence of high circulating concentrations of this
hormone required for continuing action in the outer myometrial layers (maintaining
myofibrils at a quiescent state) (Noe et al. 1999).
1.2.5 Progesterone effects on the uterus
Progesterone acts upon the endometrium to initiate either directly or indirectly
appropriate changes in structure responsible for the required functional end points,
implantation, regeneration and repair. If fertilisation were to occur, the high circulating
levels of progesterone that result, facilitate implantation, stimulate uterine growth and
16
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oppose the action of factors involved in myometrial contractility. Conversely, at the end
of an infertile cycle, withdrawal of progesterone will induce menstruation. Moreover, the
anti-proliferative / anti-oestrogenic effects of progesterone in the endometrium have
been extensively studied; They include the down-regulation of ER (Hsueh et al. 1970;
Katzenellenbogen et al. 1980), the increased metabolism of oestradiol to less active
oestrone (Tseng & Gurpide 1975), and the decrease of oestrogen-induced proteins and
proto-oncogenes (Bhakoo et al. 1977; Kirkland et al. 1992; Elger et al. 2000).
1.3 Levonorgestrel
LNG (systemic name 170 hydroxy- 17a ethinyl- 130 ethyl- 4 gonen- 3 - one) is the
biologically active dextro-rotatory isomer of the synthetic progestin norgestrel, and has
more potent progestational and anti-ovulatory action than the naturally occurring
progesterone (Khan et al. 1983; Stanczyk et al. 1994). Various formulations of LNG are
currently being used clinically, including; (i) in combination with ethinyloestradiol for
the combined oral contraceptive pill or for Yuzpe regimen of post coital contraceptive,
(ii) in combination with 'natural' oestrogens for hormone replacement therapy, (iii) on
its own as LNG only post coital contraception and as LNG releasing IUCD, intravaginal




Figure 1.4 Structure of Levonorgestrel
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1.3.1. Pharmacokinetics of LNG
Since LNG is not metabolised through the entero-hepatic circulation (Fotherby et al.
1994), the bio-availability of the oral dose is high. When administered orally, it is rapidly
absorbed, and achieves the maximum serum concentration (t max) within 2 hours
(Goebelsman et al. 1986; He et al. 1990; Kuhnz et al. 1992; Kook et al. 2002). In
common with the other synthetic gestagens (Fotherby 1983) LNG shows a large inter-
and intra individual variability in the terminal half-life of elimination (mean values
ranging from 8-26 hours) (Weiner et al. 1976; Goebelsman et al. 1986; Back et al.
1987; Fotherby et al. 1990; Tremblay et al. 2001; Kook et al. 2002). The importance of
hormone sensitive sex hormone binding globulin (SHBG) in LNG pharmacokinetics has
been reported by several investigators (Victor et al. 1976 &1977; Affandi et al. 1987). In
blood, LNG binds to both albumin, and (with high affinity) to SHBG. LNG dissociates
slowly from the stable LNG-SHBG complex (Juchem et al. 1990; Fotherby et al. 1994),
and only the unbound fraction in serum (less than 2% of the total drug) is responsible for
the biological action. On the other hand, LNG directly affects serum SHBG, and a single
dose of 0.75 mg LNG was able to reduce the circulating SHBG by 25% (He 1990).
However, this action is reversed by the concomitantly administered ethinyloestradiol,
thereby affecting the pharmacokinetics of LNG (Fotherby et al. 1990). The studies
evaluating the pharmacokinetics of LNG had small numbers, and did not determine the
SHBG level at the time of administration of LNG. These deficiencies may explain the
variability seen in the pharmacokinetic profile of LNG since the range of SHBG levels
among healthy women is reported to be wide (Fotherby et al. 1995). The metabolites of
LNG are present in the circulation at greater concentrations than LNG for a longer time
period (Warren et al. 1974). If biologically active, they may sustain the progestagenic
effects for a much longer period than expected. Once more, this possibility is yet to be
elucidated. Therefore, the complex pharmacokinetics of LNG makes its correlation to
the pharmacodynamic activity difficult. However, recent studies have shown that
following 0.75mg of LNG taken twice 24 hours apart, the plasma LNG level remains
above 1 nmol/L for approximately 4.5 days (Tremberly et al. 2001). This is of particular
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importance, as it is the minimal plasma level of LNG required to inhibit ovulation
(Nilsson et al. 1980).
1.4 Mifepristone
Agents that antagonise the effects of progesterone were actively sought even prior to the
present day understanding of the cellular mechanism of action of hormones. Although
unsuccessful in finding a synthetic anti-progestagen, Pincus was the first to postulate the
potential value of a compound with anti-gestagenic activity in fertility control (Pincus
1965). Since then, many others have made several important contributions (Sherman et
al. 1970; Belanger et al. 1981) that finally led to the discovery of mifepristone (RU
38486, subsequently abbreviated to RU 486), which was the first potent anti-gestagen to
be synthesised (Philibert et al. 1981). Two decades have passed since and, unfortunately
the political controversy surrounding mifepristone as an "abortion pill" has hindered its
many other potential therapeutic uses being put to practise.
Mifepristone exerts its potent antiprogesterone and antiglucocorticoid action in humans
by binding to the intracellular receptors of the antagonised hormones. Despite the close
structural relationship between the steroid receptors, mifepristone does not bind to ER or
the mineralocorticoid receptor (MR) yet demonstrates high affinity for PR, GR, and also
(somewhat lower affinity) for AR. Upon binding mifepristone maintains the PR in a
biologically inert conformation that precludes progesterone binding (Evans et al. 1988;
Baulieu 1989) and itself does not activates the PR.
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Mifepristone is a 19-norsteroid that lacks the C19-methyl group of natural progesterone
and of glucocorticoides. The chemical structure of mifepristone shows two important
distinctive differences from the steroidal skeleton, a 4-dimethyl amino-phenyl group
substituted at the lip position, and a 1-propynyl-chain substitution at the 17a position
(Figure 1.5). The higher binding affinity of mifepristone to PR is thought to be due to
both these variations, while the size and positioning of the former determines the anti-
progesterone action (Evans et al. 1988; Baulieu 1989; Garcia et al. 1992; Spitz et al.
1993). Thel7a-propynyl side chain appears to confer pure-glucocorticoid activity, and
various modifications at C-17 position of the RU 486 structure resulted in compounds
with relatively lower anti-glucocorticoid activity. However, to date no pure progesterone
antagonist that is totally devoid of glucocorticoid activity has been described.
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1.4.2 Pharmacokinetics ofmifepristone
Mifepristone is usually administered orally as a single or multiple doses and the dosage
varies from 0.5 mg to 800 mg daily in various studies. The oral dose is absorbed rapidly
(70%) and is subject to the first-pass metabolism in the liver. Bio-availability after the
oral dose in humans (40%) does not appear to be affected by the pregnant status or the
ethnicity but it is reduced in some animal species (Spitz et al. 1993, Sarkar 2002).
Mifepristone is metabolised in the liver and is excreted mainly in urine and faeces as
biologically active demethylated and hydroxylated metabolites.
1.4.2.1 Receptor binding and ligand-induced trans-conformation
Mifepristone is a potent antagonist of progesterone action in vivo, however the
mechanism of this antagonism is poorly understood. Mifepristone binds to PR with a
relative binding capacity five times that of progesterone (K of dissociation <1 nM) and
does not activate the receptor (Philibert 1984; Skafar et al. 1991). The affinity of
mifepristone for the GR is also of same order of magnitude as that for PR. The
magnitude of the anti-glucocorticoid activity however, is influenced by the phase of
cicardian rhythm and the negative pituitary feed-back of Cortisol secretion and, requires a
higher dose than that which has anti-progesterone activity (Healy et al. 1983 & 1985;
Gaillard et al. 1984; Bertagna et al. 1984).
The PR ofmost species including humans contains a large hydrophobic pocket that can
accommodate the equally hydrophobic lip substitution of mifepristone (Teutsch et al.
1985). Mifepristone appears to require a set ofN-terminal region amino acids of LBD on
the PR that overlap with the progesterone binding, but are non-co-incidental. A
monoclonal-antibody to a 14 amino acid sequence in the C-terminal of LBD only blocks
progesterone binding, but not mifepristone (Weigel et al. 1992). Point mutations have
been identified in the LBD that distinctly affect binding of either mifepristone {at
Gly722 of the human PR (Benhamou et al. 1992)} or, progesterone {Cys575 of the
chicken PR (Baulieu 1993)} but not the other; and a C-terminal mutant PR has been
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shown to bind only mifepristone, but not progestin (Vegeto et al. 1992). The qualitative
property of hormone antagonism however, does not appear to equate to mere binding
ability. Although mifepristone does not bind to chicken PR (cPR), a change of a single
amino acid in the N-terminal region of cPR LBD (Cys 575 to Gly) allows binding of
both mifepristone and RU 39115 (RU 39115 is an antagonist of the human PR and, lacks
the N-dimethyl substituent of mifepristone). Upon this binding however, the
antiprogesterone activity is only observed with mifepristone. RU 39115 on the other
hand, exhibits agonist activity in the mutant receptor (Gronemeyer et al. 1992; Baulieu
1993). Therefore, the overall structure of the LBD and the antagonist and, the TAF-2
function may influence the biological activity of a steroid hormone agonist or antagonist.
Mifepristone competes with progesterone for binding to PR and promotes many of the
normal activation steps elicited by progesterone, including dissociation of the heat-shock
proteins, dimerisation, and acquisition of high affinity for target DNA binding (Baulieu
et al. 1988; El-Ashry et al. 1989; DeMarzo et al. 1992; Gass et al. 1992; Beck et al.
1993a). Although mifepristone-PR complex has higher affinity for PRE than that of
progesterone-PR complex, upon binding to the PRE only the latter and not the former,
activates the transcriptional machinery. Therefore, mifepristone is defined as a type II
antagonist (other antiprogestagenic substances which form complexes with PR but are
unable to bind to PRE (e.g. ZK 98299) are defined as type I antagonists) that appears to
recapitulate the early steps of agonist-activation of receptor yet fails to activate a
transcriptional response. Our understanding of the molecular mechanisms of this
receptor inactivation is still far from complete. Nevertheless, the existing evidence is as
follows. Mifepristone-PR complexes may form inactive, mixed ligand-dimer hetero-
dimers with progesterone-PR complexes, while actively competing with them for PRE
binding sites (Edwards et al. 2000); mifepristone induces 'an inappropriate' structural
conformation at the extreme carboxy-terminus of the LBD, which is distinct from that
induced by progesterone (Allan et al. 1992; Weigle et al. 1992); This altered
conformation can prevent both the agonist-dependent TAF-2 activity and the binding of
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PR co-activators that enhance receptor-dependent transcription such as SRC (Edwards et
al. 1999 & 2000); Mifepristone may also promote recruitment of inappropriate co-
activators that are not selected by progesterone such as L7/SPA (Jackson et al. 1997);
Additionally, it may actively recruit PR co-repressors and the co-activator and co¬
mpressor concentration ratios may determine the antagonist or partial-agonist activity of
mifepristone (McDonnell et al. 1992; Jackson et al. 1997; Smith et al. 1997).
In particular tissues, mifepristone may behave as a progesterone agonist. In the absence
of progesterone, mifepristone exhibits a progesterone-like anti-oestrogenic effect in an
oestrogen-primed endometrium (Wolf et al. 1989; Van Uem et al. 1989). However, if
progesterone was present mifepristone acts as a pure antagonist. The repressor role of
PRa on ER has been suggested as the explanation for this anti-oestrogenic effects of
mifepristone (see Cadepond 1997 and references therein). Recently, Brenner et al.
suggested that this non-competitive anti-oestragenic effect of mifepristone seen on
rhesus macaque endometrium is mediated via inducing AR expression (Brenner et al.
2002). Similar to progesterone, mifepristone inhibits prolactin Stat5- mediated induction
of P-casein Luciferase receptor in the mammary epithelial cells. It has been postulated
that this is due to the occupancy of the composite DNA-binding element located in the
P-casein promotor by the mifepristone-PR complex which precludes the Stat5 binding,
thereby suppressing Stat5 trans-activation function (Edwards et al. 2000). In vitro
studies have exposed conditional agonist activity similar to other type II antagonists with
mifepristone. Alteration of cellular conditions by either activation of protein kinase A or
stimulation of cAMP signalling pathway resulted in antagonist-to-agonist switch in
mifepristone activity in vitro (Beck et al. 1993b; Nordeen et al. 1995). It is of further
interest that the weak partial agonist activity is associated with only mifepristone bound
PRb but not PRa (Leonhardt & Edwards 2002).
In summary, the structure of mifepristone and of the LBD combine ultimately to direct
the trans-conformation of PR, and DNA binding; but do not activate the TAF-2 or
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induce transcription and thus, mifepristone acts as an antagonist. The production of a




A single oral dose of mifepristone is eliminated within 6-7 days of administration
(Sarkar 2000). The effects of short-term administration of mifepristone have been well
characterised and, appear to be safe. Administering 200 mgs of mifepristone daily for 8
days to healthy men resulted in a hormonally detectable antiglucocorticoid state and a
reversible Cortisol overproduction with preservation of adrenocortical and pituitary
reserves. Importantly, no concurrent clinical symptoms of peripheral Cortisol deprivation
were observed with these effects (Bertagna et al. 1994). Others have shown that the
disinhibition of the pituitary-adrenal axis is only observed during the morning hours of
the circadian rhythm, thus lowering the dosage and changing the time of administration
may be important to minimize the side effects (Gaillard et al. 1984). One study reported
that mifepristone at high doses (10 mg/Kg taken daily for a week) induced a diffuse
maculo-papular erythematous cutaneous eruption within 2 weeks of discontinuation of
the drug in the majority (73%) of the healthy male volunteers. Histologically, this
generalised examthum showed a diffuse dermal peri-vascular lymphocytic infiltration
that resolved spontaneously (Laue et al. 1990). However, none of the affected subjects
demonstrated an increase in the eosinophil count, which does not support the possibility
of drug hypersensitivity or glucocorticoid deficiency being responsible for the skin
reaction. Moreover, after taking even higher doses (20 mg/kg) for longer periods, others
have not developed similar complications (Chrousos et al. 1988).
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1.4.3.3 Chronic administration
Most novel therapeutic indications of mifepristone require long-term administration (e.g.
breast cancer, endometriosis) and, its antiglucocorticoid action has raised the issue of
safety with chronic exposure to the drug. Prolonged administration of daily low doses
was not associated with a cumulative increase in plasma concentration of the drug
(Heikinheimo et al. 1987 & 1989; Sarkar 2002). At doses above 200 mg a day, clearance
of mifepristone from the body appears to reach a limiting value and this may produce
elevated plasma levels over a long duration (Sarkar 2002). In a small proportion of
volunteers, when high doses of mifepristone was administered continuously for more
than several days, symptomatic glucocorticoid deficiency has been observed. Chronic
exposure of 200 mgs a day was associated with symptoms of Cortisol deprivation that
were severe enough to be treated with concomitant prednisolone (Lamberts et al. 1991).
Lambert et al. postulated that mifepristone activated and reset the hypothalamo-pituitary-
adrenal axis at a higher level. However, this observation has not been reported by others,
using a similar regimen for as long as 15 months for the treatment of unresectable
meningiomas (Heikinheimo et al. 2000). In pre-menopausal women, a similar regimen
induced amenorrhoea, or metrorrhagia (in one case with endometrial hyperplasia)
(Grunberg et al. 1993). The main concern with this chronic dose however, was the
reported increase in oestrogen (as a consequence of the compensatory overproduction of
androgen), which might limit the use of mifepristone in treating oestrogen dependent
cancer. Conversely, recent data, which demonstrated a low oestrogen level with no
discernible change in SHBG after chronic 200 mg daily dose, suggest that enhanced
systemic oestrogen effects are unlikely during long-term mifepristone treatment
(Heikinheimo et al. 2000).
Studies using long-term daily doses of mifepristone up to 10 mg/kg, or using once-off
doses of up to 25 mg/kg, did not report any other adverse events. Since the doses
required for most potential therapeutic applications of mifepristone are well within these
dose limits, the safety aspect ofmifepristone appears to be reassuring.
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1.4.3.2 Teratogenicity
The use ofmifepristone in the induction of abortion and as a contraceptive agent and the
fact that it traverses the placental barrier (Hill et al. 1991), raises concerns about the
possibility of teratogenic effects in infants who are exposed to mifepristone during early
gestation (Doherty et al. 1992). Unfortunately, the available data on this possibility are
rather limited. In rabbits, even at sub-abortive doses mifepristone induced foetal
abnormalities (Yost et al. 1986; Wolf et al. 1990). However, monkey embryos did not
show teratogenicity when exposed to mifepristone either before implantation (10" M) or
immediately post-implantation (50 mg/day for 7 days) (Wolf et al. 1990). Henrion et al
in 1989 reported a single case in which administration of mifepristone in the first
trimester was associated with second trimester fetal-malformation (Henrion et al. 1989).
In a more recent report, Sitruk-Ware et al. reviewed 71 cases of continuing pregnancy
following failed early medical termination (occurred between 1987-1998) and reported
only one case of fetal abnormality after the use of mifepristone alone. There were 7
further cases of fetal abnormality following treatment of mifepristone in combination
with prostaglandins (Sitruk-Ware et al. 1998). No other instances of possible
teratogenicity had been reported despite the growing use of mifepristone in inducing
medical abortion around the world. Conversely, there have been reports of human
fetuses that have been exposed to mifepristone but not subsequently aborted, developing
normally (Lim et al. 1990).
1.5 Menstrual cycle
Throughout a woman's reproductive life, the dynamic relationship between the pituitary
and ovarian hormones allows the cyclical sequence of events, which commences with
folliculogenesis and proceeds to extrusion of a mature oocyte and transformation of the
follicular granulosa cells into a corpus luteum which eventually undergoes luteolysis,
thus terminating an infertile cycle.
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1.5.1 Progesterone regulation of the hypothalamo-pituitary-ovarian axis
The feed back mechanism that exists between the ovary and the hypothalamo-pituitary
unit is responsible for the normal cyclical ovarian activity (Knobil et al. 1980). The
anterior pituitary produces LH and Follicle Stimulating Hormone (FSH) in a pulsatile
fashion in response to the hypothalamic neuropeptide; gonadotrophin releasing hormone
(GnRH). The ovarian hormones oestrogen, progesterone and inhibin also influence this
regulation, and conversely, LH and FSH directly regulate these hormones. Normal LH
secretion (in a pulsatile manner) and ovulation are dependent on the release of GnRH
pulses that happen at a critical frequency and amplitude (Dierschke et al. 1970;
Leyendecker et al. 1979). The LH pulses increase in frequency immediately before
ovulation, then following ovulation slow down while increasing their amplitude in the
first half of the luteal phase (Backstrom et al. 1982; Wildt et al. 1981; Filicori et al.
1986). It has been shown that the pre-ovulatory surge of LH triggers ovulation by
initiating a series of changes in the dominant follicle causing the rupture and the
subsequent release of the ovum. Furthermore, LH can stimulate a transient increase in
PR mRNA expression in pre-ovulatory follicular granulosa cells suggesting an LH
induced progesterone responsiveness in those cells (Natraj et al. 1993; Park-Starge et al.
1994). Normal women have a pre-ovulatory rise in progesterone preceding the initiation
of the mid-cycle LH surge (Hoff et al. 1983). This is thought to facilitate oestrogen in
releasing the LH surge (Odell et al. 1968; Chang & Jaffe 1978; March et al. 1979 &
1981; Wildt et al. 1981; Lui & Yen 1983; Mahesh & Muldoon 1987; Permezel et al.
1989; Leyendecker et al. 1990) and may also play an important role in the
contemporaneous discharge of the gonadotrophins (Aono et al. 1976).
Presently available evidence for the effects of progesterone on the neuro-endocrine axis
during the luteal phase is questionable, since studies using antiprogesterone have not
always produced the expected results (Herrman et al. 1982; Critchley et al. 1988; Garzo
et al. 1988; Shoupe et al. 1990). After ovulation, the facilitatory role of progesterone in
releasing LH reverses rapidly into one of an inhibitory nature, (Leyendeker et al. 1972;
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Drouin & Labrie 1981; Araki et al. 1985) changing the high frequency, low amplitude
LH pulses of the follicular phase to pulses of low frequency and high amplitude (Hoff et
al. 1983; Soules et al. 1984). The pulse frequency of LH declines progressively during
the luteal phase and correlates with cumulative progesterone exposure (Filicori et al.
1984; Soules et al. 1984). Moreover, exogenous progesterone has been shown to
decrease LH pulse amplitude (Soules et al. 1984). Endogenous opioids appear to
influence LH pulsatility via inhibiting GnRH secretion (Rasmussen et al. 1983). Since
the maximum suppression occurs when high progesterone levels are seen (Soules et al.
1984; Shoupe et al. 1985) and this effect is reversed by naloxone infusion in the luteal
phase (Quigley & Yen 1980), it was thought that progesterone was important in
modulating the endogenous opioid mediated inhibitory process (Quigley et al. 1980;
Shoupe et al. 1985). More complex actions of anti-gestagens that are not solely due to
progesterone antagonism may explain the unexpectedly different results seen in studies
using anti-progesterone (Herrman et al. 1982; Critchley et al. 1988; Garzo et al. 1988;
Shoupe et al. 1990). Nevertheless, immunisation of the ewe against progesterone has
consistently produced an increase in the LH pulse frequency supporting the inhibitory
effect of progesterone on gonadotrophin secretion (Thomas et al. 1987).
1.5.2 Control ofOvarian cycle
In humans, folliculogenesis, ovulation and corpus luteum formation occur under
pituitary gonadotrophic control.
1.5.2.1 Follicularphase
Various ovarian follicular compartments interact in a highly integrated manner to
respond to cyclic gonadotrophic hormones by secreting sex steroids and producing a
fertilizable, mature ovum. Progesterone and oestrogen levels remain low during the
menses, and thereafter, in the follicular phase, the developing Graafian follicle produces
increasing levels of oestradiol (Yoshinga et al. 1978). FSH stimulates the growth of the
follicles beyond the stage of antrum formation (Baird 1987 & 1990 and references
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therein). By the mid-proliferative phase of the cycle, FSH-inducible granulosa cells of
the apparent single dominant follicle (>10 mm diameter) produce increasing amounts of
oestrogen by aromatising the androgens derived from LH-dependent theca cells
(Yoshinga et al. 1978). Oestrogen and inhibin secretion from the enlarging preovulatory
dominant follicle (usually one per menstrual cycle) suppresses (negative feed back) the
pituitary FSH release, while inducing an LH surge, which initiates ovulatory process
(Baird 1990 and references therein). Ovulation seems to occur approximately 36 hours
after the onset of the LH surge (Seibel et al. 1982).
1.5.2.2 Control ofOvulation
The LH surge initiates a cascade of proteolytic events that control ovulation and, also
induce PR gene expression in granulosa cells of the mature preovulatory follicles (Natraj
et al. 1993). Furthermore, around the time of the mid-cycle LH surge in women, pre¬
ovulatory follicles appear to secrete increasing levels of progesterone (Zander et al.
1954; Hoff et al. 1983; Djahanbakhch et al. 1984). The presence of PR in most follicular
cell types, failure of ovulation in PR null mice despite having mature preovulatory
follicles (Suzuki et al. 1994; Lydon et al. 1995) and, the inability of the mature follicle
to rupture in the absence of mid-cycle progesterone secretion (Schenken et al. 1986)
suggest that the ovulatory process is regulated by progesterone. It is postulated that this
regulatory pathway may involve relaxin, kallikrein, proteases (e.g. cathepsin L,
ADAMTS-1), and plasminogen activator (Yki-Jarvinen et al. 1985; Too et al. 1984;
Tanaka et al. 1992; Robker et al. 2000).
1.5.2.3 Luteal phase
The luteal phase of the cycle is dominated by progesterone arising from the corpus
luteum. Conversely, formation of corpus luteum appears to be progesterone-dependent
and, indeed PR is expressed in the corpus luteum despite high local progesterone
concentrations (Aladin Chandrasekher et al. 1994). After ovulation, progesterone levels
reach a peak by day 8 or 9 and, if implantation does not occur, progesterone declines by
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day 10-12 (first gradually and then precipitously). In the latter part of the infertile cycle,
the corpus luteum regresses, stops the release of progesterone and, consequently a
decline is observed in the circulating levels. This withdrawal of progesterone causes the
endometrial pseudo-decidua to degenerate, which results in menses. Luteal regression
permits initiation of a subsequent cycle, by allowing the development of a fresh batch of
follicles.
1.5.3 Effects of mifepristone on the hypothalamo-pituitary-ovarian axis and on
the ovarian cycle
Mifepristone binds to PRs in the hypothalamus, the anterior pituitary and in the ovary as
well as the uterus. It thereby has multiple effects on the hypothalamic-pituitary-ovarian
axis and on the ovarian cycle depending on the time of the cycle and the dose used.
1.5.3.1 Follicularphase administration ofmifepristone
During the early follicular phase except for a minimal decrease in oestradiol level,
mifepristone (at a dose of 3 mg/kg) has no effects on the ovarian cycle (Stuenkel et al.
1990). However, later in the follicular phase, mifepristone arrests folliculogenesis and
inhibits or delays ovulation, while decreasing oestradiol and LH levels during treatment
(Shoupe et al. 1987; Permezel et al. 1989; Stuenkel et al. 1990). In vitro studies have
shown mifepristone to inhibit LH secretion by cultured rat pituicytes (Wolf et al. 1989).
Additionally the reduction of LH pulse amplitude seen after late follicular administration
of mifepristone to women suggests a pituitary site of action (Permezel et al. 1989).
Therefore, the inhibition of ovulation seen after administering high doses (>50 mg) in
the mid-late follicular phase of the cycle seems to be due to the suppression of the
secretion of pituitary gonadotrophins (both LH and FSH) thereby arresting follicular
growth (Luukkainen et al. 1988; Nieman 1993; Liu et al. 1987; Shoupe et al. 1987;
Permezel et al. 1989). Afterwards, follicular recruitment can reinitiate once the
treatment is discontinued and ovulation can occur approximately 2 weeks later (Liu et al.
1987; Shoupe et al. 1987).
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The delay of the mid-cycle LH surge seen after continuous administration of
mifepristone (1 mg daily, over 5-15 days after the dominant follicle selection) in the late
follicular phase can be prevented by concomitantly administered exogenous
progesterone (Batista et al. 1992 a). The mechanism for this appears to be via inhibition
of the positive feed back effect of oestrogens (Baird et al. 1995). It has been shown that
daily administration of 2 mg of mifepristone does not affect the pulsatile pattern of LH
secretion (Baird et al. 1995). Therefore, the impairment of oestrogen induced LH surge
is not due to an effect of mifepristone at the hypothalamic level and nor is it due to a
decreased responsiveness of the pituitary to exogenous GnRH. On the basis of these
observations Baird et al. concluded that mifepristone at this dose (2 mg daily) interferes
with the mid-cycle LH surge by a complex mechanism, possibly by directly reducing the
sensitivity ofpituitary gonadotroph to the positive feed-back effects of oestrogen.
It is important to note that the above studies reported blocking of the LH surge when
multiple doses of mifepristone were administered continuously in the follicular phase.
The lowest single dose, which will prevent the LH surge and ovulation consistently, is
not known and once the LH surge is initiated mifepristone does not seem to be able to
arrest ovulation (Liu et al. 1987; Marions et al. 2002; Brown, A. unpublished data
through personal communication).
1.5.3.2 Lutealphase administration ofmifepristone
In the mid-luteal phase a single dose ofmifepristone (5 mg/kg) acutely increases both the
amplitude and the frequency of LH pulses (Critchley & Baird 1988). After this initial
effect, some authors have reported a decline in the secretion of total LH and in the pulse
amplitude, but no discernible effect was seen on the pulse frequency (Garzo et al. 1988;
Shoupe et al. 1990). It has therefore been suggested that this failure of an anti-
progesterone to influence LH pulse frequency may be due to a lack of a direct
hypothalamic effect. Although others have reported a decrease in LH pulse frequency
after mifepristone, due to the low frequency of LH pulses detected, the validity of their
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result is uncertain (Schaison et al. 1985). Low doses, 10 mg for example, do not affect
LH levels (Greene et al. 1992). Therefore, during the mid-luteal phase, mifepristone may
initially relieve a suppressive effect of progesterone on the frequency and amplitude of
LH pulses, and thereafter it may have a direct pituitary action in decreasing the LH pulse
amplitude. Moreover, naloxone did not reverse this mifepristone (a single dose of 100
mg mifepristone) induced decrease in the LH pulse amplitude (Shoupe et al. 1990)
suggesting that the inhibitory hypothalamic effect of endogenous opioid peptides may
not be fully dependent on progesterone as previously thought.
In the late luteal phase a single dose of 600 mg ofmifepristone significantly reduces both
the frequency and amplitude of LH pulses, suggesting a hypothalamic-pituitary action
(Garzo et al. 1988).
In summary, mifepristone acts at multiple sites within the hypothalamic-pituitary-ovarian
axis to produce the observed effects.
1.6 Endometrium and Menstruation
Endometrium is a specialised organ that is composed of two layers: a superficial
functional layer and a basal layer. During the reproductive age, the superficial layer
undergoes cyclical changes closely controlled by the ovarian hormones, and disappears
after the menopause. It is composed of epithelial cells that line the uterine cavity, simple
and tortuous glands, and stroma with cells of different lineages and vessels. Following
menstrual shedding at the end of a cycle, the functional layer regenerates from the
reserve cell layers in the basal zone.
Before ovulation, the oestrogen dominated proliferative phase of the endometrium is
characterised by glandular and stromal mitoses. Progesterone, which is the dominant
hormone in the post-ovulatory secretory endometrium, inhibits proliferation while
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inducing the synthesis and the release of endometrial secretory products and
neovascularisation (Critchley & Healy 1998b and references therein).
Therefore, the menstrual cycle can be defined as a repeated expression of the action of
the hypothalamo-pituitary-ovarian system with associated structural and functional
changes in the target tissues of the reproductive tract (Yen et al. 1991).
1.6.1 Endometrial vessels
Sex steroids have shown to have a direct effect on the vessels in the upper functionalis
layer of the endometrium (Schmidt-Matthiesen et al. 1963; Johannisson et al. 1986) and
these vessels may play an important role in implantation (Akerlund 1991). Following the
original report by Markee in 1940, the increasing need for efficient contraceptive
methods and improvement of technology related to assisted conception have renewed
interest in studies of the human endometrium, including endometrial vascularisation.
The rate and the volume of the blood flow to the superficial layers of the endometrium
are thought to be regulated via the dynamic changes of these vessels (Ramsey 1977;
Peek et al. 1992). During the pre-ovulatory period, the capillaries have a narrow lumen
and are thin-walled. The discrepancy in growth rate (the five fold increase in the length
of the spiral arteries while the endometrium thickness only doubling) that is apparent
during the proliferative phase might be the reason for the pre-ovulatory coiling of these
arteries (Markee 1940). Ovulation seems to provoke an immediate dilatation of the
endometrial capillaries (Peek 1992). Herein after, in the luteal phase of the cycle, the
vessels in the sub epithelial capillary plexus sustain this dilatation (up to day LH +7/ +9)
up to the time of implantation (Bartelmez 1956; Sheppard et al. 1980; Seppala et al.
1991). Furthermore, this dilatation of vessels correlates with the serum progesterone
levels circulating in the plasma 72 hours preceding biopsy and coincides with the
development of stromal odema (Peek et al. 1992). Later, immediately preceding the
onset of menses, the endothelial cells undergo contraction and degeneration (Peek et al.
1992).
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1.6.2 Menstruation
The superficial or functionalis layer of the endometrium disintegrates at the end of an
'unsuccessful' cycle where conception has not occurred, and this process is defined as
menstruation. Menses is also the climax of events that occur in the cells and vessels of
the endometrium, which follow the natural withdrawal of progesterone. The current
understanding of the mechanism of menstruation stems from a series of outstanding
experiments performed by Markee in 1940. Using endometrial auto-transplants in the
anterior chamber of the eye of rhesus monkeys, he produced a detailed account of
vascular changes associated with menstrual bleeding. Subsequently two hypotheses have
being advocated as the trigger mechanism for menstruation: the inflammatory hypothesis
focused on pro-inflammatory cells, MMPs, chemokines and cytokines (Finn 1986;
Salamonsen et al. 1999 and references therein), while the vasoconstrictor hypothesis
emphasised the actions on prostaglandins (Baird 1996) and endothelins (Marsh 1996;
Campbell & Cameron 1998). The vasoconstrictor hypothesis seems more plausible and
thus, is progressively gaining recognition (Baird 1996, Figure 1.6; Critchley et al. 2001).
Moreover, this second hypothesis integrates the previously suggested inflammatory
pathway at a downstream level to the initial step, vasoconstriction.
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Figure 1.6 Mechanism ofmenstruation. Adapted from Baird (2000) with
permission.
1.6.2.1 Prostaglandins and menstruation
Prostaglandins (PGs) are a family of fatty acids synthesised from arachidonic acid (AA)
which are able to elicit a wide variety of biological actions. The amount of free AA
available for cells is limited; therefore, liberation of AA from precursors (present as
membrane bound phospholipids) by the action of phospholipase A2 (PLA2) is one of the
first and rate limiting steps in PG synthesis (Lapetina 1982; reviewed in Poyser 1992).
PLA2 appears to be present in the endometrium in two different iso-forms; the calcium
dependent and inducible PLA2(j) which is localised in the endometrial glands, and the
calcium independent PLA2(jj) that is predominantly confined to the stroma (Bonney 1987
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dependent and inducible PLA^i) which is localised in the endometrial glands, and the
calcium independent PLA2(ii) that is predominantly confined to the stroma (Bonney 1987
a & b). Free AA is then either converted to cyclic endoperoxides by the actions of
cyclooxygenase or to 5-hydroperoxy acids by the action of 5-lipoxygenase (Figure 6.1).
The end products of the cyclooxygenase pathway include prostanoids (PGE2, PGF2a,
PGI2) and thromboxane A2 (Bergstrom 1968; Poyser 1992; Baird 1996). PGF2a is a
strong vasoconstrictor and a stimulant of uterine contraction. Cyclo-oxygenase is a
cytoplasmic enzyme (bound to the endoplasmic reticulum) and exists as two isoforms
produced by two different genes (COX-1 and COX-2) (Fletcher 1992). COX-I is
constitutively expressed in both glandular and stromal cells of the endometrium, while
COX-2 expression is modulated by a variety of stimuli including growth factors and
hormones and is usually limited to luminal, and glandular epithelial cells. In the
endometrium, PGs are not stored, but are immediately synthesised and released, then
rapidly metabolised into biologically inactive metabolites. The major site of
prostaglandin synthesis during the normal menstrual cycle appears to be the endometrial
glandular cell compartment (Lumsden 1984). The NAD+ dependent enzyme 15-
hydroxyprostaglandin dehydrogenase (PGDH) belongs to the family of short chain
dehydrogenase and is responsible for the metabolism of PGs (Ensor 1990). The
endometrial release of PGs varies at different stages of the menstrual cycle, which
suggests an ovarian hormonal influence.
The evidence (both in vitro and in vivo) for progesterone control of endometrial PG
activity are as follows; secretory endometrium has a higher level of PGs (both PGE2, and
PGF2<x) (Downie et al. 1974; Sing et al. 1975; Maathuis & Kelly 1978) and has a greater
capacity to synthesise PGs than the proliferative endometrium (Abel & Baird 1980;
Smith et al. 1981); in-vitro, progesterone suppressed both the oestradiol-stimulated and
basal PG production by endometrial explants and cells in culture (Abel & Baird 1980;
Schatz et al. 1986; Kelly & Smith 1987); large amounts of PGs are released with the
withdrawal of progesterone e.g. menstruation and abortion (Lumsden et al. 1983;
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Norman et al. 1991 a & b; Cheng et al. 1993 b; Poyser 1995); during pregnancy, when
progesterone levels are high, basal endometrial PG production is reduced (Maathuis &
Kelly 1978); antagonising progesterone in vitro shows a dose-dependent induction of
PGF2a release from endometrial stromal cells (Kelly et al. 1986); the observed increase
in uterine contractility after treatment with mifepristone is possibly due to increase PGs
(Norman et al. 1991b; Gemzell-Danielsson et al. 1994). Therefore, under normal
conditions at least, progesterone appears to enhance the PG biosynthetic capacity of the
secretory endometrium, while suppressing their release. However, mifepristone still
increases the uterine activity even when prostaglandin production is suppressed by
indomethacin (Norman et al. 1991a).
The concentration of PG in any tissue is related to its rate of synthesis and metabolism.
Thus, attempts have been made through evaluating the enzymes involved to demonstrate
the mechanism by which progesterone controls endometrial PGs activity. An increase in
PGDH expression (Casey et al. 1980; Kelly et al. 1994), and a decrease in the expression
of COX-2 (Jones et al. 1997) is seen with the rising levels of progesterone in the
secretory endometrium; progesterone has an inhibitory effect on the endometrial PLA2
activity (Bonney et al. 1987 a & b); the withdrawal of progesterone from an
endometrium that has been primed with progesterone and oestradiol results in an
increase in COX-2 expression (Critchley et al. 1999), while continuing exposure to
progesterone is associated with low levels of COX-2 expression; following treatment
with antiprogesterone, glandular PGDH expression is markedly reduced (Cameron et al.
1996); glandular PGDH immunostaining in the endometria of women receiving
mifepristone in early pregnancy also shows a reduction (Cheng et al. 1993a) while it is
increased in the endometria of women using a LNG releasing intrauterine system
(Critchley et al. 1998a); and finally, transfection studies have shown progesterone
induced PGDH expression via interaction with a specific promotor (Greenland et al.
2000). Thus, progesterone is responsible for stimulating PGDH and suppressing COX-2
and PLA2.
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Consequently, although progesterone enhances the PG biosynthetic capacity of the
endometrium, withdrawal of progesterone is necessary for its full potential to be evident.
Moreover, progesterone appears to exert these effects through inhibiting enzymes
involved in the synthesis of PGs (PLA2 and COX-2) and by stimulating PGDH, which
metabolises PGs.
1.6.3 Mifepristone and the uterus
Mifepristone blocks the specialised uterine actions of progesterone firstly enabling the
reception of the blastocyst by the endometrium and the continuous nourishment of the
developing fetus and secondly containing the growing fetus until the eventual expulsion.
1.6.3.1 Effects ofmifepristone on the endometrium
The endometrial effects are dependent on the dose of mifepristone used and on the time
of administration in the menstrual cycle. In several studies mifepristone was tested in
doses that varied between 0.5 mg and 800 mg, given either as single dose, multiple doses
intermittently or continuously for several months.
Although an anti-proliferative effect has been reported in the absence of progesterone
(Slayden & Brenner 1994; Brenner & Slayden 1994; Elger et al. 2000), mifepristone in
general does not directly affect the endometrium. The persistent proliferative activity
observed following follicular phase administration is a result of the delay in ovulation
(Swahn et al. 1988). However, the endometrial effects of luteal phase (progesterone
dominant) administration ofmifepristone are numerous.
The endometrial effects of early luteal phase administration of antiprogesterones have
been extensively investigated (Swahn et al. 1990; Gemzell-Danielsson et al. 1996;
Cameron et al. 1996). Early luteal phase administration of a single or multiple doses of
mifepristone disrupts endometrial maturation without affecting vaginal bleeding
patterns. Treatment with early luteal phase mifepristone chronologically retards the
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development of the secretory endometrium with glandular contraction, reduced luminal
secretions and a decreased number of vacuolated cells (Swahn et al. 1990; Gemzelle-
Danielsson et al. 1994a). In the early luteal phase mifepristone inhibits progesterone
induced down-regulation of PR and ER (Berthois et al. 1991; Gemzelle-Danielsson et al.
1994a; Cameron et al. 1997) while antagonising the progesterone action on endometrial
markers such as PGDH, which are known to be progesterone dependent (Casey et al.
1980; Greenland et al. 2000). Moreover, PGDH has been postulated as a useful marker
of the "closure" of the implantation window, and the effect of mid-luteal administration
on such markers may add to our current understanding of potential contraceptive actions
of mifepristone. Antiprogesterone also increase AR expression in both glandular and
stromal compartments (Cameron et al. 2000; Slayden et al. 2001). Furthermore, when
200 mg mifepristone is administered immediately following ovulation, uterine PGF2a
release (Gemzell-Danielsson et al. 1994b), the luminal expression ofCOX-2 (Marions et
al. 1999), and the glandular expression of leukaemia inhibitory factor (LIF: a cytokine
involved in implantation process) are significantly reduced, while the immunoreactivity
of Ki67 (a nuclear marker of cellular proliferation) is increased (Cameron et al. 1997).
The reduction in the endometrial metabolism of oestradiol (Maentausta et al. 1993), and
the reduction in the markers of endometrial maturation (Gemzelle-Danielsson et al.
1994a) suggest that early luteal phase treatment with mifepristone inhibits the normal
secretory transformation of the endometrium.
In the mid-luteal phase, mifepristone at a single dose of more than 50 mg induces
menstrual bleeding within 72 hours (Greene et al. 1992; Schaison et al. 1985; Shoupe et
al. 1987). Luteolysis was incomplete in two thirds of the subjects, and they experienced
a further episode of vaginal bleeding at the expected time of menses. In the remainder
there was complete luteolysis with only one episode of bleeding. Thus the vaginal
bleeding observed after mifepristone without a persistent decrease in the circulating
progesterone values, appears to be due to a direct effect on the endometrium.
Observations similar to those seen before menstruation such as shrinkage of glandular
lumen, leucocyte infiltration and vascular necrosis have been reported (Li et al. 1988;
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Swahn et al. 1988). Johannisson et al. in 1988 suggested that the menstrual bleeding
induced by mifepristone in mid-luteal phase is a direct endometrial vascular effect.
Following treatment with 50 mg of mifepristone in the mid luteal phase (days 20 - 23),
they described a significant reduction in the capillary luminal area and diameter
associated with degenerative changes in the endothelial cells, which preceded the
menstrual shedding. They interpreted the decreased capillary luminal area as
vasoconstriction. These changes did not always accompany regressive changes in the
adjacent stroma. This effect of mifepristone on the endometrium (at a time when the
endometrial progesterone receptor level is relatively low) is poorly understood, and has
hardly been investigated. Mifepristone may induce bleeding by increasing local
concentration of prostaglandins, which are potent vasoconstrictors. Indeed, the evidence
is available for similar action ofmifepristone on local PG in the early pregnancy where it
has been known to reduce the PG metabolising enzyme PGDH (Cheng et al. 1993a).
Moreover, in the early-luteal phase progesterone values are relatively low, and as a
consequence the PR and ER expression is maximal, while the converse is true for the
mid-lueal phase of the cycle. Therefore, in the early luteal phase mifepristone may
prevent the effects that are yet to be exerted by progesterone, whereas in the mid-luteal
phase it may antagonise the actions of progesterone, which at that time appears to be the
suppression of release of PGs.
When given as a daily pill, the threshold dose of mifepristone required to disturb the
endometrial development appears to be 1 mg/day (Batista et al. 1992b; Croxatto et al.
1993). 5 mg weekly dose will also be sufficient to inhibit the normal secretory
development of the endometrium (Gemzelle-Danielsson et al. 1996).
In the absence of progesterone, mifepristone induced agonist-like secretory changes in
the oestrogen primed postmenopausal endometrium suggests it to be a partial rather than
a pure antagonist (Gravanis et al. 1985).
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1.7 Contraceptive potential ofmifepristone
Progesterone is essential for the establishment and the maintenance of pregnancy, thus
the anti-progesterone mifepristone has multiple potential anti-fertility actions.
Mifepristone is potentially contraceptive by virtue of its effects either on the
hypothalamic-pituitary-ovarian axis, and/or, by direct effects on the uterus. The
hypothalamic-pituitary effects are particularly apparent in the follicular phase of the
cycle, where mifepristone in large doses inhibits gonadotrophin secretion, consequently
arrests follicular-growth and prevents or delays ovulation (Shoupe et al. 1987; Permezel
et al. 1989; Stuenkel et al. 1990). The endometrial effects are largely confined to the
luteal phase. Mifepristone is able to retard the normal endometrial development or to
induce endometrial shedding depending on the time of administration in the luteal phase.
Moreover, the recently reported actions ofmifepristone on the embryo, sperm and tubal
function, may also have additional contraceptive effects(Yang et al. 1994; Baldi et al.
2000; Spitz 2000).
The use ofmifepristone in the following contraceptive options has been explored.
1.7.1 Occasional menstrual regulation
Some have suggested using mifepristone early in the pregnancy when mestruation is
delayed (up to 6 weeks of gestation) as a method of contraception. Women, even after
having sexual intercourse during the fertile period of the cycle do not fall pregnant each
month. Therefore, a menstrual regulatory agent that has to be taken occasionally (only if
the conception had occurred and menstruation is delayed) can be attractive to some.
However, this approach of using mifepristone alone to interrupt a pregnancy in the first 6
weeks was neither very effective (success rates about 85%) nor acceptable to many
women (Couzinet et al. 1990; Spitz et al. 1993a; Glasier et al. 1998). Some reports have
suggested that if given in combination with a prostaglandin to women with menstrual
delay of up to 11 days, mifepristone may have a role as an occasional 'menstrual
regulator' (WHO 1995), while others have shown that this regimen is ineffective when
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given at the expected time of menses (Dubois et al. 1988; Swahn et al. 1999). Although
this method has an important practical implication in those countries that allow
menstrual regulation even when abortion is prohibited, its legality or acceptability in
general is likely to be limited.
1.7.2 "Once-a-month " lutealphase administration
Mifepristone may prevent implantation in luteal phase either by preventing the
development of the normal secretory endometrium, or by inducing endometrial shedding
(mid luteal phase). When administered immediately following ovulation, although able
to alter the endometrial development causing a delay in the emergence of the
implantation window, a single-dose of mifepristone 200 mg did not affect the menstrual
cycle length (Swahn et al. 1990). Preliminary results of clinical trials have confirmed the
contraceptive efficacy of this approach. In the first study, after taking 200 mg of
mifepristone on day LH+2 only one pregnancy occurred in 124 cycles, in which women
were exposed to the risk of pregnancy (Gemzelle-Danielsson et al. 1993). Although
many women find this approach to be an attractive option, the feasibility of
administering mifepristone in this manner is deterred by the requirement of precise
detection of the LH surge. An easy, highly effective, and cheap method to define the LH
surge (probably in a urine sample) would be necessary for this approach to be suitable
for wide-spread use.
1.7.3 "End ofthe month " regular late lutealphase administration
Although a simpler, and more practical approach to the above, since it will induce
menstrual bleeding at the expected time of the month (Croxatto et al. 1987), the existing
data on the contraceptive efficacy of mifepristone as a regular 'end of the month pill' in
the late luteal phase are disappointing. Reported failure rates of approximately 5% per
treatment cycle and 17% - 19% per pregnancy cycle (Ulmann et al. 1987; Dubois et al.
1988; Couzinet et al. 1990; Reviewed in Swahn et al. 1996b), are comparable to the
failure rates of mifepristone when used on its own to terminate early pregnancy.
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Addition of 400 pg misoprostol to 200 mg mifepristone used regularly at the expected
time ofmenses did not improve the success rates (Swahn et al. 1999).
1.7.4 Emergency contraception
In theory mifepristone approximates the 'ideal' emergency contraceptive. If unprotected
intercourse occurs before ovulation it is able to prevent pregnancy by delaying ovulation.
Conversely, if unprotected inctercourse occurs after ovulation, mifepristone may prevent
implantation via its endometrial action. Two randomised trials comparing 600 mg of
mifepristone with the standard Yuzpe regimen of combine oestradiol and Levonorgestrel
have confirmed its efficacy as an emergency contraceptive, when given within 72 hours
of unprotected intercourse (Webb et al. 1992; Glasier et al. 1992). They also reported a
significantly low incidence of side-effects with mifepristone. However, the main draw¬
back with this dose is the delay in the onset of subsequent menses, presumably when it
was administered in the follicular phase. Reassuringly, a recent large multi-centre study
comparing 10, 50, or 100 mg doses ofmifepristone reported that the delay in the onset of
the next menses and the side effects are dose-related, and the reduction of the dose to 10
mg did not compromise the efficacy (WHO 1999).
1.7.5 "Once-a-week" use
Weekly doses of either 2.5 mg or 5 mg mifepristone can delay endometrial maturation
and the appearance of progesterone dependent markers of the endometrium, without
affecting ovulation, hormonal profile or the menstrual cycle (Gemzell-Danielsson et al.
1996). However, in unprotected women the regimen of 5 mg every week failed to
demonstrate efficacy in preventing pregnancy (Marions et al. 1998). When the weekly
dose is increased to 10, 25 or 50 mg a considerable disruption of the menstrual pattern
was observed with inconsistent inhibitory effect on ovulation (Spitz et al. 1993b & 2000;
Chen et al. 1997). In view of this data, intermittent administration of mifepristone has
been abandoned as a potential contraceptive method.
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1.7.6 Daily low dose and cyclical administration
Continuous daily doses of above 2 mg ofmifepristone reproducibly suppresses ovulation
(Ledger et al. 1992; Corxatto et al. 1993) and, clinical trials have confirmed its
contraceptive effect (Brown et al. 2002). A 5 mg dose consistently inhibits ovulation,
while ovulation was permitted in 10% of the cycles with 2 mg dose. However, probably
due to the additional anti-fertility effect on the endometrium, both doses are effective as
contraceptives (Ledger 1992; Corxatto et al. 1993). When women either took 2 or 5 mg
mifepristone daily as their only method of contraception, there were no pregnancies in
the 200 months of treatment (Brown et al. 2002).
Cyclical daily regimens ofmifepristone in doses of 5 or 10 mg for the first 15 days of the
cycle followed by a progestin for the subsequent 14 days had been tested with the view
to produce a more 'natural' regular bleeding pattern. Although this regimen resulted in a
regular bleeding pattern as expected in a significant number of patients, it did not
suppress ovulation (Croxatto et al. 1996 & 1998). Furthermore, the contraceptive
efficacy of this approach remains to be investigated.
1.7.7 Male contraception
Mifepristone opposes the effects of progesterone on calcium influx, sperm motility and
the acrosome reaction by inducing a rapid, transient, and dose dependent decrease of
intracellular free calcium and a drop in the fraction of hyperactivated sperm (Yang et al.
1994). This approach however, has not been pursued because of difficulty in reproducing
these results.
1.7.8 Other clinical uses ofmifepristone
Mifepristone has been widely used for pregnancy termination in the first and second
trimester and it is licensed for this use in many countries in the world. The other possible
uses of mifepristone include induction of labour, cervical ripening prior to suction
termination of pregnancy or surgical intervention of the uterine cavity such as
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hysteroscopy, for the treatment of endometriosis, fibroids, and progesterone receptor
positive breast cancer. Potential non-gynaecological uses of mifepristone include
reduction of intra-ocular pressure in glaucoma and steroid induced myopathy, treatment
for PR positive brain tumours such as meningioma, and Cushing's disease due to ectopic
ACTH secretion or adrenal carcinoma. These effects reported are believed to be
secondary to its anti-glucocorticoid properties (Sakar 2002).
1.8 Emergency Contraception
Emergency contraception is defined as the use of a medication or a device to prevent
pregnancy once sexual intercourse had occurred (Glasier & Baird 1997) yet many
perceive EC as abortifacients. This is because the action is taken after, rather than before
intercourse. However, the definition of an abortion is interference with a pregnancy after
implantation and, the time from ovulation to implantation takes an estimated seven days.
Since the ovum, once ovulated, is capable of being fertilised for only up to 24 hours, use
of an EC within 72 hours of sexual intercourse (that is responsible for fertilisation)
cannot induce an abortion. Nevertheless, this confusion and misinterpretation among the
providers and the users of EC may be the main impediment to the widespread use of
emergency contraceptives, which could prevent millions of unwanted pregnancies in the
world (Trussell et al. 1992). A detailed understanding of the precise mechanism by
which an emergency contraceptive prevents a pregnancy can be advantageous in
clarifying these misconceptions.
Unfortunately, the exact mechanism of action of most widely used emergency
contraceptives is still poorly understood.
1.8.1 Methods available
Not using a contraceptive at all or failures in a method used (e.g.: burst condom) are
common reasons for a woman to seek emergency contraceptives. Today, the available
methods of post-coital contraception in the UK include Yuzpe regimen of a combination
of oestrogen (ethinyl oestradiol) and progestin (Levonorgestrel), progestin alone
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(Levonorgestrel) and the emergency insertion of intrauterine device (IUD). Although the
methods involving steroid hormones eclipse the highly effective yet inconvenient IUD in
post coital contraception, they are associated with high incidence of side effects. The
data available on the safety of these regimens when used as EC are limited, yet at least
theoretically they appear to be extremely safe. All the above regimens can be used as
long-term contraception and there is an abundance of data indicating their safety when
used in these ways (reviewed by Turner & Ellerston 2002). Furthermore, WHO and the
US Food and Drug Administration, have declared that EC has an excellent safety profile
in nearly all women. In their review of EC safety, Turner et al. went on to suggest that
whether carried to term or terminated, an unwanted pregnancy is more hazardous to the
well-being of the woman than the risks posed by taking EC.
1.8.2 Efficacy of EC
Generally efficacy of EC is defined as how well the method prevents pregnancies in
ideal conditions. There are no placebo-controlled trials quantifying the efficacy of
emergency contraceptives. Conventionally, the effectiveness of emergency contraceptive
methods have been calculated by comparing the observed number of pregnancies with
the number expected in the absence of treatment (Yuzpe & Lancee 1977; Ho et al. 1993;
Glasier et al. 1997; WHO 1998). In most studies to date, the anticipated number of
pregnancies is estimated by using external data based on two studies of couples planning
pregnancy (Barrett & Marshall 1969; Wilcox et al. 1988). The two studies calculated the
probability of pregnancy resulting from unprotected intercourse on a particular day of the
cycle, relative to the predicted day of ovulation. This approach poses some obvious
problems. Only women with regular cycles can be used to estimate the efficacy; the
validity of the results is directly dependent on the accuracy of the reported menstrual
data; the estimates are sensitive to errors in identifying the day of ovulation (Dunson et
al. 1999); other factors can affect the probability of pregnancy (e.g. was there an actual
spillage of semen, fertility of the couple) that are unrelated to the timing of intercourse
(Schwartz 1980) and conception is used synonymously with implantation, not
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fertilisation (Trussell et al. 1998). It has been suggested that the true effectiveness of EC
may be higher than the calculated figure for the following reasons; the estimated number
of pregnancies tend to be smaller since the estimates are based on studies which are
deficient; the number of pregnancies observed tend to be higher due to women either
being pregnant at the time EC was administered or they become pregnant by a
subsequent act of intercourse (Tmssell et al. 1998). Conversely, the argument remains
that the effectiveness has been overestimated because the risk of pregnancy without EC
is less than that calculated from Dixon / Wilcox tables. The women in Dixon / Wilcox
estimates were trying to get pregnant, without any history of infertility and had regular
menstrual cycles. Many women who present for EC are not at risk because they are
nowhere near ovulation, and they may not have had vaginal intercourse with sperm in
the vagina. Thus the effectiveness of EC may be overestimated.
Table 1.1 illustrates the reported efficacy of the different methods.
1.8.3 Mechanism of action of emergency contraceptives
An emergency contraceptive can be effective by inhibiting or disrupting ovulation /
fertilisation, interfering with the transport of the blastocyst, or inhibiting its implantation
in the endometrium. Sex steroids have several effects on the ovulatory cycle and on the
endometrium depending on the time of administration, hence have been used as
emergency contraceptives.
Today, a quarter of a century since its initial discovery, the mechanism by which Yuzpe
regimen (Yuzpe & Lancee 1977) acts as an EC remains unclear. Although different
theories are on offer, based on reported effects after administering the Yuzpe regimen
such as, interference with ovulation (Ling et al. 1983a; Rowlands et al. 1986; Swahn et
al. 1996a; Croxatto et al. 2002), or disrupting endometrial maturation (Ling et al.
1983b), they appear to be insufficient to fully explain the observed clinical efficacy of
the regimen (Tmssell & Raymond 1999). The minor changes observed in the
endometrium
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during the implantation period following Yuzpe {changes in endometrial ER and PR
(Kubba et al. 1986), MUC-1 expression (Raymond et al. 2000), minor morphological
changes (Raymond 2000)} are inconsistent (e.g Swahn et al. 1996b; Marion et al. 2002)
and may even be incapable of preventing implantation.
1.8.4 LNG as an emergency contraceptive
Two consecutive doses of Levonorgestrel (LNG) 0.75 mg administered 12 hours apart
within 72 hours of the unprotected coitus, has been shown to be an effective method of
post coital contraception (PCC). This regimen acquired a licence as an emergency
contraceptive in the UK during the latter part of the year 2000. It is also being used for
this purpose in Eastern Europe, the Far East and many developing countries. There have
been only 2 trials (Ho et al. 1993; WHO 1998) published to date comparing the efficacy
of this regimen with the standard method of emergency contraception, the Yuzpe
regimen. The two studies showed that LNG performed effectively as an emergency
contraceptive and had fewer side effects than the Yuzpe regimen. Neither of the two
studies was designed to identify the possible mechanism(s) of action by which LNG
exerts its post-coital contraceptive effect. Hence, the mechanism of action of LNG used
in this manner remains unknown. Furthermore, in some countries, introduction of EC
requires evidence on mechanism of action that suggest further exploration into the effect
ofLNG would be advantageous.
1.8.5 Possible EC mechanisms of action of LNG
1.8.5.1 Effect ofLNG on theLH surge, ovulation & lutealfunction
In physiological doses progesterone initially promotes the oestrogen elicited mid-cycle
LH surge in oestrogen treated ovariectamised women (Odelle & Swerloff 1968), and in
women with intact ovaries (Permezel et al. 1988). Long-term administration however,
enhances the negative feedback effects of E2 (Dierschke et al. 1973; Clifton et al. 1975;
March et al. 1981). In combination with oestrogen, continuous administration of
progestin (in the form of COCP) abolishes the pre-ovulatory LH surge and suppresses
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the LH levels down to those observed during the luteal phase (Swerdloff et al. 1968;
Klopper et al. 1973). The Yuzpe regimen also has been shown to suppress or delay the
LH surge and ovulation (Croxatto et al. 2002). On their own, synthetic progestins
(Norgestrel) at supra-physiological doses have been shown to abolish the mid cycle LH
surge leading to anovulation and delay of the onset of the subsequent menses (Weiner et
al. 1975). The lowest plasma level reported to inhibit ovulation appears to be 1 nmol/L
(Nilsson et al. 1980). Repeated supra-physiological doses of (0.75 mg) LNG in the peri-
ovulatory phase of the cycle delayed the LH surge and disrupted ovulation and normal
luteal function in some women (Landgren et al. 1989). Others have also reported a
decrease in the mid-luteal LH surge after treatment with LNG in the follicular phase,
with the exception of some women this was associated with a normal luteal phase
pregnanediol excretion (Kessaru et al. 1974; Sopna et al. 1975; Marions et al. 2002).
Progestins suppressed FSH induced E2 production by rat granulosa cells in culture
(Schreiber 1980; Fortune 1983), decrease synthesis of oestrogen pre-cursor
(androstendione) and inhibit follicular development in monkeys, despite FSH
enhancement (Goodman et al. 1982; Weibe et al. 1984). These observations suggest that
the pre-ovulatory administration of LNG may interfere with the E2 signal that precedes
the LH surge.
During the luteal phase of the cycle, progestins depress basal LH secretion (Weiner et al.
1975). In the human, basal level of Lutenizing Hormone (LH) is essential for the normal
secretory function of the corpus luteum (Vande Weile et al. 1970). In 1971 Johansson et
al., suggested that synthetic progestins may have a possible post ovulatory contraceptive
effect by interfering with normal luteal function and decreasing plasma progesterone.
Many have reported a shorter luteal phase after progestin administration, which
accompanied a lower than usual luteal progesterone production (Johansson 1971;
Kessaru et al. 1975; Durand et al. 2001).
Table 1.2 illustrate the effects of synthetic progestins on the menstrual cycle reported in
the literature.
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1.8.5.2 Effect ofLNG on endometrium
The main effects of short-term administration of LNG on the endometrium seem to be
secondary to the delaying of ovulation. Landgren and colleagues (Landgren et al. 1989)
showed that follicular phase administration of multiple doses of 0.75 mg LNG
suppresses the secretory activity of the endometrium. However, the same dose of LNG
did not affect the endometrium when given in the luteal phase. Glandular atrophy,
stromal decidualisation and epithelial cell inactivation have been observed after chronic
local exposure of the endometrium to LNG (Pakarinen et al. 1995). Locally administered
LNG also induces expression of the potent contraceptive glycoprotein Glycodelin A
during the implantation period (Mandelin et al. 1997). At high doses (20 - 40 ng/ml)
progesterone inhibits the growth of human capillary endothelial cells in culture (Peek et
al. 1995). Similarly, although LNG stimulates angiogenesis in the dose range 100 pmol/1
to 10 nmol/1, this effect was reversed at higher doses (Hague et al. 2002). Recently,
Marions et al. reported that the emergency contraceptive dose of LNG administered in
the peri-ovulatory period did not change any of the endometrial parameters including
integrin a4 and p3 (these are surface receptors for extracellular cell adhesion proteins to
cytoskeletal components and are involved in blastocyst implantation), COX 1, COX 2,
progesterone receptors, pinopodes and Dolicos biflorus agglutinin lectin binding
(illustrates the secretory activity of the endometrial cells) (Marions et al. 2002).
Therefore, the question remains as to whether any alterations occur in the endometrium
after taking the emergency contraceptive regimen of LNG at other times in the cycle, and
whether those changes are sufficient to prevent implantation and contribute to the
observed contraceptive efficacy ofLNG used in this manner.
1.8.5.3 Effect ofLNG on cervicalmucus
The endocervical mucosa of the human uterine cervix consists of pockets of columnar
epithelium (comprises different types of secretory cells) forming the so called 'crypts'
that vary in structure with age, disease and stage of the menstrual cycle. The secretions
from these cells (principle component of the cervical mucus) are regulated by the
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circulating ovarian hormones, thus show a cyclical variation. Oestrogens stimulate
secretion of acellular, elastic, watery mucus, and progesterone blocks the oestrogen-
induced secretory activity of the cervical mucosa to produce a cellular, viscous, scanty
mucus that is hostile to sperm. It has been proposed that cervical mucus plays several
key functions including: aiding sperm penetration at or near ovulation while interference
with entry at other times; protecting sperm from the hostile vaginal environment;
supplying nutrients; selecting sperms (by working as a filter) on the basis of differential
motility; storing sperm; and initiating sperm capacitation (WHO laboratory manual
1992). The effect of progestagens on cervical mucus and on the cervix is well
documented and this is thought to be the main mechanism by which the progestagen
only pill exerts its anti-fertility action (Odeblad et al. 1972; Daunter et al. 1976;
Moghissi et al. 1973). However, to be of an emergency contraceptive significance, these
effects require treatment to be initiated relatively early once intercourse has taken place.
The transportation of sperm from the vagina to the fallopian tube seems to be extremely
rapid (Kuntz et al. 1996), so even if LNG has an effect on cervical mucus that interferes
with sperm penetration, that action is unlikely to prevent a pregnancy when taken some
12-72 hours after coitus.
1.8.5.4 Effects ofLNG on the sperm
Although it is widely accepted that progesterone has an important role in sperm function,
the precise mechanism by which it exerts this action is not known. In order to fertilise
the ovum, the spermatazoa is required to penetrate through the cumulus mass and
progesterone is a main secretory product of the cumulus matrix. Progesterone stimulates
a rapid influx of calcium into the spermatozoon via a non-genomic action (Plant et al.
1995; Tesarik et al. 1996; Aitkin et al. 1996), induces an acrosomal reaction (Oehninger
et al. 1994), and increases hyperactive motility of the sperm (Uhler et al. 1992). An
impaired response of the spermatozoon to progesterone is a clinically well-recognised
defect in the infertile male (Tesarik et al. 1992; Falsetti et al. 1993). Given their total lack
of transcriptional ability, it would appear that in the sperm the non-genomic
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progesterone receptor would have to be responsible if LNG were to have an emergency
contraceptive effect.
1.9 Patient Compliance
1.9.1 Definitions and history
Generally, compliance is defined as yielding; complaisance; or submission (Chambers
dictionary), hi a clinical context, it is described as following the instructions of the health
care professional (Haynes 1979) and is synonymous with adherence; maintenance;
fidelity and concordance (Sackett 1976). Most of these definitions denote obedience -
"following doctors orders". Therefore, the word "compliance" can be associated with
somewhat 'negative' connotations for the patient. If the patient perceives the very
concept of compliance as one that is morally and psychologically flawed, non-compliant
behaviour can be as deviant as compliance in itself (Mullen, BMJ editorial 1997).
However, to the prescriber, these definitions explain the patient's behaviour and, also
describe the relation between prescription and the clinical outcome (Eisen 1991).
Patient adjusting or discontinuing the therapeutic regimen without professional medical
advice is not a novel concept. Rather, it dates back to the period before Hippocrates
(Wright 1993). Therefore, human nature may be at blemish for individuals selecting to
follow the many deviations in the prescribed therapeutic plan. Whatever the reason is,
non-compliance has serious implications for drug regulation, research and medical care.
1.9.2 The magnitude of the problem of non-compliance
Medicines are rarely taken as prescribed (Marinker 1997). This may adversely affect the
quality of medical care and may waste resources. Over 50% of the patients suffering
from chronic disease do not take the prescribed medicines in doses sufficient to achieve
the therapeutic effect (Sackett 1979). Reflecting on their own adherence behaviour, a
group of health care professionals who formed a working party on medicine taking
admitted that their behaviour rarely coincided with the prescribed medical advice
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(Marinker 1997). In any medical discipline, non-compliance disrupts and mitigates the
benefits of the preventative or curative regimen offered. Since the medical profession is
reportedly poor in identifying non-compliers (Gilbert et al. 1980; Bonner & Carr 2002),
consequences of non-compliance can lead to unnecessary diagnostic tests or additional
treatment procedures, thus generating further financial wastage. In 1995 Rosenburg and
colleagues estimated $2.6 billion as the cost associated with unintended pregnancies that
occurred due to poor compliance with the oral contraceptive pill.
Non-adherence to a protocol can have an undesirable influence on study power and
interpretation of results. When undetected, poor compliance can invalidate results of
efficacy studies (Rudd 1991; Urquhart 1991; Dominik et al. 1999).
Although many investigators have shown an active interest in the field of patient
compliance since mid 1960's, the ambiguity and the divergence in their viewpoints have
only confused our current understanding of the nature and the extent of the problem.
Compliance has been described in terms of problems of omission (e.g.; failure to report
an event, failure to take a medicine or to report an adverse effect) or commission (e.g.;
inaccurately over reported events, overdose) (Green et al. 1991). It can be linked to the
clinical outcome as either the cause (e.g.; a reason for a medicine that is effective for a
certain population being labelled as ineffective) or the effect (e.g.; side effects of a
treatment causing patients to be non-compliant with the regimen) (Hurley 1991). Patient
and behavioural parameters (age, life style (Potter 1991; Rapoff & Barnard 1986;
Meichenbaum 1987)), regimen parameters (dose interval, route of administration (Puller
et al. 1988; Rapoff 1989; Cromer et al. 1989)) and response feedback parameters (side
effects, positive drug effects) are recognised by some as the determinants of compliance
(Haynes 1979; Hurley 1991).
Unfortunately, this renewed interest has not delivered the desired new concepts for
improving patient compliance, yet it seems unfair to criticise the studies that explored
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the issue of compliance for their poor methodology. There is a lack of sound techniques
to quantify compliance. The existing knowledge of quantitative and qualitative features
of non-compliance behaviour that is prerequisite for a 'good' study design has been
limited. Thus future research should be directed towards rectifying these deficiencies.
Otherwise, it is difficult to conjecture progress.
1.9.3 Measuring and monitoring compliance
There are direct and indirect methods of quantifying compliance yet limitations exist in
all these methods.
1.9.3.1 Direct methods
Direct observation of the patient ingesting a medicine, biologic parameter affected by the
medication and physiologic changes induced by the medication, therapeutic drug
monitoring using blood or urine tests, unannounced spot checks on patients, and clinic
attendance are used in various instances as methods to measure compliance directly
(Spilker 1991).
Direct observations by the investigator is only suitable for inpatient studies and a few
studies where the patients are required to attend the clinic to obtain infrequent doses of
medicines. In our study patients took the 200 mg of mifepristone tablet under the direct
supervision of the investigator. Even under these exceptional conditions, some patients
can still be non-compliant (e.g.; pretend to put the medicine in the mouth but spitting it
out later) (Spilker 1991). Furthermore, methods such as measuring biological markers
and drug levels in biological fluids cannot disclose the chronic adherence behaviour and
several other variables apart from compliance may affect pharmacokinetic values
(Cramer 1990). Spot checks in particular are a potential invasion of patient's privacy.
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1.9.3.2 Indirect methods
Patient self-report (SR), pill counts (PC), the frequency of obtaining repeated
prescriptions and a variety of electronic devices (For example; devices that monitor self
testing of daily urine or record removal of each tablet) have been used to ascertain
compliance indirectly (Pullar 1988; Waterhouse et al. 1993; Simmons et al. 2000).
Although SR remains the most widely used tool measuring compliance in clinical
practice and in research, many have reported significant overestimation of compliant
behaviour with SR (Potter et al. 1996; Waterhouse et al. 1993; Simmons et al. 2000). A
group of OC users self reported missing only 34% of the pills, when the data from an
electronic device with diary entries showed 75% of the pills being missed (Potter 1996).
Similarly, when compared to a micro-electronic monitoring system, traditional measures
(SR and pill counts) significantly over estimated the adherence behaviour in a group of
women receiving oral tamoxifen for treatment of invasive breast cancer (Waterhouse et
al. 1993).
Anyhow, finding a method that measures compliance efficiently and that can be applied
universally is just the beginning. One has to then, find a reference point in compliance,
to discern compliers from non-compliers.
1.9.4 Non-compliance in research studies
Poor patient compliance is one of the most commonly overlooked problems in clinical
research (Dahlstrom & Eckernas 1991). If undetected, it can make the results of a
clinical trial invalid. Furthermore, the results from a compliant patient population may
not be appropriate to extrapolate to a non-compliant group and vice versa (Dominik et
al. 1999). The significance of the occurrence of non-compliance with a particular aspect
of a trial depends on its relationship to the outcome. Though it is irrefutably wrong to
overlook the issue of non-compliance in our approach to patient care, due to the complex
nature of behaviours that involves, many doctors and investigators choose to ignore it
completely.
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Randomised controlled trials may not necessarily recreate or mirror clinical practice in
general. They are highly artificial scientific endeavours hence; their interpretation is
dependent on the possibility of the scientific principle being applied in the clinical
setting (Hurley 1991). However, common sense suggests that the prevalence of non-
compliant behaviour is likely to rise in the general population compared with that of a
typical research study.
For a volunteer, taking part in a research study usually involves extra effort. Volunteers
in clinical trials are required to attend extra clinics, answer questions, collect samples
such as daily urine, allow invasive tests such as blood tests, and keep accurate records of
daily events in order to comply with the study protocol. People volunteer for research
studies for various reasons. Some may seek positive health benefits from a 'new'
treatment in a study, and this may become their motivation to volunteer. However, in
most randomised trials with a control arm and in preliminary biomedical studies the
participants are aware that they may not experience a favourable effect from the
treatment. They may expect other benefits; such as health screening, individual attention
from health care professionals, first-hand knowledge into new discoveries, and financial
gains; or they may just be altruistic. Anyhow, if the volunteer perceives the sacrifices
necessitated by being involved in a research study to be more burdensome than their
perception of the personal or other benefits of the study, non-compliance will be
inevitable.
Even though non-compliers are more likely to withdraw or drop out from a study, they
should not be excluded from the analysis of phase III trial results. The dropout rate may
indirectly provide extra information on the true effect of a treatment regimen that can be
expected in general use. In phase I trials however, non-compliance can affect the
findings thus non-compliers may be withdrawn.
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1.9.5 Compliance with contraceptives
Naturally, an improved understanding of the causes of non-compliance can aid in finding
means to achieve better compliance. In order to introduce a new contraceptive method
successfully, effort must be made to minimise "adverse events" and particularly side
effects, in order to maintain a good level of compliance. What factors will interest
women in a new method of contraception and encourage them to continue using it?
Conversely, what will confound its success and dissuade women from using it?
Inferences can be drawn from the information on acceptability of existing contraceptive
methods among different groups. We can assume that life-stage, age, level of education
and personal experience might play an important role in women's knowledge of and
attitudes towards contraception. Moreover, the reliability, accessibility, and minimal
interference with sex life may be major motives for the choice of contraceptive.
The psychosocial literature on health behaviour concludes that the "health belief model"
is the best explanation for non-compliant behaviour undertaken by a healthy person
(Kasl & Cobb 1966). If this model is applied to the contraceptive compliant behaviour,
following key elements have to be recognised.
1. The users perception of their own susceptibility (probability) of pregnancy.
2. Their attitude towards pregnancy and the perception of severity of the consequences
of pregnancy (physical, financial, psychological and social).
3. Their personal definition of compliance and understanding of the importance of
perfect compliance.
4. Their perception of the effectiveness of the contraceptive method if properly used.
The users of contraceptive regimens are usually young and healthy and, for the
individual, the serious outcome of non-compliance (pregnancy) is rare. They have to
adhere to a contraceptive regimen on a long-term basis. They may find the daily
requirement for medication taking as in oral contraceptive pills or daily urine testing as
in Personal Hormone Monitoring device to be complicated or inconvenient. Side effects
of the method may not be acceptable and, they may not have faith in the effectiveness of
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the method. Considering these odds, it is not difficult to infer why compliance problems
are frequent.
Most of the literature on contraceptive compliance is concentrated on the combined oral
contraceptives (COC). For example, Emans and colleagues showed that among
adolescents COC non-compliant behaviour was more pronounced (only 48% compliant)
in inner-city teenagers attending a hospital clinic than among their suburban upper
middle class counterparts (over 84% complaint with the COC) visiting a private clinic.
Although several other patient characteristics have been associated with COC non¬
compliance (Rosenburgh et al. 1995a & 1995b), the relevance of these findings in other
contraceptive use is open to question.
1.10 Detecting the fertile period of the cycle and ovulation
A simple and reliable means of ovulation detection will be invaluable in clinical practice
as well as in research. In a clinical setting this information can be used by couples to
time sexual intercourse in order to avoid or achieve pregnancy. Since the effects of sex
steroids depend on the time of administration in the menstrual cycle, such information
can assist in contraceptive research. An example would be the evaluation of the
endometrial effects of peri-ovulatory administration of LNG.
The length of each menstrual cycle changes to a great extent in the same woman and also
between women. The intra-subject and inter-subject variation of the length of the
menstrual cycle is wide. This makes reliable prediction of the day of ovulation difficult.
Estimates using clinical data have suggested the number of fertile days in each cycle to
be around 6 days, ending on the probable day of ovulation (Wilcox et al. 1995). For
years attempts have been made to identify potential markers of the fertile period, which
would predict and detect ovulation. These include measurement of systemic changes
that accompany the hormonal changes (basal body temperature (BBT) change & cervical
mucus changes), assays of reproductive hormones in serum and urine, assays of cellular
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and secretory elements of endometrium, trans-vaginal sonographic imaging of ovarian
follicular activity, and sonographic evaluation of the vascular and morphological
changes in the uterus.
1.10.1 BBT change
BBT at rest shows a detectable shift of 0.2-0.4° C following ovulation due to the
increasing production of progesterone from the corpus luteum. Hand-held electronic
devices that utilise this temperature change to identify the end of fertile period have been
tested claiming up to 94% agreement with the day of maximum follicular diameter as
determined by ultrasound (Ismail et al. 1989; Flynn et al. 1991). However this method is
neither prospective in estimating the day of ovulation, nor does it identify the onset of
the fertile period.
1.10.2 Cervical-vaginal mucus or saliva changes
Under the influence of circulating sex steroids, the physical characteristics of the cervical
mucus changes, and these changes are employed to prospectively identify the fertile
period (WHO 1980) and to retrospectively estimate the day of ovulation (WHO 1983).
NaCl in the saliva or cevico-vaginal mucus increases cyclically under the influence of
oestrogens. This is responsible for the observed 'ferning' or crystallization pattern of
these secretions that coincides with the fertile period in the cycle. A variety of small
hand-held devices have been developed for the purpose of self-observing ferning
patterns in either saliva or cervical- vaginal mucus. Small microscopes to determine the
ferning in the context of other markers of fertility have been suggested with only limited
success (Fehring et al. 1998).
Further attempts have been made to detect the cyclical volumetric changes in cervico-
vaginal fluid (CVF), which correlate with levels of steroid hormones. By measuring the
CVF volumes using a vaginal aspirator (Rovmeter) and correlating it with serial
ultrasound measurements of the dominant follicle, Flynn et al. showed a consistent CVF
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volume peak occurring the day before ovulation. They went on to demonstrate an abrupt
fall in CVF volume following ovulation, which marked the onset of the infertile phase of
the cycle (Flynn et al. 1988). Although the preliminary work suggests this an attractive,
easy to use and inexpensive method of identifying the fertile period, further development
and larger clinical studies are needed to substantiate these claims.
1.10.3 Hormone assays
It has been known for years that detecting the mid-cycle LH surge is the best marker of
impending ovulation (WHO 1983). However, daily laboratory testing of serum or
urinary LH did not offer a realistic means to be used in the community to detect
ovulation in large scale. The subsequent development of enzyme-linked immuno-
absorbent assay provided the answer with commercially available LH detection kits to
test urine every 6, 12 or 24 hours (Garcia et al. 1981; Kasper et al. 1984; Hirsch et al.
1986; Vermesh et al. 1987). These were simple to use at home, and were rapid and
reliable in detecting the mid-cycle urinary LH surge. However, the LH peak in urine
precedes ovulation by approximately 24 - 48 hours (WHO 1980; Collins et al. 1996),
hence if only LH was used to predict impending ovulation, the possible number of days
of advanced warning achieved would be limited to two.
Further studies have investigated the possibility of incorporating information from rising
levels of oestradiol that accompany the development of the dominant follicle and
precede the LH surge, to make the warning of onset of the fertile period to be of more
realistic length. Several authors identified a positive correlation between the early
morning urinary levels of oestrone-3-glucuronide (E3G), the principal metabolite of
oestradiol and the serum levels of oestradiol (Branch et al. 1982; Catalan et al. 1989). A
rise of >50% of urinary E3G concentration over the mean value of the previous 3 days
will forewarn the onset of the fertile period in between 83% - 90% of the ovulatory
cycles (Aldercreutz 1982; WHO 1983; Schiphorst et al. 1985). Others have suggested
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that it may be possible to use the urinary levels of progesterone metabolites to mark the
end of the fertile period (Blackwell et al. 1998).
In 1999 Bonner and colleagues reported the development of a hand-held device
(Personal system of Contraception or Persona®) as an aid to avoid sexual intercourse
dining the fertile period, and in 2000 Behre et al. described a similar system
(ClearPlan® Fertility monitor) to be used for the opposite effect, i.e. to maximize the
chance of conception by timing intercourse to the fertile period (Bonner et al. 1999;
Behre et al. 2000). Both systems utilise information from E3G and LH levels in early
morning urine to predict the fertile period and to detect ovulation, although they employ
a different monitors, software and urine test sticks. It is fundamental that the algorithms
utilised to warn of the fertile period in the two systems are different, since the
contraceptive device requires a narrower margin of error and therefore indicates warning
of potential fertility for at least 7 days (median 11, range 7-17 days), while the opposite
is true for the pro-conceptive device in order to aid conception (median warning 6 days,
range 0 - 20). The reported detection rate of LH peak (within 2 days ofmonitor indicated
day of peak fertility) is around 91.1%.
1.10.4 Endometrial secretory elements
Biochemical tests of changing concentrations of cellular and secretory constituents of the
endometrium that occur in response to ovarian hormones have been used to detect
ovulation. Seif et al. reported the use of a monoclonal antibody to a cycle-dependent
sialo-glycoprotein (Seif et al. 1989) to identify the peri-ovulatory period. Clearly, more
studies in this direction are needed.
1.10.5 Ultra-sonography
For over two decades ultrasound has been used to monitor follicular growth and to
identify ovulation (Queenan 1980; Vargyas, 1982). The reported ultra-sonic indices of
ovulation include disappearance or sudden decrease of follicle size, appearance of
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ultrasonic echoes in the follicle, irregularity of follicular wall, and appearance of free
fluid in the pouch of Douglas (Ecochard et al. 2000). Disappearance of the dominant
follicular diameter appears to be the most sensitive of the indices with over 84%
specificity and nearly 90% sensitivity (Vermesh et al. 1987; Behre et al. 2000; Ecochard
et al. 2000). The urinary LH surge is also associated with ultrasonic changes in the
uterus, including a continuous rise in endometrial thickness, and a gradual decrease in
uterine artery pulsatility index (Bourne et al. 1996). However, the use of ultrasound is
not suitable for home-use or for population based contraceptive studies.
1.11 Summary
Clinical research carried out to date suggests an urgent need for new methods of
contraception and a need to explore the mechanisms of the existing contraceptives. Side
effects such as unscheduled vaginal bleeding affect the acceptability of a contraceptive
method and the detailed understanding of the mechanism of these side effects enables us
to take appropriate steps to prevent them. The studies conducted as part of this Thesis
aim to further the advancement in contraceptive research in such areas.
In order to explain the mechanism of post-coital contraceptive, we investigated the effect
of LNG on the menstrual cycle and we also assessed the feasibility of using mifepristone
as a once-a-month contraceptive pill.
Although compliance is a fundamental prerequisite for achieving the full potential
efficacy of all drugs, including contraceptives, there is a dearth of information available
on patient non-compliance with the use of different contraceptive methods. We sought to
obtain insight into the compliant behaviour of women taking part in the contraceptive
trial assessing the feasibility of administering once a month mifepristone.
The frequent and regular laboratory assays of steroid hormones in either blood or in
urine have traditionally played a major role in research into female contraception. We
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analysed the use of a personal fertility monitor as a reliable and more simple means to
predict the potentially fertile period by monitoring frequently changing hormone levels.
To investigate the unexplained mechanism of mifepristone-induced endometrial
shedding and vaginal bleeding, we evaluated the effects of mid-luteal phase
administration ofmifepristone on endometrial parameters.
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CHAPTER 2
THE EFFECTS OF PERI-OVULATORY ADMINISTRATION
OF LEVONORGESTREL ON THE MENSTRUAL CYCLE
LNG on menstrual cycle
2.1 Introduction
LNG 0.75 mg administered twice with the two doses 12 hours apart has been shown
to be an effective method of EC when used within 72 hours of unprotected
intercourse (Ho et al. 1993; WHO et al. 1998). Although the regimen is now licensed
in the UK, USA and throughout much of Europe and is widely regarded as the EC
method of choice (Guillebaud et al. 1998), the mechanism of action remains
unknown. The mechanism of action of the Yuzpe regimen of emergency
contraception (ethinyl estradiol 100 meg and 0.5 mg LNG, two doses 12 hours apart,
Yuzpee and Lancee 1977) is also incompletely understood but there is good evidence
that it delays or inhibits ovulation in at least some cycles (Swahn et al. 1996;
Croxatto et al. 2002). In the WHO study (1998) the efficacy of both LNG and the
Yuzpe regimen decreased with time after intercourse (Piaggio et al. 1999) and both
regimens had a similar effect on the timing of the subsequent menses, suggesting that
the mechanism of action of the two regimens may be similar. It has also been shown
that supra-physiological amounts of synthetic progestogens abolish the mid cycle
LH surge leading to anovulation and delaying the onset of the subsequent menses
(Kesseru et al. 1974; Landgren et al. 1990; Craft et al. 1975; Sopna et al. 1974; also
refer Table 1.2).
To test the hypothesis that it acts as a post-coital agent by abolishing the pre¬
ovulatory LH surge and by delaying ovulation, we administered LNG 0.75 mg twice
to 12 healthy female volunteers in the fertile period (immediately before ovulation)
of the menstrual cycle and investigated the effects on the timing of ovulation and of
the next menses; bleeding patterns; ovarian activity and LH concentrations.
2.2 Materials & Methods
This was a prospective, randomised, double blind, cross-over study undertaken in one
centre. Twelve healthy women (mean age 33 (range 26-41 years)) with regular
cycles (mean 27.63 days (range 25 - 30 days) and mean BMI 25.71 (range 20 - 34))
were recruited. They were all using a reliable non-hormonal method of contraception
or were abstinent during the study. All subjects gave written informed consent to
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participation in the study, which was approved by the Lothian Research Ethics
Committee.
A method was sought to provide a convenient means of identifying the fertile period
prior to ovulation, and thereby to time the administration of LNG. A home-use
fertility monitor was used for this purpose. This product is similar to the Personal
System of Contraception (Persona, Unipath Bedford UK) (Bonnar et al. 1999) in that
it monitors E3G and LH in urine, but differs in that it has been specifically designed
for maximising the chance of conception. Unipath Diagnostics Co., Princeton, NJ,
markets the fertility monitor in the US and Unipath Ltd., Bedford, UK markets it in
Britain as ClearPlan Easy Fertility Monitor (CPEFM) (Figure 2.1).
Figure 2.1 ClearPlan Easy Fertility Monitor with a urinary test stick
(LCD on the monitor shows peak fertility).
The system comprises a hand-held monitor and disposable dual-assay urine test
sticks, and is used to simultaneously detect LH and E3G levels in early morning
urine. The monitor optically measures the intensity of the lines that form on the test
sticks after sampling, and the system will delineate three levels of fertility (Low,
High and Peak fertility) according to the optical signal changes detected. Low
Fertility will be displayed from day 1 of the menstrual cycle, until the hormone levels
rise above the baseline levels. A change from Low to High Fertility is triggered by
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detection of elevated E3G levels. The change from High to Peak Fertility is triggered
by the detection of an LH surge. Peak fertility is displayed on the day of the LH surge
and on the following day before returning to low fertility.
Each woman was studied during four cycles, and was issued with a monitor at the
beginning of the study. Subjects were asked to use the CPEFM according to
instructions, and familiarised themselves with the monitors by using it during a pre-
study cycle to identify the days of high fertility and the day of the LH surge. They
also recorded days of vaginal bleeding.
Data from the pre-study cycle was used to predict the timing of the LH surge and of
the fertile phase during the study cycles and thereby to predict when treatment should
be administered. The three study cycles followed immediately after the pre-study
cycle. Six subjects were randomly assigned to treatment arm A and received LNG in
the first study cycle and placebo in the third study cycle. The remaining six subjects
were randomised to treatment arm B and received placebo in the first study cycle and
LNG in the third study cycle. The second study cycle was a "washout" phase for all
women during which time they also received placebo tablets (Figure 2.2).
The randomisation list was produced using SPSS Rv.Bernouilli function such that
each study number was randomly assigned to either treatment arm A or treatment
arm B with the same probability i.e. 0.5.
LNG and placebo were visually identical and were pre-packed. Each subject
collected a sample of early morning urine daily from the first day of the first study
cycle until and including the first day of the menstrual bleed signalling the end of the
last study cycle. Samples were frozen and later assayed in batches (with all samples
from one subject assayed in a single batch) for measurement of urinary LH, E3G and
pregnanediol-3-glucuronide (P3G).
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Figure 2.2 Study design
Quantitative assessment of urinary LH was performed using a LH MAIAclone kit
(BIOSTAT-DIAGNOSTICS, Stockport, Cheshire, UK). This method incorporates
two high affinity monoclonal antibodies into an immunoradiometric assay system
and offers a working range of 1.5 - 200 mlU/ml. Urinary P3G was measured using a
direct enzyme immunoassay sensitive (working range 0.16 ug/L - 20 ug/L), while
direct immunoassay was used to measure E3G levels (working range 8.36 nmol/L -
2140 nmol/L). Intra-assay coefficients of variation were 6% for E3G, 10% for P3G1
and 3% for LH (Yong et al. 1992). Geometric means of daily replicates were divided
by the respective daily creatinine concentration to correct for variations in the
dilution of the urine specimen.
During study cycles 1 and 2 women were asked to take the study medication on the
first day of high fertility as identified by the monitor. However, by the third study
cycle, the variation in the number of High Fertile days (range 0-8 days) meant that
the monitor could not be used to administer medication on LH-2 in every cycle.
Therefore, we had to adopt a different method of calculating the anticipated day of
the LH peak for each cycle based on the monitor information from the previous
cycles (including the pre-study cycle). Hence, in the third study cycle, the medication
was taken two days prior to the anticipated day of the LH peak. In all cycles the first
tablet was taken at 11.00 hours and the second at 23.00 hours. A sample of venous
blood was collected 5-7 days after treatment, stored and later assayed for
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progesterone using Coat-A-Cont solid-phase radio-immunoassay. The subjects kept a
daily record of all vaginal bleeding experienced during the 4 cycles, the fertility
status information displayed each day on the monitor LCD and the days on which the
study medications were taken.
2.2.3 Statistical Analysis
We calculated that a total of six subjects in each of the two treatment arms would
give more than 90% power to detect a delay ofmenses of > 5 days in 95% of cycles.
The sample size calculation indicated that only 2 subjects per treatment order arm are
required for 90% power if we assumed that LNG delayed (> 5 days) the subsequent
menses in 95% of cycles and the menses would be delayed in 5% of cycles after
placebo administration. Since greater numbers were required for the reliability of
estimates and to take account of the fact that the menstrual cycles of subjects may
have been less regular during the study than had been indicated at the recruitment
stage, we recruited 12 subjects.
Preliminary analysis was performed to determine whether parametric tests were
appropriate for analysis of the data. Outlying data points were investigated while the
treatment was still blinded. The period effect and interaction between treatment and
period effect were tested (two sample t-test) before progressing to testing of a
treatment effect and was non-significant. Comparisons between LNG versus placebo
cycles, was tested by paired t-test. Since the data appeared to be skewed a non-
parametric Mann-Whitney U test was performed to compare the difference between
urinary E3G levels on the day of LNG treatment in cycles that had delayed LH peak
and the 8 cycles that did not.
For the purpose of the study the following definitions based on the quantitative data
were created.
A significant delay in the onset of next menses: Delay of 5 or more days from the
expected onset ofmenses (based on the mean cycle length for the 2 placebo cycles).
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The LH peak was defined as a significant rise in urinary LH concentration, with a
minimum of 50% rise above the average baseline level for 4 preceding days and
which remained elevated for a minimum of 3 days.
The first day of the LH peak was defined as the day of the first significant rise
(>50% above the baseline) seen at the beginning of the LH peak.
Retrospectively predicted first day of the LH peak for the treatment cycles was
the calculated mean of the first day of LH peak in the two placebo cycles.
A significant delay in the first day of the LH peak: Delay of 5 or more days from
the expected first day of the LH peak in the treatment cycle (based on the mean first
day of the LH peak during the 2 placebo cycles).
Follicular phase: time from the first day of the menses until the day of the first
significant rise in urinary LH (LH+0) inclusive.
Luteal phase: time from the day after the first day of the urinary LH peak (LH+1)
until, and including, the day before the first day of the next menses.
2.4 Results
A total of 48 menstrual cycles were studied - 12 pre-study cycles and 36 study cycles.
Data from daily urine samples were available for 34 out of the 36 study cycles. In one
woman (SI03) the first study cycle, which was a placebo cycle, was prolonged (41
days) as a consequence of a delay in ovulation. Her usual cycle length was 25 days,
this cycle was excluded from the analysis. In a second woman (SI 10) there were no
daily urine samples available from the washout cycle as she was abroad on holiday.
Therefore, daily urine samples were only available for this subject from two study
cycles (the treatment cycle and one placebo cycle).
2.4.1 Timing of administration of LNG
Six women took LNG in the first study cycle and six took it during the third study
cycle. During the first study cycle, 10 women took the tablet (either placebo or LNG)
on the first day of high fertility as indicated by the monitor. The remaining two
women took the tablet on the first day of the urinary LH peak because the monitor
failed to identify any High fertile days prior to the LH peak.
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The variation in the number of High fertile days (0-8 days) declared by the monitor
meant that the system could not be used to predict LH-2 in every cycle. Therefore for
cycle three we calculated the anticipated first day of the urinary LH peak from the
information gathered from the pre-study cycle and study cycles 1 and 2 for each
woman and instructed subjects to take the tablet two days before the anticipated day
of the LH peak.
After completion of the study, we retrospectively calculated the predicted first day of
the urinary LH peak for every treatment cycle based on the mean of the first day of
LH peak in the two placebo cycles and the pre-study cycle. When we applied this
retrospectively predicted definition to all 12 treatment cycles, the day of taking LNG
ranged from six days before until one day after the first day of the anticipated LH
peak. However, in reality, LNG was never taken after the first significant rise in
urinary LH concentrations in any treatment cycle. The timing of the LH peak in each
of the four cycles, the predicted day of the LH peak day and the timing of LNG and
placebo treatment in relation to the start of the actual LH peak are shown in table 2.1.
2.4.2 Cycle length
Treatment with LNG in the pre-ovulatory period significantly prolonged (by 5 days
or more) the mean cycle length in four women (33 % of the sample, Table 2.2). All
four women reported vaginal spotting two to three days after taking LNG and they all
had a second episode of vaginal bleeding between 9 and 16 days after the delayed LH
peak. In the remaining eight women there was no significant difference in cycle
length between treatment and placebo cycles. One of this group of women however,
reported light vaginal bleeding starting a week after taking LNG, the bleeding
continued until she started what she regarded as a normal menstrual period which
followed a fall in urinary pregnanediol levels. Her hormone profile during the
treatment cycle follows a normal pattern. The four women, who had prolonged
cycles, took LNG on a day when urinary E3G was at a low level when compared to
the remaining 8 women but this difference did not reach significance (8 vs. 19.16
mmol/mol, p = 0.12).
75















































































































++Thewomanithn r alLHpeakbutosignific ntrisipreg an diolthlut lp ase=anovulat rycycle. M=LHpeakmissedbythCPFM **=excluded,unusuallydelayeovulation££=excl ded,noailyurinav ilable *WomenwhohaddelayfthLHpe kby>5da s.
LNG on menstrual cycle
Table 2.2 Mean length ofplacebo and treatment cycles
Mean cycle length Treatment cycles Placebo cycles
All cycles n=12' 32.17 (SD+/-3.36) 26.33 (SD +/-.42)
N = 4, Delay of> 5days2 42.75 (SD +/-8.42) 27.13 (SD +/-1.84)
N = 8, remaining cycles 24.88 (SD+/-2.1) 26.13 (SD +/-1.69)
1. p = 0.14, 2. p = 0.04, 3. p = 0.12
2.4.3 The first day of the LH peak.
In the four women with long cycles, LNG appeared to abort the LH peak and a
subsequent LH peak occurred 7 to 16 days later followed by a normal rise in urinary
pregnanediol. The urinary hormone profile of one-woman (SI 10) is illustrated in
charts 2.1a and 2.1b. In the remaining eight women, LNG did not affect the timing
of the LH peak when taken immediately before ovulation. Chart 2.3 illustrates the
hormone profile in one of these women (S101).
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Charts 2.1a & 2.1b
Daily levels of LH (®), E3G (A), and pregnanediol (O), in urine relative to the cycle
day.
2.1a Placebo cycle of a woman (SI 10).
2.1b Treatment cycle of the same woman (SI 10) showing significantly prolonged
cycle following pre-ovulatory LNG.
\ Day of taking LNG or placebo tablet Day of the LH surge
Menses Vaginal bleeding
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Charts 2.2 and 2.3
Daily levels of LH (®) E3G (A), and pregnanediol (0), in urine during the treatment
cycles,
2.2 Of the woman (SI 05) with no significant rise in pregnanediol following LNG
2.3 Of a women (S101) with apparently normal cycle length
m
■
^ Day of taking LNG Day of the ^ LH surge in the placebo cycle
Day of the LH surge
Day of the cycle
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2.4.4 Length of the luteal phase
In all twelve volunteers the luteal phase was significantly shortened following
treatment with LNG as compared with the placebo cycles (mean length 11.5 days
(SD +/-1.8) vs. 12.9 days (SD +/-2.5) p = 0.005, Table 2.3).
Table 2.3 Length of the luteal phase (n = 12)








105 ++ 11 13.5
106 * 12 12
108 * 10 11.5
109 * 13 16.5
110 * 9 9
++ The woman with normal LH peak but no significant rise in pregnanediol in the
lutealphase = anovulatory cycle.
* Women who had a delay of the LHpeak by >5days.
2.4.5 The effect on total LH during the luteal phase
Daily urinary LH concentrations were summated from the first day of the LH peak
(LH +0) up to the day before the first day of the next menses to give a value for total
LH concentrations. The eight women in whom pre-ovulatory LNG did not affect the
cycle length, showed a significant (p = 0.01) decrease in total LH in the treatment
cycles (18.66 U/mol creatinine (SD +/-8.9)) as compared with the placebo cycles
(27.08 U/mol creatinine (SD +/-13.57)). In contrast among the four women with
significantly longer cycles after taking LNG, there was no difference in the total LH
secretion in the luteal phase (mean total LH = 18.83 U/mol creatinine (SD +/-8.3)
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versus mean total LH for placebo cycles of 17.75 U/mol creatinine (SD +/-2.8) p =
0.81).
2.4.6 Effect on pregnanediol in the luteal phase
Comparing the sum of daily pregnanediol concentrations in the luteal phase (from
LH +1 onwards up to the day before the first day of next menses) during the
treatment and placebo cycles was employed to indirectly assess corpus luteal
function.
In one woman (SI05) after taking LNG, there was no significant rise in urinary
pregnanediol levels (>0.5 mmol/mol creatinine as expected in the mid-luteal phase)
despite an apparently normal LH peak. The mid-luteal serum progesterone level
during this treatment cycle was consistent with an anovulation (<5 nmol/L) (chart
2.2).
In the remaining 11 subjects the total values of pregnanediol did not show a
significant difference between placebo or treatment cycles.
2.5 Discussion
Evaluation of daily hormone concentrations confirmed that all twelve women in our
study took LNG before the LH peak, and before ovulation.
Seven women had apparently normal ovulatory cycles after taking LNG. Five of
them took LNG on the day before the LH surge and one on the day of the surge. It is
possible that the timing of LNG in these women was "too late" to influence an event
already well underway. Recently, others have shown a similar effect when LNG is
taken immediately prior to the LH surge, late in the follicular phase (Durand et al.
2001).
In four women (25%), LNG aborted the LH peak, delayed the ovulation and
lengthened the cycle. All four women took LNG 2 to 4 days before the predicted LH
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surge (based on the two placebo cycles). One woman did not ovulate at all despite
having an LH surge 2 days after taking LNG.
It is apparent that different women respond differently to the administration of LNG.
The effects observed may be related to administering LNG at a specific stage in
follicular development. Even though the timing of the LNG in relationship to the
onset of the LH surge did not appear to be different between women in whom
ovulation was affected and those in whom it was not, it would be nai've to accept that
our predicted day of the LH peak based on information gathered in two cycles was
always accurate. In fact, the four women with delayed ovulation had apparently low
urinary E3G on the day the treatment was administered. This suggests that they took
LNG at an earlier stage of follicular maturation and a similar effect was not seen in
the others who took LNG at a more advanced stage of follicular development. A
more detailed study by Duran et al. also suggested that LNG in mid follicular phase
suppress follicular maturation and secretion of E2 and P4, and thereby inhibit LH
surge and ovulation (Duran et al. 2001). When administered immediately prior to the
onset of the LH surge, LNG did not affect the LH surge, ovulation or the cycle length
in their study. They employed daily serum levels of gonadotrophins and steroid
hormones and ultrasound scans to correlate follicular size and maturity to the time
the administration of LNG. In agreement with this explanation, another recent study
has also shown that when LNG was administered 2 days before the anticipated LH
surge, the ovulation was not affected (Marions et al. 2002).
The available literature suggests a direct suppression of pre-ovulatory E2 rise by
progestins (Schreiber et al. 1980; Goodman et al. 1982; Fortune et al. 1983; Weibe et
al. 1984) and that may be the mechanism by which LNG inhibits the LH surge.
Many have reported a shorter luteal phase, after peri-ovulatory administration of
LNG (Johansson et al. 1971; Sopna et al. 1975; Craft et al. 1975; Landgren et al.
1989; Duran 2001). In our study, the seven women who apparently ovulated normally
had a reduced total luteal LH and a shortened luteal phase. Basal levels of LH are
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essential for the normal secretory function of the corpus luteum (Vande Wiele et al.
1970). In the mid-luteal phase LH inhibition by the administration of GnRH
antagonists consistently resulted in luteolysis in women as well as in non-human
primates (Hutchison et al. 1984; Hall et al. 1991; Ravindranath et al. 1992). There
are no direct ways ofmeasuring the corpus luteal function. Although we did not find
a significant difference in the urinary pregnanediol levels after LNG, it is possible
that the shortened luteal phase observed was a consequence of reduced total LH and
may have a contra-gestive effect.
If LNG acts as an emergency contraceptive only by interfering with ovulation, the
expected efficacy should fall below 42% (5 out of 12 women). Ho and colleagues
reported that LNG reduced approximately 60% of the expected number of
pregnancies (estimates were based on the table of probabilities of pregnancy at
different cycle days by Dixon et al. 1980). LNG faired better in the WHO study
(WHO 1998) with overall 85% reduction of expected number of pregnancies (the
analysis of the prevented fraction was based on the modified Wilcox estimates of
conception probabilities (Trussed et al. 1998)).
Both studies reported effectiveness against estimates based on historical data. The
fertile period was determined on the assumption that ovulation occurred 14 days
before the next expected menses. The validity of using these estimates directly relies
on the accuracy of reported menstrual cycle data. Women do not always record their
menses, and the sexual intercourse responsible for requesting EC maybe
unpremeditated. Reporting errors are common and the estimates can be inaccurate. In
addition, other factors such as biological variability of the day of the ovulation and
the length of the luteal phase, factors affecting the probability of pregnancy unrelated
to the timing of intercourse, and heterogeneity among couples in fecundability can
distort the estimated number of pregnancies. In a study comparing the efficacy of the
Yuzpe regimen of EC with a single dose of mifepristone (Glasier et al. 1992), there
were frequent discrepancies among subjects between the stage of the cycle as
estimated from the date of the LMP and that suggested by circulating concentrations
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of progesterone. In a recent report, Sterling & Glasier went on to confirm their
previous suggestions, and they showed that the date of LMP, timing of intercourse,
and the number of acts of intercourse in the same cycle were inaccurately recalled by
a significant proportion of women requesting EC (Sterling & Glasier 2002). There
has never been a placebo-controlled trial of EC. Thus, it is possible that the genuine
effectiveness of LNG as an EC is less than 42%.
On the other hand, the discrepancy noted in the estimated effectiveness of LNG and
the prevalence of ovulation delay or inhibition in our study may be due to
mechanisms of action other than interference with ovulation. Our study was not
designed to investigate the other possible mechanisms by which LNG works.
However, one woman in our study reported slight vaginal bleeding after taking LNG
with an apparently normal LH peak, cycle length and hormone profile. This may
suggest an additional effect of LNG on the endometrium. Landgren and colleagues
(Landgren et al. 1989) showed that follicular phase administration of multiple doses
of 0.75 mg LNG suppressed the proliferative activity of the endometrium, while no
significant endometrial effect was seen if it was taken in the luteal phase. Glandular
atrophy, stromal decidualisation and epithelial cell inactivation has been observed
after chronic local exposure of the endometrium to LNG (Pakarinen et al. 1995).
Locally administered LNG also induces expression of the potent contraceptive
glycoprotein Glycodelin A during the implantation period (Mandelin et al. 1997). In
high doses (20 - 40 ng/ml) progesterone inhibits the growth of human capillary
endothelial cells in culture (Peek et al. 1995). Therefore, the question remains as to
whether similar alterations occur in the endometrium after taking the EC regimen of
LNG, and whether these changes are sufficient to prevent implantation and account
for the observed contraceptive efficacy of LNG. The two recent studies, which
examined the effect of peri-ovulatory phase administration of LNG on endometrium,
did not report any significant morphological changes (Duran et al. 2001; Marions et
al. 2002).
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The effect of progestogens on cervical mucus and on the cervix is well documented
and this is thought to be the main mechanism by which the progestogen-only pill
exerts its anti-fertility action (Odeblad et al. 1972; Daunter et al. 1976; Moghissi et
al. 1973). However, even if LNG has an effect on cervical mucus, which interferes
with sperm penetration, that action is unlikely to prevent pregnancy when taken some
12-72 hours after coitus.
Progesterone stimulates a rapid influx of calcium into the spermatozoon via a non-
genomic action (Tesarik et al. 1996; Aitken et al. 1996; Blackmore et al. 1996) and
induces an acrosomal reaction (Oehninger et al. 1994). An impaired response of the
spermatozoon to progesterone is a clinically well-recognised defect in the infertile
male (Falsetti et al. 1993). Given their total lack of transcriptional ability, it would
appear that in the sperm the non-genomic progesterone receptor would have to be
responsible if LNG were to have an EC effect.
One woman (SI03) in our study showed a delayed LH peak (on day 27) during a
placebo cycle and subsequently the length of that cycle was prolonged to 41 days (her
usual cycle length was 25 days). In contrast to the four women who experienced
similar prolongation of the cycles after taking LNG, this woman (SI03) did not
report any inter-menstrual vaginal bleeding. Although we excluded this cycle from
our analysis, similar spontaneously occurring prolonged cycles (with delayed
ovulation) can influence the results of studies into EC.
The fertility monitor is a product designed to indicate the potentially fertile days
leading up to ovulation, through the detection of a significant rise in the levels of the
urinary oestrogen metabolite E3G. The position of this rise relative to the time of
ovulation will vary between women, and therefore the monitor will not consistently
provide two days warning of the LH surge in every cycle. It was understood that no
home use method could consistently provide such focussed warning of ovulation, but
the monitor was considered to represent the best available home use technology for
ovulation prediction.
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The reason for using the monitor to time the administration of LNG or placebo also
to avoid having to subject the volunteers to regular blood samples and ultrasound
scans.
However, due to the variability in the number of high fertile days declared prior to
the LH surge, greater reliance had to be placed on calendar calculations to predict the
LH surge.
In conclusion, we suggest that LNG taken immediately before ovulation acts as an
EC by delaying or preventing ovulation. Other plausible actions of LNG including
the retardation of the endometrium, interfering with sperm motility and altering
cervical mucus may be important, and need to be explored further.
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CHAPTER 3
FEASIBILITY OF ADMINISTERING MIFEPRISTONE AS
A ONCE-A-MONTH CONTRACEPTIVE PILL
Mifepristone as a once-a-month pill
3.1 Introduction
While hormonal contraception is extremely popular (it is used by almost 100 million
women world-wide) many women continue to be deterred from using it because of
perceived risks to health such as breast cancer and due to side effects such as weight
gain. Most of the risks and the side effects are the results of prolonged exposure to
steroids and many women, in a variety of cultural settings, find the idea of a pill, which
they need take only once each month, an attractive concept (Rimmer et al. 1992; Glasier
etal. 1999).
Progesterone is essential for the establishment and maintenance of human pregnancy.
The anti-progesterone mifepristone is a synthetic 19-norsteroid, which acts by blocking
the action of progesterone at the receptor level (Spitz & Bardin 1993), and thus, having
multiple potential anti-fertility actions. When administered in the early luteal phase
mifepristone retards endometrial development, without disturbing the timing of menses
(Swahn et al. 1988; Berthois et al. 1991; Mentausta et al. 1993). It also changes uterine
contractility to a pattern more usually seen in the late luteal phase (Gemzell-Danielsson
et al. 1990). In 1993 Gemzell-Danielsson and colleagues conducted a pilot study in
which a single dose of 200 mg of mifepristone was given in the early luteal phase (2
days following the peak of the LH in urine). Out of 124 cycles in which coitus took
place during the fertile period, they observed only 1 pregnancy. There was no disruption
of the timing of the subsequent menstrual bleed, although in 32% of the cycles slight
vaginal bleeding was reported 2-3 days after treatment.
The main problem in developing a once-a-month contraceptive is finding a method that
both reliably and easily identifies the start of the LH peak. Gemzell-Danielsson tried to
solve this problem by using the LH sticks for home urine testing (Ovu-quick, Organon).
In their study 12 out of 169 cycles were deemed to be anovulatory. However, it is not
possible to determine if the LH peak tmly was absent, or if the method failed to detect a
surge. The woman may have read the test result wrongly or even forgot to perform a test
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on the appropriate day. Moreover, anovulatory cycles would not be expected to exceed 5
per cent among healthy women in that age group (18-35 years) (Vollman et al. 1977).
Unipath (Bedford, UK) have developed a Fertility Awareness Monitor, which
simultaneously detects LH and E3G in a sample of early morning urine. The monitor
utilises the information from both of these parameters to determine the day of the LH
peak. The time from first significant rise of LH in the urine to ovulation is reported to be
around 24 - 48 hours (Collins et al. 1996). The monitor thus, should provide a
convenient method of identifying the early luteal phase. In addition, it provides a 6-
month record of the actual signal levels corresponding to daily hormone levels in urine,
and of the days on which tests were performed.
We investigated the use of the monitor to identify the LH surge in a group of women
who used 200 mg ofmifepristone on day LH +2 as their sole method of contraception.
3.2 Subjects and Methods
3.2.1 Subjects
This was a single centre study in healthy female volunteers, approved by the Lothian
research ethics committee. All subjects gave written informed consent to participation.
Fifty two sexually active women, with regular (25 - 32 day) menstrual cycles were
recruited from a large Family Planning Clinic in Edinburgh. If any women had a
significant medical condition or if they or their partners had a history of fertility
problems, they were excluded from the study.
3.2.1.1 Treatment group
Thirty two women were recruited to the treatment group. None had been taking
hormonal preparations within the 2 months prior to the start of the study and all had at
least 2 spontaneous menstrual periods since stopping hormonal contraception. All
women underwent screening at the time of recruitment including routine physical and
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gynaecological examination. A venous blood sample was taken for full blood count,
serum biochemistry and liver function. The study period was from day 1 of the menstrual
period following screening, and lasted for up to seven consecutive menstrual cycles in
which subjects took 200 mg mifepristone once per month.
3.2.1.2 Control group
The control group consisted of 20 healthy women with regular menstrual cycles who
were trying to become pregnant (for less than 6 months prior to the enrolment into the
study) and hence, were not using contraception. They were provided with a monitor,
which they used according to the manufacturer's instructions. Women were advised that
their chance of conception would be higher if they were to have sexual intercourse
during the fertile period, identified by the monitor. The controls took part in the study
until pregnancy occurred or for a maximum of 6 cycles if they did not conceive.
3.2.2 Method
All subjects and controls were provided with a home use hormone monitoring system
(Unipath, Bedford, UK). The system comprises a hand-held monitor and disposable
dual-assay urine test sticks, and is used to simultaneously detect LH and E3G levels in
early morning urine (Figure 2.1). The monitor optically measures the intensity of the
lines that form on the test sticks after sampling, and the system will delineate three levels
of fertility (Low, High and Peak fertility) according to the optical signal changes
detected. Low fertility will be displayed from day 1 of the cycle, until the hormone levels
rise above the baseline levels. A change from Low to High fertility is triggered by
detection of elevated E3G levels. The change from High to Peak fertility is triggered by
the detection of an LH surge.
Peak fertility is displayed on the day of the LH surge and on the following day.
Subsequently High fertility is displayed for one day prior to a return to Low fertility. At
the start of each menses, the subjects pressed the'm' button on their monitor to initiate
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that cycle of use, at a time suitable for testing the first urine of the day. For the rest of the
month, the subjects were required to consult the monitor display each morning (3 hours
either side of the time when'm' button was set) to determine whether they needed to
perform a test that day. Outwith this six hour time window the monitor would not accept
a test. The system requests one test every day for up to a total of 10 or 20 tests,
depending on the length of the woman's cycle, and the timing of her LH surge.
Embedded software within the monitor collects and analyses data from each cycle to
identify and display fertility status to the user, and stores data for several months (Figure
3.2 & 3.3). This product is similar to the Personal System of Contraception (Persona,
Unipath Bedford UK) (Bonnar et al. 1999) in that it monitors E3G and LH in urine, but
differs in that it has been specifically designed for maximising the chance of conception.
Unipath Diagnostics Co., Princeton, NJ, markets the fertility monitor in the US and
Unipath Ltd., Bedford, UK markets it in Britain as Clearplan Easy Fertility Monitor
(CPEFM) (Figure 2.1).
Mifepristone was taken two days after the day of the first day of Peak Fertility (LH
surge). With each cycle, subjects followed the same protocol, and were reviewed by the
investigator monthly, on day LH +2. Just before taking the 200 mg tablet of
mifepristone, a venous blood sample was taken, and later assayed for progesterone. At
the beginning of the study, if the LH surge was not identified by day 21 of the cycle, the
subject was instructed to continue testing, but mifepristone was not given in that cycle.
The subject was also advised to use barrier contraception from day 21 until the onset of
the next menses. After the second pregnancy (which occurred due to a failure in
detecting an LH surge), we changed this practice. We calculated the estimated day of LH
surge for each month based on information from the previous cycles. If the women did
not detect an LH surge either within 3 days after the anticipated day of LH surge or by
day 19, a blood sample was taken for rapid serum progesterone assay. If the
progesterone level was >5nmol/L and if the woman was at risk of pregnancy,
mifepristone was administered. All subjects and controls kept a menstrual record card,
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recording all vaginal bleeding experienced during the study and the days on which they
had sexual intercourse.
Figure 3.2 Information retrievedfrom the Fertility monitor-!
This figure illustrates the monitor display as seen by the volunteer each day.
Empty box = low fertility, 1 lalf filled box = high fertility,
Completely filled box + egg = peak fertility.
Underneath each box, a solid line represents a correctly performed test while a
missed / inaccurately performed test is represented by a broken line. Volunteer
using this particular monitor showed perfect compliance.
Cycle: 1, Start: 22 February 1999, Length: 29 days
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Figure 3.3 Information retrievedfrom the Fertility monitor-11
This Figure illustrates the additional information that ean be stored and retrieved
from the monitor on the details of each test.
The closed circles represent the LH signal, and the open squares represent the
E3G signal. The solid green line indicates the LH peak. Fertility status is
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Subjects also marked the first day of the Peak fertility as identified by the monitor and
the day of taking the study medication.
If menstruation was overdue by more than one week the investigator performed a
pregnancy test. Provided this was negative, the subject continued in the study and the
next cycle was deemed to start with the onset of menses. Since the effect ofmifepristone
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taken in very early pregnancy is unknown, and teratogenic effects could not be ruled out,
women who would not consider terminating any pregnancy were not recruited to the
treatment group.
At the end of the study, the subjects attended for a final visit, when a routine physical
and gynaecological examination was performed. Full blood count, serum biochemistry
and liver function were reassessed.
The following definitions were created for the purpose of the study.
Imperfect Use was defined as failure to detect an LH surge through performing the test
incorrectly (e.g.; dipping a test stick in urine 30 or more minutes before it being read by
the monitor), or failing to perform tests as requested by the monitor.
Monitor method failures were defined as failure to detect an LH surge despite
performing all tests as requested.
High fertile days: days preceding the urinary LH surge as indicated by the monitor to be
potentially fertile.
Peak fertile days: The first day of a significant rise in urinary LH detected by the
monitor, and the following day.
The Fertile period of the cycle was defined as three days before until two days after the
urinary LH surge (LH -3 to LH +2).
Exposure cycles were cycles in which women reported having sexual intercourse at
least once during the fertile period.
3.2.3 Statistical analysis
Cycle lengths and serum progesterone concentrations were compared by two-sample
t-tests. Confidence limits for efficacy were derived from confidence limits for relative
risk calculated by the Greenland and Robins method (Greenland & Robins 1985).
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3.3 Results
Table 3.1 shows the demographic characteristics of the women who took part in the
study. The women in treatment group were slightly younger (mean age 30 years) than
those in the control group (mean age 32.92 years). Otherwise there were no differences
between subjects and controls.





Age Range 18-39 26-40
Mean (+/- SD) 30 (+/-5.4) 32.9 (+/-4.5)
BMI Range 19-38 21-29
Mean (+/- SD) 23.6 (+/-4.3) 23.8 if!-2.1)
Smokers (%) 7 (21.9) 1 (5)
Non-smokers (%) 21 (65.6) 16 (80)
Ex-smokers (%) 4 (12.5) 3 (15)
Previous pregnancies 1+ (%) 19 (59.4) 14 (70)
never been pregnant (%) 13 (40.6) 6 (30)
Ever abortion (%) 15 (46.9) 5 (25)
Married / Co-habiting (%) 28 (87.5) 20 (100)
Single (with a regular boy friend) (%) 4 (12.5) 0 (0)
3.3.1 The probability of pregnancy in the control group
20 women were recruited to the control group and three withdrew before completing the
study. Two withdrew from the study as they found using the system "too stressful" and
one withdrew because she no longer wished to plan a pregnancy. Data were collected
from 50 control cycles during which 12 pregnancies occurred. Average frequency of
intercourse was 1.7 episodes per week in the 39 control cycles in which the women kept
a record of their sexual activity. In 37 cycles women had intercourse at least once during
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the fertile period. In two cycles intercourse did not occur during the fertile period, while
in 11 cycles the exposure status was unknown, as women failed to keep a record of
sexual activity. Eight pregnancies occurred in the first exposure cycle.
If we assume that all 11 cycles from which information on sexual activity was lacking
were exposure cycles, the probability of pregnancy was 0.25. However if those cycles
were all non-exposure cycles, the probability of conception would be 0.32. Therefore
among the control group the overall probability of pregnancy if sexual intercourse took
place at least once during the fertile period lies between 0.25 - 0.32.
3.3.2 Contraceptive efficacy of the method
Thirty two volunteers were treated with a single dose of 200 mg of mifepristone
administered in luteal phase of the cycle as their sole method of contraception between
one and seven cycles. They contributed a total of 178 cycles, and in 167 cycles
mifepristone was administered. Eight women withdrew from the study before
completion, two women moved out of the area, three ended their relationship, two
conceived during the study and one lost confidence in the method.
Two clinical pregnancies occurred in the 178 cycles studied. The first pregnancy was a
true treatment failure, which occurred in a woman (para 1) who took mifepristone on day
14 (LH +2) of her first treatment cycle. She opted for a surgical termination of
pregnancy, which was performed at eight weeks of gestation (confirmed by ultrasound
scanning). In the second woman (para 3), an LH surge was not identified in her third
study cycle hence she did not receive treatment with mifepristone (Figure 3.4), menses
did not occur and on day 37 after her last menstrual period an ectopic pregnancy was
diagnosed and treated surgically. In a third woman a biochemical pregnancy was
diagnosed (serum (3 hCG only rising to 34 U/L), which was spontaneously and
completely aborted by day 34 of the third study cycle after taking mifepristone on day 14
(LH +2). This woman continued in the study and completed 6 treatment cycles.
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Figure 3.4 This figure illustrates the down loaded test data from the CPEFMused
by the woman who missed the LHpeak due to monitor error
The E3G and a subsequent low LH peak occur "too early'' in the cycle hence the
monitor does not declare peak fertility. The closed circles represent the LH
signal, and the open squares represent the E3G signal. Fertility status is indicated
as
L = low fertility, H = high fertility, & P - peak fertility. The solid green line
indicates the monitor declaring an LH peak because of cross reactivity of rising
[3hCG with the LH assay.
Day in Cycle
CFM E3G Signal (1/%T) CFM LH Surg<
• • • CFM LH Signal (%T)
The mean frequency of sexual intercourse was 1.8 episodes per week in 167 treatment
cycles in which sexual activity was recorded. If we assume the probability of pregnancy
in the treatment group is similar to the control group (0.25 - 0.32), the expected number
of clinical pregnancies during the 178 cycles (in which 140 were exposure cycles)
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studied should be between 35 - 48.3. The observed number was 2. Therefore, the
efficacy of the method is 94.3% (95% confidence interval 75.4 - 98.7) - 95.9% (95% CI
82.5 - 99.0). When calculating the efficacy of the method, we excluded the 29 cycles
during women were not exposed to a risk of pregnancy, and the three cycles in which
mifepristone was taken in the follicular phase (Table 3.2).
3.3.3 Contraceptive efficacy of luteal phase administration of mifepristone
In 145 cycles in which mifepristone was taken in the early luteal phase (within 2 days of
the urinary LH surge) 117 were exposure cycles. Exposure status was unknown in eight
cycles and in 20 cycles women were not at risk of pregnancy. In the 117 exposure cycles,
there was only one clinical pregnancy.
In 19 (10.7%) cycles, the monitor declared no LH surge but mifepristone was given as
coitus had taken place during the fertile period of the cycle (calculated according to the
usual cycle length and usual day of LH surge). Occurrence of ovulation was confirmed
by serum progesterone of >5 nmol/L in all 19 cycles and treatment was administered
prior to day 21 of the cycle in each case (between day 13-21 of the cycle (Mean 16.9
(SD +/-2.1) days). There were no pregnancies in these cycles.
If the probability of pregnancy in all exposure cycles in the study is 0.25 - 0.32 (the same
as that of the control group), 34 - 46 clinical pregnancies would be expected in the 136
ovulatory cycles in which mifepristone was taken in the luteal phase. The observed
number was one. Hence, the contraceptive efficacy of luteal phase mifepristone is
between 97.1% (95% CI 78.00 - 99.6) and 97.8% (95% CI 83.9 - 99.7) (Table 3.2).
3.3.4 Performance of the home use hormone monitor
In 140 treatment cycles an LH surge was identified by the monitor, which equates to






































































Mifepristone as a once-a-month pill
imperfect use cycles are also included in the total. In 127 cycles this was confirmed by a
subsequent rise in serum progesterone of >5 nmol/L in the early luteal phase. This
information was not available from 9 cycles (blood samples lost or not collected). In the
remaining 4 cycles serum progesterone was between 2-5 nmol/L, one or two days
following the urinary LH surge as detected by the monitor. This may have been due to an
early detection of the first significant rise in urinary LH. None of these five cycles were
prolonged after taking mifepristone hence; it is unlikely that they were anovulatory.
There was a total of 38 (21.3%) cycles in which an LH surge was not detected. Among
them, one (0.6%) was an anovulatory cycle, defined by serum progesterone not rising
above 5 nmol/L in the mid-luteal phase. In three (1.7%) other cycles we administered
mifepristone on day 19, before the monitor had identified an LH surge. Serum levels of
progesterone (taken on the day of administering mifepristone) confirmed that in these
cycles mifepristone was administered in the follicular phase. All three cycles were
prolonged (43 - 52 days).
In the remaining 34 cycles an LH surge probably occurred (as suggested by a rise in
serum progesterone of >5 nmol/L) but was not identified by the monitor. Fourteen were
missed due to monitor method failure (7.9%) and 20 were a consequence of imperfect
use of the system (11.2%).
3.3.5 Cycle length
Mifepristone, when given in early luteal phase, did not significantly affect the cycle
length (p = 0.35). The mean of the usual cycle length was 28.3 days (SD +/-1.3) and
during the treatment cycles it was 28.0 days (SD +/-1.9).
3.3.6 Side effects
Women kept a record of vaginal bleeding in 139 out of the total 144 cycles where
mifepristone was taken on LH +2. Mifepristone induced vaginal bleeding within 72
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hours in 21 cycles (15%). In further 19 cycles, volunteers took mifepristone in the luteal
phase but the LH status was not known. In 17 of those cycles (>89%), mifepristone
induced a vaginal bleed.
Serum progesterone values in blood samples taken just prior to mifepristone
administration were available for 136 cycles. The mean serum progesterone value was
significantly (p <0.0001) higher in those cycles where mifepristone induced bleeding
when compared to the mean value for the cycles without bleeding (21.72 (SD +/-9.04)
nmol/L Vs. 13.33 (SD +/-6.23) nmol/L).
Two women spontaneously reported improvement of their pre-menstrual symptoms
during cycles in which mifepristone was administered, while one reported worsening. In
one woman hepatic alanine aminotransferase (ALT) was elevated at 103 U/L (normal
range 10-40 U/L) at the end of the study but returned to normal within 2 months. One
woman complained of diarrhoea 12 hours post mifepristone in one cycle, 3 reported
menstmal cramping within 72 hours of taking mifepristone; 2 women reported a
reduction in menstrual blood loss.
3.4 Discussion
A single dose of 200 mg of mifepristone administered once a month is an effective
contraceptive method with an overall efficacy of 95% increasing to 97% if administered
at the correct time (i.e., the early luteal phase). Thus, our results are in agreement with
the findings of the previous study by Gemzell-Danielsson (Gemzell-Danielsson et al.
1993).
One criticism of previous work in this field has been the lack of a suitable control group
for the subjects studied. Unlike the Gemzell-Danielsson study, we were able to compare
the results with a contemporaneous control group using the same methodology in the
same cultural setting. In this control group, if sexual intercourse took place on a fertile
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day the probability of a pregnancy was 0.25 - 0.32. The calculated probability of
pregnancy in a cohort of couples monitored during a study of natural family planning
(WHO 1983) was 0.486 if intercourse took place 3 days prior to and a day after the peak
day of mucus discharge. The difference in the probability of pregnancy between our
study and a variety of other published series (Table 3.3) may be explained by the fact
that we have extended our definition of the fertile period to 6 days (3 days prior to the
urinary LH surge until 2 days after). Other authors (Wilcox et al. 1995) have shown that
the likelihood of conceiving during an ovulatory cycle to be 0.37 (95% confidence
interval 0.31 to 0.48) if daily sexual intercourse took place during a 6 day fertile period
(four days before and a day after ovulation). The lower frequency of intercourse in our
group (untimed intercourse averaging 1.7 per week) may also explain the lower
probability of pregnancy.







Wilcox study+ 129 34 0.26





(mifepristone in luteal phase)
136-143 1 0.007
G-D study group* 124 1 0.008
WHO study* 72 35 0.48
*The length of the fertile period defined as 4 days
+The length of the fertile period defined as 6 days
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The limiting factor in this once-a-month approach to administering anti-progesterone is
the accurate detection of the LH surge. Clearly, the failure to detect accurately the LH
surge has a big impact on the overall effectiveness of the method. Using laboratory
assay of LH in blood or urine to identify ovulation is neither practical nor convenient for
long term use in the general population. The monitor provided us with an opportunity to
overcome these problems. Gemzell-Danielsson reported 49% accuracy using home LH
detection sticks. Although the monitor performed better (over 80.5% accuracy), both of
these methods remain below the required standard. We studied 32 women over a total of
178 cycles. Imperfect use of the system accounted for failure to identify an LH surge in
11.8% cycles while 7.9% were due to monitor method failure. Compliance difficulties
are associated with all contraceptives and non-compliance in approximately 12% of
cycles is probably no worse than with any other method which demands action from the
user, for example, compliance rates reported from oral contraceptive pill users range
from 3.4% - 100% (Wheble et al. 1981, Hamilton et al. 1989, Molloy et al. 1985).
Although our study population consisted of women who were motivated and committed
and some of them already had experience in using natural family planning methods, they
found the short, inflexible testing window set on day 1 of the cycle to be particularly
demanding. This is inconsistent to couples using the monitor in order to get pregnant
(Bonnar et al. 1999). The prevalence of imperfect use is likely to rise in the general
population compared with that typical of a research study.
During the course of the study we developed an algorithm (Figure 3.1) for the
administration mifepristone if an LH surge was not identified. In 19 exposure cycles (out
of 28 cycles in which an LH surge was not identified) mifepristone was administered
using this algorithm and there were no pregnancies. Given that the methods available to
be used in real life to time the administration ofmifepristone cannot be 100% accurate,
such an algorithm will be essential to deal with a missed LH surge.
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In our study, mistimed administration of mifepristone led to predictable effects. When
administered during the proliferative phase of the menstrual cycle, mifepristone inhibited
follicular development, and delayed the mid cycle LH surge, leading to a delay in
ovulation and subsequent prolongation of the menstrual cycle (Liu et al. 1987,
Luukkainen et al. 1988, Swahn et al. 1988). Ovulation may occur later in that cycle,
leaving women at risk of conception. In our study, when administered in the late
follicular phase (in error) in 3 cycles, mifepristone prolonged the cycle length (43 - 52
days). The women were advised to use condoms for the remainder of that cycle and none
of the three cycles resulted in pregnancy.
Figure 1. Algorithm for administering mifepristone
when the LH surge is not identified.
Administration of mifepristone in the mid or late luteal phase induces a bleed within a
few days of treatment, which may or may not be followed by a second bleed at the time
of expected menstruation (Shoupe et al. 1987; Swahn et al. 1988). The disturbance in
vaginal bleeding induced by a method of contraception is an important side-effect
because of its potential impact on acceptability. In our study, in 17 out of the 19 cycles
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where mifepristone was taken after ovulation (the LH status unavailable and probably
later than on LH +2), inter-menstrual vaginal bleeding occurred (89.5%). Moreover,
there was an increased risk of bleeding seen in those women who may have taken
mifepristone slightly later in the LH +2 window. The mean serum progesterone
concentration was significantly higher in those women who had bleeding after taking
mifepristone within LH +2, when compared with those who did not. The higher serum
progesterone value in some on LH +2, could be due to a delayed identification of the
first significant rise in urinary LH, or because of a more rapid increase in serum
progesterone due to early ovulation. Nevertheless, in our group of women, in all cycles
where mifepristone induced a vaginal bleed, a second bleed occurred at the time of the
expected menses. Therefore, while the bleeding may have been inconvenient, it did not
jeopardise efficacy or continued use of the method. There was less inter-menstrual
bleeding (15% of the cycles) reported in our study when mifepristone was taken within
LH +2, less than half of that reported by Gemzell-Danielsson et al. (32%). This is
possibly due to the fact that the majority ofwomen in our study received mifepristone at
the correct time. In their study, in 51% of the cycles, mifepristone was taken between 3
and 5 days after the LH surge. Anyhow, this predictability in the bleeding pattern
following luteal phase administration is likely to be mere inconvenience, as opposed to
the follicular phase administration.
The mean serum progesterone value was significantly more in those women who had
mifepristone induced bleeding in the early luteal phase, when compared with those who
did not. The higher serum progesterone value in some on LH +2, could be because of
delayed identification of the first significant rise in urinary LH, or because of a faster
increase in serum progesterone due to early ovulation.
The upset in menstrual pattern that may follow administration of mifepristone in the
proliferative phase or in mid / late luteal phase can be unacceptable to women. However,
there is new evidence (Mations et al. 2002; Brown, A. unpublished observation) that the
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time window for administering once a-month mid-cycle mifepristone is wider than
previously thought. This may be tested in the future where mifepristone is taken on a
specific day of the cycle, arbitrarily chosen according to each woman's usual menstrual
cycle length.
Women are not exposed to the risk of contraceptive failure unless they have intercourse
on a fertile day. Therefore, when calculating the contraceptive effectiveness of the
method we excluded those cycles where the women reported that no intercourse had
occurred during the fertile period and those cycles where insufficient information was
available to determine whether intercourse has taken place. In our study, women marked
only the days in which they had intercourse on the diary card, hence leaving no way to
distinguish the days they forgot to mark sexual activity from those days when they
actually did not have any. One might object that those who did not keep a record, still
may have had intercourse during the fertile period and were nevertheless at risk of
pregnancy. On the other hand, complex and more detailed diary cards may encourage
errors of omission.
In conclusion, the use of the combination of home use fertility monitor with once a
month administration of mifepristone (especially if mifepristone is administered at the
early luteal phase) is an attractive contraceptive option with minimal side effects.
However, to be an effective contraceptive method, the women have to be committed to
using a device, which identifies the LH surge, in order that the pill can be taken at the
correct time in the cycle. Whilst this regimen may be acceptable to motivated women, it
may be regarded as too complicated for others to adopt on a routine basis. There was
evidence of such non-compliance in this study, with 11.2% ofLH surges being missed as
a consequence of imperfect use of the monitor. Unfortunately, it is difficult to envisage




SEX, LIES AND NON-COMPLIANCE
"Keep watch also on the faults of the patients, which often makes them lie about the
taking ofthingsprescribed"
Hippocrates.
Sex, lies & non-compliance
4.1 Introduction
When the first woman on earth chose to contradict the instructions of her Provider in the
Garden of Eden, expecting her descendants to comply perfectly with a contraceptive
regimen may seem rather unrealistic. However, regardless the culture, race or the
religious beliefs of a woman, unintended pregnancy is undoubtedly a major life-
changing event. The consequences of such pregnancy generally make it unwelcome.
Non-compliance with a particular contraceptive method is linked with an increased risk
ofunintended pregnancy (Rosenburgh et al. 1995). Therefore, conventionally it has been
assumed that the users of contraception are 'highly motivated' because the consequence
of non-compliance - pregnancy - is so obvious, and so significant. Studies involving
organ transplant recipients have shown however, that no consequence of poor
compliance is severe enough - not even the rejection of a transplanted kidney - for all
patients to follow their prescribed regimen reliably (Rovelli et al. 1989). Converging
evidence from all disciplines, in the treatment of chronic disease that requires suffers to
adhere to particular medical regimens over a long period of time, indicates that poor
compliance is pervasive (Haynes 1979). Furthermore, women on contraceptives are not
suffering from a disease.
The studies that have evaluated the patient's compliance with oral contraceptives show a
wide range between the highest (100%) and the lowest (3.4%) compliance rates (Wheble
et al. 1981, Molloy et al. 1985; Hamilton et al. 1989). This discrepancy may be due to
the methodology of the studies as well as the differences in the patient characteristics -
there is no "gold standard' measurement for patient compliance (Spilker 1991).
Poor compliance - in both clinical practice and research - is associated with a number of
factors. Though several patient characteristics (e.g. age, education, socio-economic
background (Rapoff 1986; Meichenbaum & Turk 1987; Potter et al. 1991),
characteristics of the treatment regimen (e.g. frequency of dosing, side effects (Puller
1988; Rapoff et al. 1989; Cromer et al. 1989)) and outcome characteristics (e.g.
treatment of incurable or terminal illnesses (Spilker 1991)) have been associated with
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non-adherent behaviour, there are no reliable and universally applicable predictors of
non-compliance (Peck & King 1982; Luscher et al. 1985; Haynes 1986). Given the
relatively crude measures of compliance that are available, caution should be taken when
trying to correlate compliance with the outcome.
When a contraceptive method is used imperfectly, its effectiveness may differ from that
during perfect use (Dominik et al. 1999). Clinical trials to determine the efficacy of new
contraceptive regimens depend on full co-operation of the volunteers. Little is known
about the prevalence of non-compliance in contraceptive trials. In these trials, volunteers
are often required to keep daily records of events such as pill taking, sexual activity,
vaginal bleeding and side effects in order to comply with a protocol. Contraceptive
efficacy is usually compared with the estimated conception rates among non-users,
which themselves directly rely on the accuracy of menstrual cycle data. Few women in
real life regularly keep records of their menses or sexual activity hence, reporting errors
are common. Moreover, incorrect reports of perfect compliance can under estimate use-
effectiveness rates. Investigators generally depend on self-reporting (SR) of non-
adherence behaviour to detect the prevalence of imperfect use.
We observed the behaviour in 32 women who took part in a trial assessing the efficacy
of a novel method of contraception (Hapangama et al. 2001b). The women took 200 mg
of mifepristone two days following the mid-cycle LH surge (measured in urine) as a
once-a-month contraceptive pill. Mis-timed administration of mifepristone can disrupt
the menstrual cycle, and can also leave the women at risk of conception. A home use
fertility monitor that could store data on daily testing events was used to time the
administration of mifepristone. While making minimal demands on the users, the
method provided objective, long-term data on their routines. Since the investigator saw
participants once each cycle throughout the study, we were able to compare the results
of this method with the traditional self-reported incidence of compliance.
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4.2 Subjects & Methods
4.2.1 Subjects
Data were collected during a study assessing the feasibility of administering
mifepristone as a once a month contraceptive pill and detailed study methodology is
reported elsewhere (Chapter 3; Hapangama et al. 2001b). Thirty-two sexually active
women were enrolled from a large family planning clinic in Edinburgh. All subjects
gave written informed consent to participation and the Lothian research ethics
committee approved the study. Data was collected from a total of 178 cycles with each
subject contributing between one and eight cycles. It was not possible to retrieve
compliance data from the monitors in 28 of the study cycles, due to infrequent
downloading of the monitor, and lost or broken devices. The study started on day 1 of
the menstrual period following screening, and lasted for up to seven consecutive
menstrual cycles in which subjects took a single tablet of 200 mg mifepristone once per
month. The timing of mifepristone depended on detection of the LH surge, which in turn
depended on compliance with daily urine testing.
4.2.2 Methods
All women underwent screening at the time of recruitment including routine physical
and gynaecological examination. They were provided with a home use fertility monitor
(Unipath, Bedford, UK). The system comprises a hand-held monitor and disposable
dual-assay urine test sticks, and is used to detect simultaneously LH and E3G levels in
early morning urine. The system will delineate three levels of fertility (Low, High and
Peak Fertility) according to the optical signal changes detected. At the start of each
menses, the subjects pressed the'm' button on their monitor to initiate that cycle of use,
at a time suitable for testing the first urine of the day. For the rest of the month, the
subjects were required to consult the monitor display each morning (three hours either
side of the time when'm' button was set) to determine whether they needed to perform a
test that day. Outwith this six hour time window the system would not accept a test. The
monitor requests one test every day for up to a total of 10 or 20 tests, depending on the
length of the woman's cycle, and the timing of her LH surge. Embedded software within
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the monitor collects, analyses and, stores data for several months (Figure 2.1; Figures
3.2 & 3.3).
The correct way to use the monitor (including the importance of the testing window)
was demonstrated to all subjects at the time of recruitment and written information was
given. Subjects were advised to contact the investigator immediately if they were not
able to perform a test during a critical period. The investigator was available by
telephone seven days a week.
Subjects were reviewed by the investigator each cycle, on day LH +2 when mifepristone
was taken.
All subjects kept a menstrual record card, recording all vaginal bleeding experienced
during the study and the days on which they had sexual intercourse. They also marked
the day of the LH surge as identified by the device and the day of taking the study
medication.
Thefollowing definitions were createdfor thepurpose ofthe study.
The period of time between the calculated earliest day an LH peak is likely to occur and
the day of the actual LH surge in each cycle was defined as the Critical period for each
patient. The Fertile period of the cycle was defined as three days before until two days
after the urinary LH surge (LH -3 to LH +2). Exposure cycles were cycles in which
women reported having sexual intercourse at least once during the fertile period.
4.2.3 Statistical Methods
Some of the compliance data were summarised for descriptive purposes using numbers
of cycles or tests as denominators. However, statistical inference was carried out on data
aggregated to patient level, in order to take account of possible heterogeneity in
behaviour amongst patients, which might have invalidated analyses using data from
individual cycles or tests. Thus percentages of tests missed were calculated for each
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patient, and these were tested for association with demographic data using Pearson
correlation. Similarly, percentages of tests missed at different stages of the cycle, and
when on and off the treatment regimen, were compared by paired t-tests. A two-sample
t-test was also used to compare the percentage of tests missed in patients who dropped
out and those who did not.
4.3 Results
Table 4.1 shows the demographic characteristics of the women who took part in the
study.
Table 4.1 Demographic data
Demographicfeature N = 32
Age (years) Range 18-39
Mean (+/- SD) 30 (+/-5.4)
BMI Range 19-38
Mean (+/- SD) 23.6 (+/-4.3)
Smokers (%) 7 (21.9)
Non-smokers (%) 21 (65.6)
Ex-smokers (%) 4 (12.5)
Previous pregnancies 1+ (%) 19 (59.4)
Never pregnant (%) 13 (40.6)
Ever abortion (%) 15 (46.9)
Married / Co-habiting (%) 28 (87.5)
Single (with a regular boy friend) (%) 4 (12.5)
162 cycles were analysed, out of which 150 were study cycles. Data were collected
during an additional 12 cycles in which subjects were using a barrier method throughout
the cycle and mifepristone was not given.
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In total 2013 tests were requested by the monitor during the 162 cycles analysed (12.4
tests per cycle, 95% C.I. 11.8 - 13.0), and 494 were missed (24.2% (95% C.I. 16.5 -
31.5). On average three tests (95% C.I. 2.4 - 3.6) per cycle were missed.
4.3.1 Compliance during the intention to treat cycles
During the 150 cycles, in which women were relying on the study method as their only
contraception, a total of 1816 tests was requested by the monitor and 411 tests were
missed (22.6% (95% C.I. 15.2 - 30.1).
Compliance before and after identifying thepeak
In the days before the women knew an LH surge had occurred, 23% of the requested
tests were missed (95% C.I. 16 - 30)) (260 out of a total 1160). Women were not more
likely to miss tests before the surge than after it (t = 0.57, NS).
Concordance ofmonitor data with the self-reported data
In 68 cycles (42%) women failed to test at all on a day of the cycle, which was critical to
the accurate detection of an LH surge. In 27 of these cycles the monitor did not detect an
LH peak. In the remaining 41 cycles despite critical tests being missed the monitor did
detect an LH peak. Women admitted to not performing tests in 24 cycles (14.8 %). In the
other 44 cycles women did not report missed tests and only admitted to it once the
investigator showed the downloaded monitor data to them. Some women actively
fabricated the information, which they reported to the investigator. In one of these cycles
when contacted, a woman declared detecting an LH peak on a day (day 13 of the cycle)
when she had not performed a test at all (Figure 4.1). Another woman performed the
tests correctly and identified an LH peak on day 13 but forgot to inform the investigator
and failed to obtain the mifepristone tablet as per protocol, when contacted on day 19 of
the same cycle, she claimed that the monitor had not detected an LH peak.
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Figure 4.1 This figure illustrates the monitor display as seen by the volunteer each day
Empty box = low fertility, Half filled box = high fertility.
Underneath each box, a solid line represents a correctly performed test while a
missed / inaccurately performed test is represented by a broken line. Volunteer
using this particular monitor neither performed a test, nor did the monitor show
peak fertility on cycle day 13. However, she declared detecting peak fertility on
day 13 (see Figure 3.2 for perfect compliance).
Cycle: 3, Start: 09 March 1999, Length: 31 days
Compliance during the critical days
Compliance with urine testing as monitored by the system was significantly higher
during the critical period (15.6% (95% C.I. 9.5 - 21.7) when compared to the non-critical
days (27.5% (95% C.I. 17.9 - 37) (paired t-test, t = 3.64, p <0.01). The self reported
percentage of missed tests during the critical period was 2.7% (95% C.I. 1.0 - 4.3) which
was significantly lower than that detected by the monitor (t = 4.48, p <0.001).
4.3.2 Compliance during the study suspension interval
In six out of these 12 cycles, the monitor was not able to identify an LH peak due to
imperfect use. During this period, a significantly high percentage of tests (41.2 % (95%
C.I. 22.4 - 60.0)) were missed when compared to the study cycles (22.6% (95% C.I.
15.2 - 30.1) (t = 2.9, p = 0.015).
4.3.3 Compliance and sexual activity
There was no correlation between the frequency of sexual intercourse per cycle and the
number of missed tests per cycle (correlation coefficient was +0.01). The percentage of
missed tests were compared between the exposure and non-exposure cycles in 12
women who had at least one exposed and one unexposed cycle. There was no significant
difference (paired t-test, t = 0.06, MS, 95% C.I. for differences between exposed and
unexposed -8.3 to +7.8) in compliance during exposed and non-exposed cycles.
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4.3.4 Demographic features and compliance
Age was negatively correlated with the percentage of missed tests - younger women
missed more tests (r = -0.36, p <0.05). There was no apparent relationship between
compliance with the method and the number of pregnancies, number of previous
abortions, or number of living children (Table 4.2). All women included in the study had
some form of tertiary education and were either employed or were undergoing tertiary
education during the study period.
Table 4.2 Demographic data and compliance
Demographicfeature Number Mean % non-compliance




BMI 19-20 6 13.7
21-25 16 27.9
26-38 7 14.3
Smoking Current 7 24.3
Never 19 21.7
Ex 4 18.4
Previous pregnancies 1+ 17 22.6
Never 14 21.9
Ever abortion Yes 14 25.3
No 17 21.9
Married/ Co-habiting 27 22.4
Single 3 18.1
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4.3.5 Compliance among dropouts
We analysed cycle data from the seven women who discontinued the study before
completion. They missed a significantly higher percentage of tests (44.4%) when
compared with the other 25 women who completed the study (17.4%) (95% C.I. of the
differences between the two percentages 10.6 - 43.3) (t = 3.39, p = 0.002). The dropouts
missed tests on a critical day in 16 out of the 22 cycles although admitted to missing
tests in only four. Therefore, the self reported incidence of non-compliance during the
critical period was 18.1%, while the monitor detected incidence was 72.7%.
4.4 Discussion
The home use fertility monitor offered us an important methodological advance in
providing reliable data on the incidence and the magnitude of non-compliance with the
contraceptive method studied, and information on when exactly the imperfect use
occurred. We sought to achieve significantly high compliance rates with employing this
monitoring system in a contraceptive regimen, which appeared to be acceptable to
women (Rimmer et al. 1993; Glasier et al. 1999). Women were counselled at the start of
the study regarding the importance of performing urine tests accurately in order to
identify the time to administer mifepristone. They were aware that if mifepristone was
not taken, they would be at risk of pregnancy. Since the teratogenic effects of
mifepristone is not known women considering participation in the study were advised
that if pregnancy occurred they should consider termination. Despite this, the
information collected from the monitor demonstrates that women failed to perform
24.2% of the tests in the 162 cycles analysed. Moreover, in 42% of the cycles women
missed tests during a day that an LH surge was likely to have occurred, i.e. at an
absolutely vital time for contraceptive efficacy.
Although non-compliance is common, by inviting only a selected group of women (all
with tertiary education) who appeared to be motivated and committed we sought to
exclude those who might be poor compliers. We expected the positive health benefit, i.e.
avoidance of pregnancy from our 'new' treatment may become their motivation to
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comply with the protocol. Interestingly, the medical profession is reportedly poor in
identifying non-compliers (Gilbert et al. 1980). Users of our method were reasonably
young (mean age 30 years) and were healthy. The serious outcome of non-compliance
(pregnancy) was rare. Women may have found daily requirement for urine testing using
the monitor on a long-term basis to be complicated or inconvenient. Side effects of the
method (although fewer than in most other methods available) may not have been
acceptable to them or they may not have had faith in the effectiveness of the method
although this seems unlikely since they did not revert to condoms. Considering these
odds, it is not difficult to infer why compliance problems were frequent.
For a volunteer, taking part in a research study usually involves extra effort. Women in
our study were required to attend clinics, answer questions honestly, test samples
accurately as requested (daily urine), allow required tests to be performed (serum
progesterone assay), obtain medicines prescribed and keep accurate records of events
(sexual intercourse, menstrual bleeding etc) in order to comply with the study protocol.
Common sense suggests that with increasing experience the women may trivialise the
need for testing on days in which an LH surge was unlikely to have occurred. All
women were made aware of the critical period for testing urine at the start of the study
and as expected, women missed fewer tests during this period. Incomplete understanding
of how to be compliant with a regimen has been suggested as a common reason for poor
compliance (Rosenberg et al. 1995). Women in our study were given detailed verbal and
written information on using the monitor at the start of the study. The importance of
accurate use of the device according to manufactures guidelines was stressed at each
monthly visit. Since there was no significant difference in the percentage of missed tests
between the first study cycle and the last study cycle, it is difficult to support the
suggestion that in the earlier cycles women were less confident about how to use the
method or more confident in their ability to guess the correct time for testing (Lusher et
al. 1985).
117
Sex, lies & non-compliance
There was a highly significant difference between the patient self-reported percentage of
missed tests (2.6 %) and that detected by the monitor (15.6 %) during the critical period
(Figure 4.2 & 4.3). This discrepancy was even greater among the seven women who
discontinued the study before completion, and is consistent with previous studies that
reported significant overestimation of compliant behaviour with SR (Potter et al. 1996).
In 1996, Potter and colleagues studied SR incidence of missed pills with the data from
an electronic device with diary entries among a group of OC users, and the compliance
ranged from 25% (Electronic Device data) to 66% SR. Patients tend to tell the doctors
what they think the doctor wishes to hear. If they assume that doctors perceive patient
non-adherence as a judgmental disappointment, they may feel guilty to report non¬
compliance.
Although, older women tended to miss fewer tests, the other demographic characteristics
such as parity, previous abortions, number of living children and educational
background did not correlate with the number of missed tests. Others have also reported
a positive correlation of increasing age with adherence behaviour (Waterhouse et al.
1993). Neither did frequency of sexual activity or exposure to the risk of pregnancy
correlate with the missed tests. However, since the information about sexual activity was
only collected by self-reporting, this association should be accepted with caution.
Most investigators work on the assumption that a patient who complies with one aspect
of a clinical protocol (e.g. attending the clinic as directed) also adheres to all other
aspects of the study, though this might not always be the case. The monitor supplied data
on daily testing of urine, which was only one part of the contraceptive method. We
cannot infer from those data, how well the women in our study complied with the rest of
the protocol, such as recording daily events (sexual intercourse, vaginal bleeding). With
no means of testing this, for validity of our results we have to depend on our volunteers
being truthful. Therefore, in future we have no other option but to work towards forming
a true therapeutic alliance with our volunteers; and to come to an agreement with our
patients rather than to impose a prescription or a protocol upon them.
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In conclusion, the use of microelectronics monitoring systems such as the home use
fertility monitor may improve our understanding of the extent of the problem of patient
non-compliance, providing precise objective information that no other monitoring
technique can produce. This understanding will empower us as health care providers, to
adopt a no fault approach to behaviour relating to non-compliance and establish "a
tailored consensual regimen" with the user which they are able to adhere to (Fink, 1976).
This provides the opportunity to make the optimum use of potentially effective
treatments and legitimate research evidence. Perhaps a small price to pay for such a
return!
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Figure 4.2 Information collected from the monitor and the diary card from a 31-day
cycle in which, the LH surge was identified. Mifepristone was
administered on day 20 (LH +2)
Panel 1: Information downloadedfrom the monitor
Level of fertility displayed to the woman on each day of the cycle.
Low fertility High fertility Peak fertility
Data on testing events.
Test performed 1 1 Test missed
Panel II: Data recorded on the diary card by the woman (Self-report)
B = days of vaginal bleeding X = days in which sexual intercourse had occurred
V = tests done during the critical period T = day when mifepristone was taken
Panel III: Downloaded information on signal levels ofLuteinizing Hormone (LH) and
Oestrone-3-glucuronide (E3G) levels.
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**Note that on several days - the woman reported performing (V) the test when the
monitor showed that she did not (M).
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Figure 4.3 Information collected from the monitor and the diary card from
a 35-day cycle. As a consequence ofmissed tests the monitor did not
identify the LH surge and, mifepristone was not administered
Panel 1: Information downloadedfrom the monitor.
Level of fertility displayed to the woman on each day of the cycle.
Low fertility [ I High fertility




Panel II: Data recorded on the diary card by the woman (Self-report)
B = days of vaginal bleeding V tests done during the critical period
X = days in which sexual intercourse had occurred
Panel III: Downloaded information on signal levels ofLuteinizing Hormone (LH) and
Oestrone-3-glucuronide (E3G) levels
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THE ROLE OF A PERSONAL HORMONE-ASSAYING SYSTEM
IN CLINICAL RESEARCH
Personal hormone assaying in research
5.1 Introduction
If sexual intercourse takes place on a fertile day of a woman's menstrual cycle, she may
fall pregnant. The potentially fertile period in the cycle is determined by the time of
ovulation. The duration of this fertile period however, is dependent upon the survival
time of the sperm and the egg in the female genital tract.
The mid-cycle peak in the urinary levels of LH precedes ovulation by approximately 24
hours (Collins et al. 1996). A variety of self-detection kits or devices measuring urinary
concentrations of LH has been used to determine the day of ovulation. The maximum
survival time of the ovum is calculated to be less than 48 hours (Royston 1982). The
rapid drop observed in the probability of conception after ovulation further supports a
short life span for ova (Wilcox et al. 1995). The enlarging dominant follicle produces
increasing levels of oestradiol in the late follicular phase (Kerin et al. 1981).
Corresponding levels of E3G, the main metabolite of oestradiol - can be detected in the
urine and have been used in conjunction with urinary LH to identify the potentially
fertile period prior to follicular rupture and ovulation (Aldercreutz et al. 1982, WHO
1983, Schiphorst et al. 1985). Estimates using clinical data have suggested the number
of fertile days in each cycle to be around 6 days, ending on the probable day of ovulation
(Wilcox et al. 1995).
An EC can be effective by inhibiting or disrupting ovulation / fertilisation or interfering
with the transport of the blastocyst, or inhibiting its implantation in the endometrium.
Sex steroids have several effects on the ovulatory cycle and on the endometrium
depending on the time of administration hence have been used as EC. Detailed
understanding of the anti-fertility mechanism of these agents may help to select the most
effective option for each individual depending on the time in the cycle when intercourse
had occurred. Therefore, a reliable yet simple method of detecting the fertile period and
the day of the ovulation is invaluable for research into EC.
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The frequent and regular laboratory assays of steroid hormones in either blood or in
urine have traditionally played a major role (in detecting the fertile period of the cycle,
the cyclical hormonal changes, and the timing of ovulation) in research into female
contraception. This approach is not only inconvenient for the volunteers but it is also
expensive and time consuming to collect samples for daily assays. For example, usually
the daily urine samples are collected and stored over several cycles and then analysed for
hormone levels. Poor compliance with collecting specimens or wrongly labelled
specimens may be difficult to detect, but if undetected can present difficulties in the
interpretation of results. We analysed the practical aspects of using a microelectronic
personal fertility monitor as an alternative to the laboratory based hormone assays, in a
study that investigated the mechanism of action of an EC.
5.2 Subjects and methods
This was a prospective, randomised, double blind, crossover study undertaken in one
centre. Twelve healthy women (mean age 33.3 (range 26 - 41 years)) with regular cycles
(mean 27.6 days (range 25 - 30 days) and mean BMI 25.7 (range 20 - 34)) were
recruited. They were all using a reliable non-hormonal method of contraception or were
abstinent during the study. All subjects gave written informed consent to participation in
the study, which was approved by the Lothian Research Ethics Committee.
A method was sought to provide a convenient means of identifying the fertile period
prior to ovulation, and thereby time the administration of LNG. A home-use Fertility
Monitor was used for this purpose. This product is similar to the Personal System of
Contraception (Persona, Unipath Bedford UK) (Bonnar et al. 2000) in that it monitors
E3G and LH in urine, but differs in that it has been specifically designed for maximising
the chance of conception. Unipath Diagnostics Co., Princeton, NJ, markets the fertility
monitor in the US and Unipath Ltd., Bedford, UK markets it in Britain as CPEFM
(Figure 2.1).
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This inter-active system comprises a hand-held monitor and disposable dual-assay urine
test sticks, and is used to simultaneously detect LH and E3G levels in early morning
urine. The monitor optically measures the intensity of the lines that form on the test
sticks after sampling, and the system will delineate three levels of fertility (Low, High
and Peak fertility) according to the optical signal changes detected. Low Fertility will be
displayed from day 1 of the cycle, until the hormone levels rise above the baseline levels.
A change from Low to High Fertility is triggered by detection of elevated E3G levels.
The change from High to Peak Fertility is triggered by the detection of an LH surge.
Peak fertility is displayed on the day of the LH surge and on the following day (Figure
3.2).
Each woman was studied during four cycles, and was issued with a monitor at the
beginning of the study. Subjects were asked to use the CPEFM according to instructions,
and familiarised themselves with the monitors by using it during a pre-study cycle to
identify the days of high fertility and the day of the LH surge. They also recorded days of
vaginal bleeding.
Data from the pre-study cycle was used to predict the timing of the LH surge and of the
fertile phase during the study cycles and thereby to predict when treatment should be
administered. The three study cycles followed immediately after the pre-study cycle. Six
subjects were randomly assigned to treatment arm A and received LNG in the first study
cycle and placebo in the third study cycle. The remaining six subjects were randomised
to treatment arm B and received placebo in the first study cycle and LNG in the third
study cycle. The second study cycle was a "washout" phase for all women during which
time they also received placebo tablets (Figure 2.2).
The randomisation list was produced using SPSS Rv.Bernouilli function such that each
study number was randomly assigned to either treatment arm A or treatment arm B with
the same probability i.e. 0.5.
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Each subject collected a sample of early morning urine daily from the first day of the
first study cycle until and including the first day of the menstrual bleed signaling the end
of the last study cycle. Samples were frozen and later assayed in batches (with all
samples from one subject assayed in a single batch) for measurement of urinary LH, E3G
and P3G.
Quantitative assessment of urinary LH was performed using a LH MAIAclone kit
(BIOSTAT-DIAGNOSTICS, Stockport, Cheshire, UK). This method incorporates two
high affinity monoclonal antibodies into an immunoradiometric assay system and offers
a working range of 1.5 - 200 mlU/ml. Urinary P3G was measured using a direct enzyme
immunoassay (working range 0.16 pg/L - 20 pg/L), while a direct immunoassay was
used to measure E3G levels (working range 8.36 nmol/L - 2140 nmol/L. Intra-assay and
inter-assay coefficients of variation were 6% and 10% for E3G, 10% and 12% for
pregnanediol and 3% and 5% for LH respectively (Yong et al. 1992). Only the intra
assay variability was relevant since the specimens for a given woman were analysed on
the same assay. Geometric means of daily replicates were divided by the respective
daily creatinine concentration to correct for variations in the dilution of the urine
specimen.
During study cycles 1 and 2 women were asked to take the study medication on the first
day of high fertility as identified by the monitor. However, by the third study cycle, the
variation in the number of High Fertile days (range 0-9 days) meant that the monitor
could not be used to administer medication in the fertile period in every cycle. Therefore,
we had to adopt a different method of calculating the anticipated day of the LH peak for
each cycle based on the monitor information from the previous cycles (including the pre-
study cycle). Hence, in the third study cycle, the medication was taken two days prior to
the anticipated day of the LH peak. In all cycles the first tablet was taken at 11.00 hours
and the second at 23.00 hours. A sample of venous blood was collected 5-7 days after
treatment, stored and later assayed for progesterone using Coat-A-Cont solid-phase
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radio-immunoassay. The subjects kept a daily record of all vaginal bleeding experienced
during the 4 cycles, the fertility status information displayed each day on the monitor
LCD and the days on which the study medications were taken.
It was not possible to retrieve monitor data in three study-cycles due to lost or broken
devices, and there were no daily urine samples available from an additional cycle as the
woman was abroad on holiday. Therefore, a total of 32 study cycles were analysed.
For the purpose of the study the following definitions were created.
Definitions based on the quantitative data.
A significant delay in the onset of next menses: Delay of 5 or more days from the
expected onset ofmenses (based on the mean cycle length for the 2 placebo cycles).
The LH peak was defined as a significant rise in urinary LH concentration, with a
minimum of 50% rise above the average baseline level for 3 preceding days and which
remained elevated for a minimum of 3 days.
The first day of the LH peak was defined as the day of the first significant rise (>50%
above the baseline) seen at the beginning of the LH peak.
Retrospectively predicted first day of the LH peak for the treatment cycles was the
calculated mean of the first day of LH peak in the two placebo cycles.
A significant delay in the first day of the LH peak: Delay of 5 or more days from the
expected first day of the LH peak in the treatment cycle (based on the mean first day of
the LH peak during the 2 placebo cycles).
Luteal phase: time from the day after the first day of the urinary LH peak (LH +1) until,
and including, the day before the first day of the next menses.
Follicular phase: time from the first day of the menses until the day of the first
significant rise in urinary LH (LH +0) inclusive.
Definitions based on the monitor data. High fertile days: days preceding the urinary
LH peak as indicated by the monitor to be potentially fertile. The monitor was
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programmed to display an additional day of high fertility following the 2 peak fertile
days.
Peak fertile days: The day of the first significant rise in urinary LH (>50% above the
basal level over the preceding 3 days) detected by the monitor. The monitor was
programmed to display a further day of peak fertility following the first rise.
4.2.3 Statistical Methods
The compliance data was summarised for descriptive purposes using numbers of cycles
or tests as denominators.
5.2 Results
Data from the monitor and from RIA of daily urines was available in 32 study cycles,
and in 11 of these (i.e. one treatment cycles per volunteer) women took LNG on a High
fertility day. In the remaining 21 study cycles, placebo tablets were taken on a similar
day. In four out of the 11 treatment cycles, LNG treatment aborted and or significantly
delayed the subsequent LH surge. However, in the remaining seven treatment cycles,
LNG did not alter the day of the LH surge or the cycle length significantly. In addition,
one of the placebo cycles was prolonged due to a spontaneous delay in the LH surge.
Therefore, the 5 cycles, in which the LH peak was significantly delayed in comparison to
the usual pattern were analysed separately (Group 2) to the other 27 cycles (which
consisted Group 1).
5.3.1 Group 1
Results from laboratory reference method for urinary hormones
The mean E3G levels in urine increased to maximum levels of 24.74 pmol/mol
creatinine (95% C.I. 17.72 - 31.76), 1.2 days before the peak urinary LH value in the 27
ovulatory cycles. In these cycles, the mean concentration of peak urinary LH was 3.91
U/mol creatinine(95% C.I. 2.8 - 5.02) (Figure 5.1). As expected, the mean urinary P3G
levels started to rise on LH +1.
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Figure 5.1 Mean urinary daily hormone levels by RIA
E3G -a- LH Pregnanediol
Day relative to the first day of the urinary LH peak
The monitor warning of the LH surge
The days of high fertility recognised by the monitor was regarded as the warning of the
LH surge, and subsequent ovulation. It had been reported that the increase in E3G
production from the enlarging follicle, with a parallel increase in serum levels and the
corresponding urinary levels were associated with the monitor indicating increasing
incidence of High fertility status on the days prior to ovulation (Behre et al. 2000).
Among the 11 women, the monitor provided on average 3.4 days (95% C.I. 2.6 - 4.2;
range 0-9 days) ofwarning prior to the first day of the urinary LH surge. In 74.07% of
the cycles the monitor provided between 1 - 4 days of warning prior to the first day of
the urinary LH surge (Figure 5.2).
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Figure 5.2 Urinary E3G and percentage ofhigh fertiity status
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Comparison between the monitor peak fertility, and the urinary LH surge
The monitor detected an LH surge in 21 out of the 27 cycles in group 1. In all 21 cycles
the monitor detected an LH surge within two days of the first day of the urinary LH surge
measured by laboratory RIA (table 5.1, Figure 5.3). In these 21 cycles, the percentage
rise in urinary (laboratory RIA) LH concentration above the baseline level (baseline
value = average value of LH concentration during the preceding 3 days) was compared
between the actual (laboratory RIA) LH peak day and the monitor peak day (Table 5.2).
Except for 1 cycle, the daily urine samples analysed in the laboratory confirmed the LH
percentage rise of > 50% above the baseline value on the day that the monitor declared
an LH peak. In the remaining six cycles, an LH surge had occurred, but was not detected
due to missed tests in one cycle; monitor error in two cycles; and could have been due to
either of the above mentioned causes in three further cycles (no compliance data
available for these three cycles).
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Table 5.1 First day of the urinary LH surge (LH + 0) measured in the laboratory by
RIA, relative to the first day of peak fertility indicated by the CPEFM
monitor in group 1
Day oftheLH surge by laboratoryRIA ofthe daily Frequency Percentage
urine samples relative to the monitorpeak %
Before the first day ofmonitor peak fertility 3 14.3
On the same day as the first day ofmonitor peak fertility 16 76.2
After the first day ofmonitor peak fertility 1 4.8
I Percentage ofpeak fertility status -a- Urinary LH
Figure 53 Urinary LH and percentage ofpeak fertility status
100 T T 4.00
20 -
-15-14-13-12-11-10 -9 -8 -7-6-5-4-3-2-10 1 2 3 4
day relative to the first day of the urinary LH surge
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Table 5.2 The average percentage rise of the LH above the baseline concentration in
collected daily urine (laboratory RIA) in group 1
The actual (laboratory
RIA) LHpeak
The average % risefrom
the baseline on the day of
the monitorpeak
The average % risefrom the
baseline on the actual (lab-
based urinary) LH surge
Before the first day
ofmonitor peak 226 244.1
fertility (n=3) (SD +/-108.0) (SD +/-196.5)
On the same day
as the first day of 357.2 357.2
monitor peak (SD +/-264.2) (SD +/-264.2)
fertility (n=16)
After the first day
ofmonitor peak 13.64 105.13
fertility (n=l)
5.3.2 Group 2
In these five cycles, the occurrence of a mid-cycle LH surge and subsequent ovulation,
were either prevented or delayed (reflected by the absence of normal rise in urinary
pregnanediol during the luteal phase). Nevertheless, a second E3G rise, a successive
peak in urinary LH and a consequent rise in mid-luteal pregnanediol were observed later
on, in the same cycle (Figure 5.4).
During these five cycles, at the expected time of ovulation for each woman the mean
urinary LH reached peak concentrations of 1.1 U/mol creatinine (significantly lower than
the value during the control cycles, p <0.0001). The urinary E3G also increased to a peak
on the same day (17.48 pmol/mol creatinine) but thereafter decreased down to an early
follicular level. Furthermore, these lower than usual LH peaks were not followed by an
increase in the urinary P3G. Subsequently, a second urinary LH peak (3.1 U/mol
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creatinine, SD +/-1.0) occurred 17.4 days later in that same cycle (Figure 5.4), and was
preceded by a peak in the mean urinary E3G level (19.06 pmol/mol creatinine SD +/-
4.14).
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Figure 5.4 Treatment cycle in subject SI 06.
Note the delayed true LH peak on day 23 which is followed by an increase in the
urinary pregnanediol levels. The white arrow represents the LNG administration.
Comparison between the monitor peak fertility, and the urinary LH surge
In three of these cycles, the monitor indicated peak fertility at the expected time for the
respective volunteer (false positive). The monitor failed to identify every one of the
second LH surges that occurred later in the cycles (between days 25 - 40). The reasons
are as follows; In three cycles by the time the second LH surge had occurred, the monitor
had ceased requesting tests; in one cycle the woman failed to perform a test requested by
the monitor on the first day of the second LH surge (user error); in another cycle,
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although a test was performed on the first day of the second surge, the monitor failed to
identify it (monitor error) (Table 5.3).
Table 5.3 Reasons for missed LH surges in group 1 (27 cycles in total)
Reasonsfor the monitor not detecting an UserError Monitor error Unknow
LH surge (%) (%) n
Number of cycles 1 2 3
Percentage of the total number of 3.7% 7.4% 11.1%
cycles
5.3.3 Objective measurement of compliance with urine testing
Compliance data on daily urine testing was available in 26 cycles, and this information
could not be retrieved from the monitors in 6 cycles due to infrequent downloading. The
eleven women failed to perform 18.9 % (95% C.I. 16.7 - 25.1) of the total tests
requested by the monitor. On average a woman missed between 2-3 tests of the average
12.2 tests requested (range 10 - 20 tests).
5.4 Discussion
A reliable and simple means to predict the potentially fertile period will provide essential
information that can be used to influence the probability of conception. If the users can
be reliably warned of the potentially fertile period in each cycle, that information can be
employed in clinical practice, to time intercourse in order to avoid or permit the
occurrence of a conception as desired. Such methods will assist in contraceptive research
to monitor the frequently changing hormone levels, and to identify the fertile period.
Hormonal methods of EC are widely used to prevent pregnancy after unprotected coitus
(Glasier 1997 review). Sex steroids that are used as ECs have several effects on both the
ovulatory cycle and on the endometrium. These effects are dependent on the time in the
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cycle that the EC is administered. Therefore, the accurate prediction of the potentially
fertile period should enable investigators to identify the particular mechanism of the sex
steroid that prevents conception when intercourse has already taken place.
The precision of the method that identifies the fertile period directly affects the accuracy
of the estimated probability of conception following an act of unprotected intercourse.
Therefore, one can see that the accuracy of the estimated efficacy of any EC method is
directly dependent on the technique used to identify the fertile period.
Previous studies have confirmed that the home-use fertility monitor data correlated well
with the laboratory measured urine hormone levels (Bonnar et al. 1999; Behre et al.
2000). In contrast to the laboratory assays that are inconvenient to women (e.g.
collection of a large number of urine samples), time consuming, and expensive, the
monitor was rather easy to use and was possibly less expensive.
The consensus of opinion is that the fertile period of the woman's cycle is around six
days, ending on the estimated day of ovulation (Wilcox et al. 1995). A peak in urinary
LH levels preceded ovulation by about 24 hours (Collins et al. 1996). In our study, to
test the hypothesis that LNG acts as a post-coital agent by abolishing the pre-ovulatory
LH surge and by delaying ovulation, we wanted to administer LNG in the fertile period
immediately before the mid-cycle LH surge. Therefore, we required in particular, the
prediction of the impending LH surge to be accurate (the warning had to be at least one
day, but not more than four days before the urinary LH surge), to administer LNG at a
matching time in each cycle in the fertile period, so the observed effects could be
compared. The correlation between the High and Peak fertility days as indicated by the
monitor and the urinary LH surge, showed (Figure 5.2) that in 25.93% of the cycles in
group 1, there was either no warning or the warning started at more than four days before
the LH peak had occurred. When the treatment had to be administered on the actual first
day of the LH peak, it created a problem when comparing the effects of LNG taken on or
135
Personal hormone assaying in research
before the day of the urinary peak. It is possible that the timing of LNG in the former
group was "too late" to influence an event already well underway. Similar obstacles were
encountered in data analysis when LNG was administered long before ovulation had
occurred (as a result of the advance warning of the imminent occurrence of an LH surge
more than four days before the actual surge). The Clearplan Easy device is designed for a
different purpose (for couples intending conception therefore the users should continue
to have intercourse until peak fertility is recorded) hence "the prolonged fertile period
does not matter" (Bhiwandiwalla et al. 2001) is not a valid argument for the following
reasons. The purpose of using the device is to time intercourse since not all couples are
able to have intercourse every day - indeed, if they were, there would be no need to
monitor ovulation. If users exhaust themselves by having intercourse for several days
before the days of peak fertility, they may be less likely to have intercourse at a time
when the chance of pregnancy is maximal.
We have previously reported a monitor error of 7.9% in identifying an LH surge
(Chapter 3; Hapangama et al. 2001b), and a similar performance with about 92%
accuracy in LH detection was expected in this group of patients. Therefore, non¬
compliance with urine testing was likely to be the cause for missing the LH surge in the
four out of the six cycles in group 1. Women missing about 19% of the urine tests
requested by the monitor is obviously significant and comparable to previous
observations by our group (Chapter 4; Hapangama et al. 2001c). The monitor stored data
simultaneously on the hormone signal levels and on the testing events (volunteer
compliance) for several months and this information could be later retrieved. Among
urine samples that have been collected daily over a period, a wrongly labeled one will be
impossible to detect, yet may affect the results. In addition, self-LH detection kits have
been commonly used to identify the LH surge, for example to time the administration of
a particular agent, and to sample the endometrium at a particular time (Cameron et al.
1996). Obviously, inaccuracy in detecting the LH surge (or undetected non-compliance)
in such studies directly affects and invalidates the results. Therefore, the monitor offered
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us an important methodological advance in providing reliable data on the incidence of
non-compliance with urine testing, and exactly when a test was missed.
Several possible improvements could be made to the system to achieve its full potential
use in clinical research studies. Although the urinary LH surge detection based on a
significant rise preceded by a similar rise in E3G may be adequate for most of the normal
cycles, it will erroneously detect an LH peak that had been aborted. If the qualifying
criteria included the rise in LH to remain elevated for a minimum of 3 days, and if the
system revalidated the declared LH surge, for example three days later, on the basis of
the sustained increase in urinary LH signal and on the rise in P3G, the monitor accuracy
will be significantly enhanced. Similarly, if the monitor requested daily urine tests
throughout the cycle, the delayed LH surges may have been identified. The daily
requirement in testing may even increase the overall compliance since the user may get
into a habit ofperforming the test every day.
This study was designed to assess the pragmatic issue of whether the home-use fertility
monitor can reliably replace the existing daily urine and whether it offers increased
convenience to women. In a significant number of cycles the monitor indicated high
fertility long before the ovulation had occurred and thus, there is really no advantage to
providing this advance warning either in a clinical or a research setting. Conversely, as
the rise in LH is the most predictable method of determining the days of high fertility
(WHO 1980), an error ofjust around 8% in LH detection can be tolerated. In conclusion,
this microelectronic system in detecting the urinary LH peak can be invaluable in
contraceptive research because it is easy to use and provides reliable data on compliance.
However, further technical adjustments are called for in giving advanced warning of the
fertile period (identifying High fertile days).
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CHAPTER 6
THE ENDOMETRIAL EFFECTS OF MID-LUTEAL PHASE
ADMINISTRATION OF MIFEPRISTONE
Endometrial effects ofmid-luteal mifepristone
6.1 Introduction
Human endometrium is a target organ for the ovarian steroidal hormones oestradiol and
progesterone. One of the fundamental roles of progesterone is the differentiation of an
oestrogen-primed endometrium (Comer & Allen 1929). The endometrial receptivity that
permits successful implantation depends upon timed and regulated synthesis and
secretion of a specific set of progesterone-induced proteins in an oestrogen-primed
endometrium. If a pregnancy fails to occur, the corpus luteum regresses with a
subsequent fall in progesterone levels. There is now compelling evidence that a period of
exposure of the oestrogen-primed endometrium to progesterone, followed by a
withdrawal of progesterone are the hormonal prerequisites for menstruation (Critchley et
al. 2001). The characteristics of the endometrial changes (including the extensive
changes observed in the endometrial vasculature) associated with the withdrawal of
progesterone and menstrual bleeding, suggest an involvement of vaso-active local
mediators. Prostaglandin (PG) activity in the endometrium is modulated by
progesterone, and their widely recognised vasoactive properties make PGs to be prime
candidates for mediators ofprogesterone action on the endometrium (Baird et al. 1996).
Prostaglandins (PGs) are synthesised from arachidonic acid (AA) thus, the liberation of
AA from precursors (present as membrane bound phospholipids) by the action of
phospholipase A2 (PLA2) is one of the first and a rate limiting steps in PG synthesis
(Bonney et al. 1987 a & b; reviewed in Poyser 1992). AA is then converted to
prostanoids including PGE2j PGF2a, and PGI2 by the actions of cyclo-oxygenase (Figure
6.1). In the endometrium, PGs are not stored, but immediately synthesised and released,
and metabolised to inactive metabolites by prostaglandin 15 dehydrogenase (PGDH)
enzyme (Ensor et al. 1990).
The antiprogesterone compound mifepristone (RU 486; Roussel Uclaf, Paris, France) is
a synthetic 19-norsteroid with a specific high affinity for binding to the progesterone
receptor. It blocks the biological effects of progesterone at the level of the progesterone
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Pathways for AA metabolism in the uterus.
Figure 6.1 Pathway ofArachidonic acid metabolism in the Uterus
Predominating in: endometrium myometrium
receptor (Spitz & Bardin 1993). In the mid-luteal phase, mifepristone at a single dose of
50 - 800 mg, induces menstrual bleeding within 72 hours (Schaison et al. 1985; Shoupe
et al. 1987). Luteolysis was incomplete in two thirds of the subjects, and they
experienced a further episode of vaginal bleeding at the expected time ofmenses. In the
remainder there was complete luteolysis with only one episode of bleeding. Thus the
vaginal bleeding observed after mifepristone without a decrease in the circulating
progesterone values, appears to be due to a direct effect on the endometrium.
Johannisson et al. in 1988 suggested that the menstrual bleeding induced by
mifepristone in mid-luteal phase to be a direct endometrial vascular effect. Following
treatment with 50 mg of mifepristone in the mid luteal phase (days 20 - 23), they
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described a significant reduction in the capillary luminal area and diameter associated
with degenerative changes in the endothelial cells, which preceded the menstrual
shedding. These changes did not always accompany regressive changes in the adjacent
stroma. This effect ofmifepristone on the endometrium (at a time when the endometrial
progesterone receptor level is relatively low) is poorly understood, and has been hardly
investigated.
The endometrial effects of early luteal phase administration of antiprogesterones have
been extensively investigated (Swahn et al. 1990; Gemzell-Danielsson et al. 1996;
Cameron et al. 1996). In the early luteal phase mifepristone inhibits progesterone
induced down-regulation of PR and oestrogen receptors while antagonising the
progesterone action on endometrial markers such as prostaglandin dehydrogenase
(PGDH), which are known to be progesterone dependent (Casey et al. 1980; Greenland
et al. 2000). Moreover, PGDH has been postulated as a useful marker of the "closure" of
the implantation window, and the effect of mid-luteal administration on such markers
might add to our current understanding of potential contraceptive actions of
mifepristone.
Our study investigated the mechanism of mifepristone-induced endometrial shedding &
vaginal bleeding in the endometria of 16 healthy women with regular cycles. The
endometrial biopsies were performed between 0 (control), and 6 to 48 hours following
mid-luteal phase administration of a single dose 200 mg of mifepristone. We examined
the expression and the distribution of sex steroid receptors in the endometrium and the
expression ofPGDH, and cyclo-oxygenase - 2 (COX-2). Alterations in the expression of
such progesterone-dependent proteins may widen our understanding of the mechanism
by which mifepristone induces endometrial bleeding in the mid-luteal phase.
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6.2 Materials & Methods
6.2.1 Subjects
Initially, 20 healthy women with regular cycles (25 - 30 days duration) aged between 26
and 42 years (mean age 34 years) were recruited in to a randomised, single centre study
with mifepristone. Women were either using a reliable non-hormonal method of
contraception or were abstinent. All women underwent a comprehensive screening
procedure before commencing the study. This consisted of a full medical history and
routine physical and gynaecological examination, together with measurement of blood
pressure, pulse, height and weight. In addition, a venous blood sample was taken for full
blood count, serum biochemistry and liver function. These blood tests were repeated at
the end of the study. All women kept a menstrual diary card, and recorded all vaginal
bleeding experienced during the study period and in the following cycle, and the day in
which they identified an LH surge using urinary dipsticks.
We also studied the endometrial samples from four women taking part in a separate
study, which evaluated the secretory endometrium. Those women also used the same
urinary dipsticks to identify the urinary LH surge and the biopsies were collected 7 or 8
days after the first day of the urinary LH surge. Since these women did not receive any
treatment the four biopsies were included in to our control group. Therefore, the total
number of biopsies analysed in the control group was seven. Lothian Research Ethics
Committee approved the study and, informed written consent was obtained from each
woman.
6.2.2 Study Design
The women were monitored over two consecutive cycles; a treatment and follow-up
cycle. Each of the 20 women in the study were allocated to the next consecutive study
number in the randomisation list before commencing the study. The randomisation list
was produced using SPSS such that each study number was randomly assigned to one of
five groups in the study. The list was balanced after each block of 5.
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Women used LH detection kits (Oviquick, Unipath, Bedford, UK) to detect the
Luteinizing Hormone surge in a first sample of urine. 16 women took 200mg of
mifepristone on day 8 after the onset of the urinary luteinizing hormone surge (LH+8).
An endometrial biopsy was obtained at 6, 24, 36 or 48 hours after taking mifepristone. In
order to assess the steroid receptor expression and endometrial parameters of the normal
secretory endometrium in the mid-luteal phase, four women were randomly allocated to
a control group. They did not take mifepristone, but had an endometrial biopsy 8 days
following the identification of the LH surge. On the occasion when the endometrial
biopsy was taken, a blood sample was also collected for serum progesterone
measurement by radio-immunoassay (See Chapter 7).
Four women were subsequently withdrawn from the study. One due to previously
undiagnosed cervical stenosis; in one woman RIA could not confirm the self-detected
LH peak; the endometrial samples were inadequate for analysis in two other women.
Therefore, we analysed the endometrial samples in 13 women after taking mifepristone
in the mid-luteal phase (n = 3, at 6 hours; n = 4, at 24 hours; n = 3, at 36 hours; n = 3, at
48 hours; after mifepristone). Three samples from our original control group, and the
above mentioned four additional samples from a separate study made the total number in
the control group to be 7.
6.2.3 Detection of the urinary LH peak
The timing of the urinary LH surge were detected by the subjects themselves using a
commercially available LH detection kit (Oviquick, Unipath, Bedford, UK), which they
used according to the manufacturer's instructions. Self-detected urinary LH peak was
subsequently confirmed by radio-immunoassay (See Chapter 7 - Methods).
6.2.4 Serum progesterone
A blood sample was collected immediately before the endometrial biopsy in all women,
stored, and later assayed for progesterone level (methods - Chapter 7). Serum
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progesterone measurements were done by using the Coat-A-Cont progesterone
procedure (a solid-phase Radio Immuno Assay).
6.2.5 Endometrial biopsies
Endometrial biopsies were obtained using a Pipelle endometrial sampling device
(Prodimed, Neuilly-en-Thelle, France) without the need for cervical dilatation or general
anaesthetic and were fixed immediately in 4% para-formaldehyde for 24 hours, routinely
processed, embedded in paraffin, and sections were cut to 5 pm thickness. All tissue
samples were labelled with a code number for anonymity, and except for this number,
the mounted sections did not contain any other information.
6.2.5 Immunohistochemistry
Immuno-histochemical staining was performed for immuno-localisation of:
i) Progesterone receptor (PR) with mouse monoclonal anti-human PR antibody
(Novocastra Laboratories, Newcastle upon Tyne, UK).
ii) Oestrogen receptor (ER) with mouse monoclonal anti-human ER antibody
ER1D5 (DAKO Laboratories, High Wycombe, UK).
iii) Androgen receptor (AR) with monoclonal mouse anti-human AR antibody (F-39,
Biogenex antibody, A Merarini Diagnostics, UK).
iv) Prostaglandin dehydrogenase (PGDH) with rabbit polyclonal antibody
(Dr H.H.Tai, University ofKentuckey, Lexington, USA).
v) Cyclo-oxygenase type -2 (COX-2) with goat polyclonal anti-human COX-2
antibody (Santa Cruz, Biotechnology, UK ).
Immunohistochemistry procedures
All protocols were optimised to determine the correct conditions for maximum specific
staining, and all sections used as negative controls did not show immunostaining. Each
immunostaining procedure was performed in a single run.
(Chapter 7 - Methods).
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6.2.6 Scoring and immunohistochemistry analysis
We employed a semi-quantitative subjective scoring system to evaluate the intensity and
the localization of immunoreactivity in entire tissue sections. Previously we have
reported that the immunostaining patterns in endometrial sections measured by the
subjective semi-quantitative scoring, showed an almost perfect correlation (regression
coefficient of 0.963) with that measured objectively by computerized image analysis
(Wang et al. 1998). Therefore, the less time consuming, semi-quantitative scoring
system provides a valid score suitable for graphical presentation.
Two independent observers using light microscopy visually assessed all coded sections.
The two separate scores were then compared to obtain a more objective final score for
each section. Once the final score had been agreed for all sections in the five-
immunostaining runs, the code was broken. Afterwards the final immuno-staining scores
were analysed by the respective groups.
The immuno-staining intensity of the steroid receptors (PR, ER, and AR) were scored
using a four point scoring scale, where the intensity of staining was assigned as 0 = none,
1 = weak, 2 = distinct, 3 = strong. However, the staining intensity of PGDH and COX-2
showed a narrow range and therefore we adapted a three point scoring scale where the
score of zero indicated an absence of immuno-reactivity; 1 = faint immuno-reactivity; 2
= strong immuno-reactivity.
6.2.7 Statistical analysis
Since mifepristone induced bleeding by 36 - 48 hours in all women, a preliminary
analysis was performed to determine the appropriate statistical test for analysis of the
data. The mean staining intensity scores between 6 hour and 24 hour groups and between
36 hour and 48 hour groups showed no significant difference, hence the 13 samples after
treatment with mifepristone were analysed in two groups; group 1 (6 to 24 hours after
mifepristone n = 7) and group 2 (36 to 48 hours after mifepristone n = 6). Comparisons
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between these two groups, was tested by non-parametric Kruskal-Wallis ANOVA test,
and the Dunn's Multiple Comparisons Test since they were discontinuous data sets.
6.3 Results
All women reported vaginal bleeding commencing 36 - 48 hours after taking
mifepristone. Four women in group 2 (one woman after 36 hours, and three women after
48 hours) had already started to bleed at the time the endometrial biopsy was taken, the
others started bleeding after the biopsy. The bleeding lasted for 12 - 72 hours, and all but
three women reported a second bleed at the time of the expected menses. In these three
women, a second episode ofbleeding occurred approximately four weeks later.
6.3.1 Serum Progesterone
Treatment with mifepristone had significantly reduced serum progesterone levels in all
women when compared with the controls (13.2 nmol/L vs. 34.8 nmol/L, p = 0.001), but
the levels between 6-24 h group and 36-48 h group were not statistically significant (p =
0.32).
6.3.2 PGDH immunoreactivity
Intense PGDH immunoreactivity was observed in the cytoplasm of predominantly
glandular epithelium (with a lesser degree of staining in the stromal cells) in all mid-
luteal phase control sections. The abundance of PGDH positive immunostaining clearly
declined to be virtually absent by 36 - 48 hours in both glands and in stroma. The
difference in PGDH staining scores between the control group and 36 - 48 h group were
significant (p = <0.05) (Figures 6.2 and 6.3).
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Figure 6.2 PGDH immuno-staining
a. Negative control = Mid-luteal endometrium.
b. PGDH immuno-staining in midluteal phase endometrium, demonstrating
positive immuno-reactivity in the glands and stroma.
e. Endometrium biopsied 6-24h after mifepristone, showing mild decrease in
immunostaining in both compartments,
d. Note the clear decrease in immuno-staining in both glandular and stromal
compartments of the endometrium biopsied 48h after taking mifepristone on
LH+8.
Scale bar. 50 /um.
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Intensity of staining for PGDH (a) and COX-2 (b) in endometrial glands ( ® ) and
stroma ( q ) in the mid-luteal phase of the cycle before (control) and at times after
administration of 200mg mifepristone.
Bar. Median and range
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«
a. Negative control b. Control (0 h) sample on LH+8
c. 6 - 24 h after mifepristone d. 36 - 48h after mifepristone
Figure 6.4 COX-2 Immunostaining
a. Negative control = mid-luteal endometrium.
b. COX-2 immuno-staining in an endometrium collected in the mid-luteal phase
illustrating negligible immuno-staining in both glands & stroma.
c. No obvious change in the endometria for COX-2 immuno-reactivity biopsied
6-24h following mifepristone.
d. Endometrium biopsied 36-48h after mifepristone, on LH+8 showing a
marked increase in immuno-staining in the glandular cytoplasm.
Scale bar. 50 ftm.
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c. 6 - 24 hours after mifepristone
b. Control (Oh) sample LH+8





















d. 36-48 h after mifepristone
Figure 6.5 PR immuno-staining
a. Mid-luteal endometrium, negative control.
b. A control biopsy displaying faintly positive PR immuno-reactivity confined
to the nuclei of both glandular epithelial and stromal endometrial cells in the
mid-luteal phase (LH+8) endometrium.
c. The weak glandular PR staining in an endometrial sample biopsied 6-24h
after mifepristone.
d. Glandular PR immuno-staining appears to decline further by 36 - 48 hour
after mifepristone. Note the persistence of the weak stromal staining across
the groups.
Scale bar. 50 pm.
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a. Negative control b. Control (0 h) sample at LH+8
6 -24 h after mifepristone d. 36-48h after mifepristone
Figure 6.6 ER immuno-staining
a. Negative control = mid-luteal endometrium.
b. Mid-luteal phase control sample, showing weak ER immunostaining
in the stroma as well as in the glands.
c. & d. Endometria biopsied 6-24h and 36 - 48h after mifepristone,
respectively, showing no obvious change in the staining.
Scale bar, 50 jam.
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a. Negative control
c. 6 -24 h after mifepristone d. 36 - 48 h after mifepristone
Figure 6.7 Androgen receptor immuno-staining
a. Negative control = Mid-luteal endometrium.
b. Control endometrium biopsied on LH+8. showing the distinct AR
immunostaining localized predominantly in the stroma with faint or
absent glandular epithelial staining.
c. & d. Endometria biopsied after mifepristone showing no apparent
change in the AR immuno-staining.
Scale bar, 50 jum.
b. 0 hours (Control) sample on LH+8
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6.3.3 COX-2 immunoreactivity
In all samples (treated / untreated), COX-2 staining was localised predominantly in the
endometrial glands with no (or barely detectable) staining in the stroma (Figure 6.4).
Untreated endometria in the mid-luteal phase showed minimal staining for COX-2 in the
glandular cellular compartments. After mifepristone, a significant increase in
immunoreactivity was apparent at 36 - 48 hours (Figure 6.3) (p = 0.0018).
6.3.4 Steroid receptor immunostaining.
Control biopsies displayed faintly positive PR immuno-reactivity confined to the nuclei
of both glandular epithelial and stromal endometrial cells. The weak glandular PR
staining appears to decline further by 36 - 48 hour after mifepristone. Stromal staining
however remains weak across the groups (Figure 6.5).
In all mid-luteal phase control samples, there was weak ER immunostaining in the
stroma as well as in the glands. There was no obvious change in the staining after
mifepristone (Figure 6.6).
The distinct AR immunostaining was localized predominantly in the stroma in the
control samples with faint or absent glandular epithelial staining, and there was no
apparent change observed in the AR immunostaining after the treatment with
mifepristone (Figure 6.7).
6.4 Discussion
Endometrial shedding and vaginal bleeding is observed after withdrawal of progesterone
(e.g. luteal regression) from an oestrogen primed endometrium that is subsequently
exposed to progesterone. Similar bleeding is also seen after the pharmacological
withdrawal of progesterone via administering the antiprogesterone, mifepristone in the
luteal phase of the cycle. While the endometrial morphology exhibits a marked
sensitivity to mifepristone, with 0.5 mg daily dose being the threshold dose for delay in
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endometrial maturation (Croxatto et al. 1993; Cameron et al. 1996; Spitz et al. 1996;
Gemzell-Danielsson et al. 1997), in general, higher doses (in excess of 10 mg) are
required to produce endometrial shedding and menstrual bleeding (Green et al. 1992;
Schaison et al. 1985; Shoupe et al. 1987).
All women in our study reported vaginal bleeding commencing at 24 to 48 hours after
taking 200 mg of mifepristone in the mid-luteal phase. The mifepristone induced
bleeding in the mid-luteal phase, was not dependent on a parallel decline in the
circulating progesterone levels, but was due to direct antagonism of the action of
progesterone on the endometrium (Swahn et al. 1988). The endometrial shedding at the
onset of normal menstruation is due to a fall in progesterone levels that follow luteal
regression. In 13 out of the 16 subjects, this was followed by a second bleed of normal
character at the expected time of the next menses. Although mifepristone significantly
depressed the serum progesterone value in all women, the occurrence of a second bleed
in the majority suggest only a partial luteolysis and a direct effect of mifepristone on the
endometrium.
The current understanding advocates a central role for PGs as a trigger mechanism for
menstruation (Figure 6.8, Baird et al. 1996; Critchley et al. 2001; Milne et al. 2001).
The concentration of PG in any tissue is related to its rate of synthesis and metabolism,
and the variation in the endometrial release of PGs at different stages of the menstrual
cycle suggests an ovarian hormonal influence. The two key-enzymes that control the
endometrial PG synthesis (PLA2 and COX) appear to be under the influence of
progesterone. COX enzyme exists as two isoforms produced by two different genes
(COX-1 and COX-2). COX-I is constitutively expressed while COX-2 expression is
modulated by a variety of stimuli and may be inhibited by progesterone in the
endometrium (Jones et al. 1997). PLA2 also appears to be present in the endometrium in
two different iso-forms; the calcium dependent and inducible PLA2(i) which is localised
in the endometrial glands, and the calcium independent PLA2(ii) that is predominantly
154
confined to the stroma (Bonney et al. 1987). Conversely, prostaglandin dehydrogenase
(PGDH) metabolises PGs to inactive metabolites and this enzyme is induced by
progesterone (Casey et al. 1980 & 1993; Kelly et al. 1986). The increase in PGDH
activity in a secretory endometrium that occurs in response to the rising levels of
progesterone in the iuteal phase (Casey & MacDonald 1980) can be prevented by
administration of antigestagens shortly after ovulation (Cameron et al. 1997). Thus
progesterone is responsible for stimulating PGDH and suppressing COX-2.
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Endometrial breakdown and vaginal bleeding
The decline in progesterone concentrations (luteal regression) or inhibition of its action
(mifepristone) exerts a primary effects on the peri-vascular region surrounding blood
vessels (bv). Adapted from; Baird et al. (2000) with permission.
In our study, treatment with mifepristone in the mid-luteal phase resulted in a decreased
PGDH and an increased COX-2 expression in the endometrial glands, which was
apparent at 36 hours following mifepristone. This effect will be synergistic in increasing
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endometrial PGs (due to a synchronized suppression of metabolism, with an
augmentation in the synthesis), and will lead to increased uterine activity and menstrual
bleeding. In addition, progesterone withdrawal mediates the degradation of the
endometrial extra-cellular matrix by inducing matrix metalloproteinases (MMP)
(Lockwood et al. 1998), and other cytokines (Critchley et al. 2001 & references therein).
Attempts have been made to demonstrate the effects of progesterone on the endometrial
PGs activity both in-vitro as well as in-vivo studies. Progesterone appears to enhance the
PG biosynthetic capacity of the secretory endometrium. This is demonstrated by the in-
vitro studies employing cell culture techniques and by maintaining endometrial explants
in culture (Smith et al. 1984; Kelly et al. 1984; Abel & Baird 1980). Conversely,
progesterone has been shown to suppress the release of PGs from the endometrium
(Abel & Baird 1980; Kelly & Smith 1987). Studies in-vitro have reported a reduction of
both the oestradiol-stimulated and the basal PG production by progesterone (Abel &
Baird 1980; Kelly & Smith 1987). Furthermore, during pregnancy, when progesterone
levels are high, basal endometrial PG production is also reduced (Maathuis et al. 1978).
It had been suggested that this effect might involve the inhibitory effect of progesterone
on the PLA2 activity (Bonney et al. 1987).
The withdrawal of progesterone from an endometrium that has been primed with
progesterone and oestradiol results in an increase COX-2 expression, while continuing
exposure to progesterone is associated with low levels of COX-2 expression (Critchley
et al. 1999). Evidence for increased PG activity by antagonising progesterone also comes
from in-vitro data, which showed a dose-dependent induction of PGF2a release from
endometrial stromal cells (Kelly et al. 1986) and also from the in vivo observation of
increased uterine contractility after mifepristone possibly due to increase PGs (Norman
et al. 1991; Gemzell-Danielsson et al. 1994). This is further supported by the inhibition
of glandular PGDH expression seen after administration of antiprogesterones in the early
luteal phase and during the early pregnancy (Cheng et al. 1993; Cameron et al. 1996).
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A decrease in the uterine PGF2C1 release (Gemzell-Danielsson et al. 1994), and in the
luminal expression of COX-2 had been reported following mifepristone in the early-
luteal phase (Marions et al. 1999). However, in the early-luteal phase progesterone
values are relatively low, and as a consequence the PR and ER expression is maximal,
while the converse is true for the mid lueal phase of the cycle. Therefore, in the early
luteal phase mifepristone may prevent the effects that are to be exerted by progesterone,
where as in the mid-luteal phase it may antagonize the actions of progesterone, which at
that time appears to be the suppression of PGs release.
Our results are consistent with previous reports (Cameron et al. 1996; Jones et al. 1997)
that demonstrated localisation of PGDH & COX-2 in the glandular epithelium and, also
supports the in-vitro evidence that glands to be the main site for PG synthesis (Lumsden
etal. 1984; Smith et al. 1988).
In our study, there was weak staining for PR in the nuclei of stromal cells in the control
samples with minimal ER staining. AR staining was confined to stroma. There was no
change in intensity or distribution of staining for steroid receptors after mifepristone
(Figures 6.5, 6.6 & 6.7).
Previous studies have reported an increased expression of PR & ER in both glandular
and stromal compartments (increase more pronounced in the glands) in the mid-luteal
endometrium after early luteal phase administration of antiprogesterones (Berthois et al.
1991; Maentausta et al. 1993; Cameron et al. 1996). In all these studies the endometrium
was sampled at least 48 hours or more later than mifepristone. We did not observe a
significant change in the endometrial immunoreactivity for all three steroid receptors
(ER, PR, and AR) after mifepristone. PR level in the mid-luteal endometrium is minimal
compared to the early luteal phase. This may be a reason why we did not see the same
level of progesterone antagonism in steroid receptor expression as seen after the early
luteal phase administration. Furthermore, the studies mentioned above described effects
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seen more than 48 hours after the administration ofmifepristone hence; their results may
not be comparable to our observations. There are further suggestions that the
predominant PR subtype in endometrial glands to be different in early and mid luteal
phase, and the functional diversity of these receptor subtypes may explain the different
results observed (Mote et al. 1999).
Although others have reported barely detectable AR immunoreactivity in the glandular
epithelium (Slayden et al. 2001), untreated normal mid-luteal endometria in our study
exhibit weak glandular and surface epithelial staining. Immediately before menstruation
in the late secretory phase, a decrease in stromal AR immuno-staining had been reported.
In contrast, an up-regulation was observed in glands as well as in stroma, following the
early luteal phase administration ofmifepristone (Slayden et al. 2001). Once more, here
the biopsy was taken more than 48 hours after administering mifepristone.
The distinct endometrial effects seen after the mid-luteal administration ofmifepristone
add to our understanding of the mechanism of menstruation. There is overwhelming
evidence that PGs are involved in the process of normal menstruation (Baird 1996 and
references therein). Our results show a down-regulation of PGDH expression and a
simultaneous up-regulation ofCOX-2 expression after administering mifepristone in the
mid-luteal phase. Therefore, we conclude that mifepristone induces endometrial-
bleeding in the mid-luteal phase by a mechanism involving both PGDH and COX-2 to






7.1.1 Serum progesterone assay
Venous blood was collected, centrifuged to separate serum, and stored serum was
later assayed for progesterone using Coat-A-Cont progesterone procedure (solid-
phase radioimmunoassay; Diagnostic Products (UK) Ltd., Glyn Rhomwy, Llanbersi,
Caernarfon, Gwwyedd, North Wales, UK).
7.1.2 Urinary hormone assays
Urine samples were frozen and later assayed in batches (with all samples from one
subject assayed in a single batch) for measurement ofurinary LH, E3G and P3G.
Quantitative assessment of urinary LH was performed using a LH MAI Aclone kit
(BIOSTAT-DIAGNOSTICS, Stockport, Cheshire, UK). This method incorporates
two high affinity monoclonal antibodies into an immuno-radiometric assay system
and offers a working range of 1.5 - 200 mlU/ml. Urinary P3G was measured using a
direct enzyme immunoassay (sensitive working range 0.16 ug/L - 20 ug/L), while
direct immunoassay was used to measure E3G levels (working range 8.36 nmol/L -
2140 nmol/L). Intra-assay coefficients of variation were 6% for E3G, 10% for P3G,
and 3% for LH (Yong et al. 1992). Geometric means of daily replicates were divided
by the respective daily creatinine concentration to correct for variations in the
dilution of the urine specimen.
7.2 Statistical Analysis
Both pragmatic and explanatory studies were undertaken as a part of this thesis. For
example, studies that evaluated the mechanism of action of LNG and vaginal
bleeding (mifepristone induced) belong to the explanatory category while the
feasibility of administration of mifepristone, as a once-a-month pill was a pragmatic
trial. During the pragmatic trials we tried to mimic real life yet close monitoring and
frequent laboratory tests were required during the explanatory studies.




Employing the t-test assessed a statistically significant difference between two
normally distributed sample means (example, Chapter 2).
7.2.2 Confidence intervals
A significance test and a p-value do not explain the precision of the estimated
treatment effect. Quoting a confidence interval, or the range of possible differences
with which the data were consistent, allowed an assessment of both the statistical and
clinical significance (example, Chapter 4).
7.2.3 Kruskal-WallisANOVA test
When the normal distribution with uniform variance cannot be assumed in a data set,
Kruskal Wallis ANOVA test was used to analyse the variances by ranks (example,
Chapter 6).
7.2.4 Correlation
In chapter 4, statistical testing on correlation was done on data aggregated to patient
level. Thus, for example, correlating each patient's age with the percentage
compliance over all her cycles tested the association between age and compliance.
Since both of these variables were quantitative and not very skewed we felt
Pearson's correlation was appropriate. Similarly, for binary factors such as whether
or not a patient had had previous children, the percent compliance was compared
between these two patient groups using a two-sample t-test, which is in fact identical
to the Pearson correlation. Clearly chi-squared or Fisher tests are not applicable in
this type of analysis where a continuous outcome is being used.
7.2.5 The Dunn's multiple comparisons test
This multiple comparison procedures provided a way to compare and identify the
differences in the means of discontinuous data sets with dissimilar numbers in each




Apparently skewed data were analysed with a non-parametric Mann-Whitney U test
(for example, in Chapter 2 the comparison of the difference between urinary E3G
levels on the day of LNG treatment in cycles that had delayed LH peak and the 8
cycles that did not).
7.3 Endometrial collection and processing
7.3.1 Endometrial sampling
Both anterior and posterior uterine endometrium was sampled using a Pipelle endometrial
sampling device (Prodimed, Neuilly-en-Thelle, France). This disposable, plastic device is
3 mm in diameter and can be easily introduced through the cervical canal into the uterine
cavity with minimal discomfort to the un-anaesthetised woman. Once the device has
reached the uterine cavity, suction can be created within the device cavity allows the
aspiration of a small endometrial sample.
7.3.2 Tissuefixation, processing andmicrotomy
Tissue samples were cut into small pieces (to aid faster fixation), fixed immediately
in 4% paraformaldehyde, for 24 hours at 4° C. This fixation preserves the intra-
cytoplasmic protein - structure, by forming cross-linking bridges. The tissue biopsy
was then stored in 70% ethanol before routinely wax embedding in a Leica TP 1050
(Leica UK Ltd, Milton Keynes, UK). Once the fixation was complete, the tissue was
dehydrated (via passage through a ascending grades of alcohol) and was embedded
in paraffin wax. 5 pm thick sections were cut from the paraffin blocks using a
microtome (HM 325, Shandon, Cheshire, UK), and the sections were dried on glass
slides (Superfrost plus, BDH, UK) at 37° C overnight.
7.4 Immmunohistochemistry
An avidin Biotin Peroxidase Complex Method (ABC) of antigen detection was
utilised for the immuno-staining protocols. This method utilises the high affinity of
avidin for biotin. After the addition of an antigen specific primary antibody, a
biotinylated secondary antibody (where biotin has been covalently linked to the
antibody) was used to link the primary antibody to a subsequently applied complex
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of avidin, biotin, and the enzyme horseradish peroxidase (ABC complex). Since
avidin has a high affinity and 4 binding sites for biotin, unoccupied sites on the
avidin of the ABC complex bind to the biotin of the biotinylated secondary anti¬
body. The reactions were visualised by the addition of the peroxidase substrate,
hydrogen peroxide (H2O2) and 3, 3' Diaminobenzidine Tetrahydrochloride (DAB).
DAB acts as a chromogen and is oxidised during the enzyme-substrate reaction to
produce an insoluble dark brown end product.
7.4.1 PR immunostaining protocol
Tissue sections were dewaxed in Histoclear (National Diagnostics, Yorkshire, UK),
and rehydrated in descending grades of ethanol in water. Then they were washed in
distilled water, and 0.01M phosphate buffered saline (PBS tablets, Sigma, Dorset,
UK, pH 7.4 - 7.6) for 10 minutes. Tissue sections were microwaved at full power in
0.01M Sodium Citrate buffer (pH 6.0) for 10 minutes and then allowed to stand in
the microwave oven for further 20 minutes, as an antigen retrieval measure. In order
to block non-specific endogenous peroxidase activity, following another wash with
PBS, the sections were incubated in 3% hydrogen peroxide in distilled water for 10
minutes at room temperature (RT). After a further wash in PBS, a non-immune block
was performed, by incubating the tissue sections in normal horse serum (Vector
Laboratories, Peterborough, UK) for 20 minutes at RT. The sections were then
incubated with a mouse monoclonal anti-human PR antibody at a dilution of 1:40
(0.88 pg/ml protein; Novocastra Laboratories, Newcastle upon Tyne, UK). Mouse
IgG at a matching immunoglobulin concentration as the primary antibody (1:6000
dilution) was substituted for the anti-human PR antibody on negative control sections
and from this step forward negative control sections were washed separately. Late-
proliferative endometrium was included as a positive control tissue, and it is known
to express high levels of PR. Following the primary antibody binding, sections were
washed in Phosphate Buffered Saline with Tween (PBST). Thereafter the tissue
sections were incubated with biotinylated horse anti-mouse IgG (Vectastain, Vector
laboratories, Peterborough, UK) at RT for 30 minutes. After a further 10 minutes of
washing in PBST, sections were incubated at RT for 30 minutes with a complex of
avidin and biotin coupled to a horseradish peroxidase enzyme (Vectastain Elite,
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Vector Laboratories, Peterborough, UK). Sections were washed again before the
antigen bound ABC-HRP enzyme was identified by applying 3,3'-diaminobenzidin
in hydrogen peroxide (DAKO liquid DAB substrate, DAKO Laboratories, High
Wycombe, UK). Sections were then washed in water before counterstaining with the
non-specific nuclear stain, Harris' Haematoxylin (Pioneer Research Chemicals Ltd,
Essex, UK). Finally, sections were washed in scott's tap water, dehydrated by
passage through graduated ethanol of increasing concentration, cleared by immersing
in Xylene for at least 30 minutes and were mounted in Pertex (Cellpath, Hemel
Hampstead, UK).
Similar protocols were employed for oestrogen receptor (ER), androgen receptor
(AR), Prostaglandin dehydrogenase (PGDH), and Cyclooxygenase-2 (COX-2).
Specific features for each protocol were as follows.
7.3.3 ER immunostaining protocol
Primary monoclonal anti-human ER antibody ER1D5 (0.58 pg/ml protein; DAKO
Corp. Laboratories, High Wycombe, UK) was used at dilution of 1:400. Non¬
immune mouse IgG at the equivalent concentration (1:2400) was used in place of the
primary antibody in the negative controls. Sections were incubated with the
secondary antibody and ABC complex (Vectastain Elite, Vector Laboratories,
Peterborough, UK) for 1 hour. Mid proliferative endometrial sections were included
as positive controls.
7.3.4 AR immunostaining protocol
Sections were subjected to a different antigen retrieval step, in which they were
pressure cooked (Tefal, Nottingham, UK) in 0.01M Sodium Citrate buffer (pH 6.0)
for 5 minutes and then were allowed to rest in buffer for a further 20 minutes. After
the wash that followed the endogenous peroxidase block, slides were incubated with
Avidin for 15 minutes followed by Biotin for 15 minutes (Avidin-Biotin blocking kit,
Vector Laboratories, Peterborough, UK) with a PBS wash in between, to block
endogenous Biotin activity. Slides were then incubated overnight at 4° C with
monoclonal mouse anti-human AR antibody (F 39, BioGenex Laboratories, Inc.
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antibody, A Merarini Diagnostics, Berkshire, UK) at a 1:480 dilution in
PBS/BSA/Gelatin gel (see recipes, table 7.2). Sections were incubated with the
secondary antibody and ABC complex for 1 hour. Mouse IgG at a 1:600 dilution was
used for negative control sections, and mid proliferative endometrium was included
as a positive control.
7.3.5 PGDH immunostaining protocol
A polyclonal rabbit anti-human PGDH antibody (Dr H. H. Tai, University of
Kentuckey, Lexington, USA) was used to identify PGDH immunoreactivity with an
avidin-biotin peroxidase detection system. An antigen retrieval step was not required
to expose this cytoplasmic epitope. Slides were exposed to a non-immune block by
incubating in 20% normal goat serum (SAPU, BSA grade) for 20 minutes. Sections
were then incubated with the primary antibody at a 1:3000 dilution overnight at 4° C,
and rabbit IgG at 1:6000 dilution, substituted the primary antibody for negative
controls. Biotinylated goat anti-rabbit was applied for 30 minutes at RT followed by
the ABC-complex (Vectastain, Elite ABC Kit, Vector Laboratories, Peterborough,
UK) for 60 minutes at RT. Late 3rd trimester fetal membranes was included as a
positive control.
7.3.6 COX-2 immunostaining protocol
Detection of COX-2 immunoreactivity employed a polyclonal goat anti-human
COX-2 antibody (0.3 pg/ml protein; Santa Cruz Biotechnology, Inc, Santa Cruz, CA,
USA) with the avidin-biotin peroxidase detection system. Endogenous peroxidase
activity was quenched with 3% H2O2 in methanol for 30 minutes at RT. An antigen
retrieval step was conducted when the sections were pressure cooked in 0.01 M
Sodium Citrate buffer (pH 6.0) for 2 minutes and then allowed to rest in the pressure
cooker (Tefal, Nottingham, UK) for a further 20 minutes. Incubating in avidin and
biotin blocked endogenous biotin, as described for the AR immunostaining protocol.
A non-immune block was conducted by incubating the sections in 20% normal rabbit
serum (Diagnostics Scotland, UK) for 20 minutes, followed by a 1 hour incubation of
the sections with the primary antibody at a 1:600 dilution at 37° C. Goat IgG at a
1:3000 dilution (matching IgG concentration as primary antibody) was substituted
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for negative control slides. Sections were then incubated in a 1:500 dilution of
biotinylated horse anti-goat antibody (Vector Laboratories, Peterborough, UK) for 30
minutes at RT followed by the ABC-complex (DAKO Laboratories, High Wycombe,
UK) for 20 minutes at RT. Menstrual endometrium was included as a positive
control tissue.
7.4.6 Scoring and immunohistochemistry analysis
We employed a semi-quantitative subjective scoring system to evaluate the intensity
and the localization of immunoreactivity in entire tissue sections. Previously we have
reported that the immunostaining patterns in endometrial sections measured by the
subjective semi-quantitative scoring, showed an almost perfect correlation
(regression coefficient of 0.963) with that measured objectively by computerized
image analysis (Wang et al. 1998). Therefore, the less time consuming, semi¬
quantitative scoring system provides a valid score suitable for graphical presentation.
Two independent observers using light microscopy visually assessed all coded
sections. The two separate scores were then compared to obtain a more objective
final score for each section. Once the final score had been agreed for all sections in
the five-immunostaining runs, the code was broken, then the final immuno-staining
scores were analysed.
The immuno-staining intensity of the steroid receptors (PR, ER, and AR) and COX-2
were scored using a four point scoring scale, where the intensity of staining was
assigned as 0 = none, 1 = weak, 2 = distinct, 3 = strong. However, the staining
intensity of PGDH showed a narrow range and therefore we adapted a three point
scoring scale where the score of zero indicated an absence of immunoreactivity; 1 =
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The main focus of the studies undertaken as a part of this thesis was to evaluate
means to advance contraceptive research methodology, while broadening our current
understanding of the anti-fertility potentials of two progesterone receptor modulators:
antiprogesterone compound mifepristone, and the synthetic progestin LNG.
When LNG was administered twice at a dose of 0.75 mg to 12 healthy female
volunteers in the fertile period (immediately before ovulation) of the menstrual cycle,
it aborted the LH peak, delayed ovulation and lengthened the cycle in four women
(25%). One woman did not ovulate at all despite having an LH surge 2 days after
taking LNG. Seven women had apparently normal ovulatory cycles after taking
LNG. It is apparent that different women respond differently to the administration of
LNG. In all twelve volunteers the luteal phase was significantly shortened following
treatment with LNG as compared with the placebo cycles (mean length 11.5 days
(SD +/-1.8) vs. 12.9 days (SD +/-2.5) p = 0.005). The eight women in whom pre¬
ovulatory LNG did not affect the cycle length, showed a significant (p = 0.01)
decrease in total LH in the treatment cycles (18.66 U/mol creatinine (SD +/-8.9)) as
compared with the placebo cycles (27.08 U/mol creatinine (SD +/-13.57)). We
suggest that LNG taken immediately before ovulation acts as an EC by delaying or
preventing ovulation. It may also have an effect on luteal function. Other plausible
actions of LNG including retardation of the endometrium, interfering with sperm
motility and altering cervical mucus may be important, and need to be explored
further.
The limiting factor in the once-a-month approach to administering anti-progesterone
as a contraceptive pill is the accurate detection of the LH peak. Clearly, the failure to
detect the LH peak accurately has a big impact on the overall effectiveness of the
method. The home-use fertility monitor provided us with an opportunity to
overcome these problems. In our own control group, if sexual intercourse took place
on a fertile day the probability of a pregnancy was 0.25 - 0.32. Thirty two women in
the treatment group contributed to a total of 178 cycles and there were two
pregnancies (probability of pregnancy 0.01). Imperfect use of the system accounted
for failure to identify an LH surge in 11.8% cycles while 7.9% were due to monitor
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method failure. During the course of the study we developed an algorithm for the
administration of mifepristone if an LH surge was not identified. In nineteen
exposure cycles (out of 28 cycles in which an LH surge was not identified)
mifepristone was administered using this algorithm and there were no pregnancies.
Given that in real life the available methods detecting LH surge are not 100%
accurate, such an algorithm will be essential to time the administration of
mifepristone when an LH surge was missed. Treatment with mifepristone in the early
luteal phase did not disrupt the cycle length but women reported slight vaginal
bleeding in 15% of the cycles. Also in our study, mis-timed administration of
mifepristone led to predictable effects. Therefore, the combination of a home-use
fertility monitor with once a month administration of mifepristone (especially if
mifepristone is administered at the early luteal phase) is an acceptable contraceptive
option with minimal side effects. Unfortunately, it is difficult to envisage how an
easier way of defining the correct timing, which required less compliance, could be
devised.
Poor compliance can make the results of a study invalid, yet is commonly
overlooked in contraceptive research. We were able to compare the incidence of non-
adherence detected by a home use fertility monitor with the traditional self-reported
incidence of compliance in a group of women who took part in a trial assessing the
efficacy of a novel method of contraception. Women failed to perform 24.6% of the
tests in the 162 cycles analysed. In 42% of the cycles they missed tests during a
critical period, which could have increased their risk of an unwanted pregnancy.
During this critical period, women missed fewer tests and admitted to missing even
less. Poor compliance was associated with younger women, those who discontinued
the study before completion, and cycles where women were not at risk of pregnancy.
The use of microelectronic monitoring systems may improve our understanding of
the extent of the problem of patient non-compliance, providing objective information
that no other monitoring technique can produce. This understanding provides the




A reliable and simple means to predict the potentially fertile period can assist in
contraceptive research in monitoring frequently changing hormone levels, and in
identifying the fertile period. In a significant number of cycles the home use fertility
monitor indicated high fertility long before the ovulation had occurred and thus, there
is really no advantage to providing this advance warning either in a clinical or a
research setting. Conversely, as the rise in LH is the most predictable method of
determining the days of high fertility, an error ofjust around 8% in LH detection can
be tolerated. Women missing about 19% of the urine tests requested by the monitor
is obviously significant, and the monitor offered us an important methodological
advance in providing reliable data on the incidence of non-compliance with urine
testing, and exactly when a test was missed. Therefore, this microelectronic system
in detecting the urinary LH peak can be invaluable in contraceptive research because
it is easy to use and provides reliable data on compliance.
The distinct endometrial effects seen after the mid-luteal administration of
mifepristone may add to our understanding of the mechanism of menstruation. There
is overwhelming evidence that PGs are involved in the process of normal
menstruation. All women in our study reported vaginal bleeding commencing at 24
to 48 hours after taking 200 mg of mifepristone in the mid-luteal phase. In 13 out of
the 16 subjects, this was followed by a second bleed at the expected time of the next
menses. Although mifepristone significantly depressed the serum progesterone value
in all women, the occurrence of a second bleed in the majority (81.25%) suggested
only partial luteolysis and a direct effect of mifepristone on the endometrium. Our
results show a down-regulation of PGDH expression and a simultaneous up-
regulation of COX-2 after administering mifepristone. Therefore, we conclude that
mifepristone induces endometrial-bleeding in the mid-luteal phase by a mechanism
involving both PGDH and COX-2 to increase local PG levels in the endometrium.
However, these preliminary data require to be confirmed by a larger study in the
future.
In summary, the studies carried out as part of this thesis have demonstrated the
importance of understanding the basic mechanisms of progesterone receptor
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modulators in various aspects of contraceptive research. They also confirmed the
contraceptive potential of mifepristone as a once-a-month pill, and demonstrated that
levonorgestrel acts as an EC mainly through directly or indirectly inhibiting
ovulation. Moreover, these studies have established the importance of patient non¬
compliance while recommending a potential methodological modification to detect
the incidence of non-compliance in contraceptive research. Finally, the study that
evaluated mifepristone induced bleeding, broadened our current understanding of the
mechanism of endometrial bleeding by illustrating the synergistic changes on PG
synthetic and catabolic enzymes that may produce an increase in the local
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Abstract
Levonorgestrel (LNG) 0.75 mg administered 12 h apart within 72 h of unprotected coitus, is an established method of emergency
contraception (EC). The mechanism of action of LNG used in this manner is unknown. We administered LNG 0.75 mg twice immediately
before ovulation, to test the hypothesis that LNG acts as an emergency contraceptive by abolishing the pre-ovulatory lutenizing hormone
(LH) surge and thereby delaying ovulation. Twelve women took LNG on or before the day of the first significant rise in urinary LH in 12
cycles. In four women, the LH peak and the onset of next menses were significantly delayed (delay of 16.8 days (SD ± 8.7) from the day
of mean LH peak in placebo cycles). One woman did not ovulate at all, despite a normal LH peak and cycle length. In the remaining eight
women, LNG did not affect ovulation or the cycle length, but the length of the luteal phase and the total luteal phase LH concentrations
were significantly reduced. We suggest that LNG acts as an emergency contraceptive by other mechanisms as well as delaying the LH surge
and interfering with ovulation. © 2001 Elsevier Science Inc. All rights reserved.
Keywords: Emergency contraception; Levonorgestrel; Mechanism of action
1. Introduction
Levonorgestrel (LNG) 0.75 mg administered twice with
the two doses 12 h apart has been shown to be an effective
method of emergency contraception (EC) when used within
72 h ofunprotected intercourse [1,2], Although the regimen
is now licensed in the UK, USA, and throughout much of
Europe and is widely regarded as the emergency contracep¬
tive method of choice [3], the mechanism of action remains
unknown. The mechanism of action of the Yuzpe regimen
of emergency contraception (ethinyl estradiol 100 meg and
0.5 mg LNG, two doses 12 h apart [4-6], is also incom¬
pletely understood but there is good evidence that it delays
or inhibits ovulation in at least some cycles [5]. In the WHO
study, the efficacy of both LNG and the Yuzpe regimen
decreased with time after intercourse [7] and both regimens
had a similar effect on the timing of the subsequent menses,
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suggesting that the mechanism of action of the two regi¬
mens may be similar. It has also been shown that large
amounts of synthetic progestogens abolish the mid-cycle
lutenizing hormone (LH) surge leading to anovulation and
delaying the onset of the subsequent menses [8-11],
To test the hypothesis that it acts as a post-coital agent by
abolishing the pre-ovulatory LH surge and by delaying
ovulation, we administered LNG 0.75 mg twice to 12
healthy female volunteers in the fertile period (immediately
before ovulation) of the menstrual cycle and investigated
the effects on the timing of ovulation and of the next
menses, bleeding patterns; ovarian activity, and LH concen¬
trations.
2. Materials and methods
This was a prospective, randomized, double-blind, cross¬
over study undertaken in one center. Twelve healthy women
(mean age 33.3; range 26-41 years) with regular cycles
(mean 27.6 days; range 25-30 days) and mean BMI 25.7
(range 20-34) were recruited. They were all using a reliable
non-hormonal method of contraception or were abstinent
0010-7824/01/$ - see front matter © 2001 Elsevier Science Inc. All rights reserved.
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during the study. All subjects gave written informed consent
for participation in the study, which was approved by the
Lothian Research Ethics Committee.
A method was sought to provide a convenient means of
identifying the fertile period prior to ovulation, and thereby
to time the administration of LNG. Unipath (Bedford, UK)
had developed a technology that can be used in the home to
monitor changes in urinary hormones [12], This monitoring
system comprises disposable test sticks and a hand-held
monitor, which together are used to detect changes in the
levels of oestrone-3-glucuronide (E3G), a urinary metabo¬
lite of oestradiol, and LH to indicate the potentially fertile
days leading up to ovulation.
The monitor optically measures the intensity of the lines
that form on the test sticks after sampling, and the system
will delineate three levels of fertility (Low, High, and Peak
Fertility) according to the optical signal changes detected.
Low Fertility will be displayed from day 1 of the cycle until
the hormone levels rise above the baseline levels. A change
from Low to High Fertility is triggered by detection of
elevated E3G levels, to concentrations typically between 20
and 30 ng/mL. The change from High to Peak Fertility is
triggered by the detection of an LH surge, typically with a
concentration higher than 30 IU/L. Peak fertility is dis¬
played on the day of the LH surge and on the following day.
Each woman was studied during four cycles and was
issued a monitor at the beginning of the study. Subjects
were asked to use the monitor according to instructions, and
familiarized themselves with the monitors by using it during
a pre-study cycle to identify the days ofhigh fertility and the
day of the LH surge. They also recorded days of vaginal
bleeding.
Data from the pre-study cycle was used to predict the
timing of the LH surge and of the fertile phase during the
study cycles and thereby to predict when treatment should
be administered. The three study cycles followed immedi¬
ately after the pre-study cycle. Six subjects were randomly
assigned to treatment arm A and received LNG in the first
study cycle and placebo in the third study cycle. The re¬
maining six subjects were randomized to treatment arm B
and received placebo in the first study cycle and LNG in the
third study cycle. The second study cycle was a washout
phase for all women during which time they also received
placebo tablets.
The randomization list was produced using SPSS
Rv.Bernouilli function such that each study number was
randomly assigned to either treatment arm A or treatment
arm B with the same probability, i.e. 0.5.
LNG and placebo were visually identical and were pre¬
packed. Each subject collected a sample of early morning
urine daily from the first day of the first study cycle until
and including the first day of the menstrual bleed signaling
the end of the last study cycle. Samples were frozen and
later assayed in batches (with all samples from one subject
assayed in a single batch) for measurement of urinary LH,
E3G, and pregnanediol-3-glucuronide (P3G).
Quantitative assessment of urinary LH was performed
using an LH MAIAclone kit (BIOSTAT-DIAGNOSTICS,
Stockport, Cheshire, UK). This method incorporates two
high-affinity monoclonal antibodies into an immunoradio-
metric assay system and offers a working range of 1.5-200
mlU/mL. Urinary P3G was measured using a direct enzyme
immunoassay (working range 0.25-32 mmol/L), while di¬
rect immunoassay was used to measure E3G levels (work¬
ing range 8.36-2140 nmol/L. Intra-assay coefficients of
variation were 6% for E3G, 10% for P3G1, and 3% for LH
[13], Geometric means of daily replicates were divided by
the respective daily creatinine concentration to correct for
variations in the dilution of the urine specimen.
During study cycles 1 and 2, women were asked to take
the study medication on the first day of High Fertility as
identified by the monitor. However, by the third study cycle,
the variation in the number of high fertile days (range 0-8
days) meant that the monitor could not be used to administer
medication on LH-2 in every cycle. Therefore, we had to
adopt a different method of calculating the anticipated day
of the LH peak for each cycle based on the monitor infor¬
mation from the previous cycles (including the pre-study
cycle). Hence, in the third study cycle, the medication was
taken 2 days prior to the anticipated day of the LH peak. In
all cycles the first tablet was taken at 1100 h and the second
at 2300 h. A sample of venous blood was collected 5-7 days
after treatment, stored and later assayed for progesterone
using Coat-A-Cont solid-phase radioimmunoassay. The
subjects kept a daily record of all vaginal bleeding experi¬
enced during the four cycles, the fertility status information
displayed each day on the monitor LCD and the days on
which the study medications were taken.
2.1. Statistical analysis
We calculated that a total of six subjects in each of the
two treatment arms would give more than 90% power to
detect a delay of menses of >5 days in 95% of cycles.
Preliminary analysis was performed to determine
whether parametric tests were appropriate for analysis of the
data. Outlying data points were investigated while the treat¬
ment was still blinded. The period effect and interaction
between treatment and period effect were tested (two-sam¬
ple t test) before progressing to testing of a treatment effect
and was non-significant. Comparisons between LNG versus
placebo cycles was tested by paired t test.
For the purpose of the study the following definitions
based on the quantitative data were created.
A significant delay in the onset of next menses: Delay of
5 or more days from the expected onset ofmenses (based on
the mean cycle length for the 2 placebo cycles).
The LH peak was defined as a significant rise in urinary
LH concentration, with a minimum of 50% rise above the
average baseline level for 4 preceding days and which
remained elevated for a minimum of 3 days.
The first day of the LH peak was defined as the day of the
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Table 1
Timing of LH peak, predicted day of the LH peak and timing of LNG in treatment cycles for all subjects
Subjects Day of the LH peak (LH > 50%) Predicted day of the Timing of LNG in Timing of LNG in





Treatment treatment cycle LH peak in the
treatment cycle
predicted day of the
LH peak
S101 12 13 9 10 11 -1 -2
S102 M 20 19 21 19.5 -1 +0.5
S103 12 IT 9 11 9 -1 + 1
S104 M 11 12 12 11.5 0 +0.5
S107 17 14 14 13 14 -1 -2
Sill 12 11 15 12 13 -1 -4
SI 12 11 11 12 13 11.5 -5 -3.5
S105a 14 13 15 14 14 -2 -2
S106b 14 14 12 23 13 -11 -2
S108b 17 18 18 25 14 -13 -2
SI 09" 14 10 10 38 10 -31 -3
S110b 18 18 ££ 40 18 -25 -3
The woman with normal LH peak but no significant rise in pregnanediol in the luteal phase = anovulatory cycle.
bWomen who had a delay of the LH peak by >5 days.
cExcluded, unusually delayed ovulation.
££ = excluded, no daily urine available.
M = LH peak not detected by the monitor.
first significant rise (>50% above the baseline) seen at the
beginning of the LH peak.
Retrospectively predicted first day of the LH peak for the
treatment cycles was the calculated mean of the first day of
LH peak in the two placebo cycles.
A significant delay in the first day of the LH peak: Delay
of 5 or more days from the expected first day of the LH peak
in the treatment cycle (based on the mean first day of the LH
peak during the 2 placebo cycles).
Luteal phase: time from the day after the first day of the
urinary LH peak (LH+1) until, and including, the day
before the first day of the next menses.
Follicular phase: time from the first day of the menses
until the day of the first significant rise in urinary LH
(LH+ 0) inclusive.
3. Results
A total of 48 menstrual cycles were studied—12 pre-
study cycles and 36 study cycles. Data from daily urine
samples were available for 34 out of the 36 study cycles. In
one woman (SI03) the first study cycle, which was a pla¬
cebo cycle, was prolonged (41 days) as a consequence of a
delay in ovulation. Her usual cycle length was 25 days, this
cycle was excluded from the analysis. In a second woman
(SI 10) there were no daily urine samples available from the
washout cycle as she was abroad on holiday. Therefore,
daily urine samples were only available for this subject from
two study cycles (the treatment cycle and one placebo
cycle).
3.1. Timing ofadministration ofLNG
Six women took LNG in the first study cycle and six
took it during the third study cycle. During the first study
cycle, 10 women took the tablet (either placebo or LNG)
on the first day of High Fertility as indicated by the
monitor. The remaining 2 women took the tablet on the
first day of the urinary LH peak because the monitor
failed to identify any high fertile days prior to the LH
surge.
The variation in the number of High Fertile days (0-8
days) declared by the monitor meant that the system could
not be used to predict LH-2 in every cycle. Therefore, for
cycle 3 we calculated the anticipated first day of the urinary
LH peak from the information gathered from the pre-study
cycle and study cycles 1 and 2 for each woman and in¬
structed subjects to take the tablet 2 days before the antic¬
ipated day of the LH peak.
After completion of the study, we retrospectively calcu¬
lated the predicted first day of the urinary LH peak for every
treatment cycle based on the mean first day of the LH peak
in the two placebo cycles. When we applied this retrospec¬
tively predicted definition to all 12 treatment cycles, the day
of taking LNG ranged from 4 days before until 1 day after
the first day of the anticipated LH peak. However, in reality,
LNG was never taken after the first significant rise in uri¬
nary LH concentrations in any treatment cycle. The timing
of the LH peak in each of the four cycles, the predicted day
of the LH peak day and the timing of LNG and placebo
treatment in relation to the start of the actual LH peak are
shown in Table 1.
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Table 2
Mean length of placebo and treatment cycles
Mean cycle length Treatment cycles Placebo cycles
All cycles, n = 12"
N = 4, Delay of >5 daysb
N = 8, remaining cycles0
32.17 (SD ± 3.36)
42.75 (SD ± 8.42)
24.88 (SD ± 2.1)
26.33 (SD ± .42)
27.13 (SD± 1.84)





Treatment with LNG in the pre-ovulatory period signif¬
icantly prolonged by 5 days or more the mean cycle length
in four women (33% of the sample, Table 2). All 4 women
reported vaginal spotting 2 to 3 days after taking LNG and
they all had a second episode of vaginal bleeding between 9
and 16 days after the delayed LH peak. In the remaining
eight women, there was no significant difference in cycle
length between treatment and placebo cycles. One of this
group of women, however, reported light vaginal bleeding
starting a week after taking LNG, the bleeding continued
until she started what she regarded as a normal menstrual
period which followed a fall in urinary pregnanediol levels.
Her hormone profile during the treatment cycle followed a
normal pattern.
3.3. The first day of the LHpeak
In the four women with long cycles, LNG appeared to
abort the LH peak and a subsequent LH peak occurred 7 to
16 days later, followed by a normal rise in urinary preg¬
nanediol. The urinary hormone profile of one woman
(S110) is illustrated in Fig. 1. In the remaining eight women,
LNG did not affect the timing of the LH peak when taken
immediately before ovulation. Fig. 2b illustrates the hor¬
mone profile in one of these women (SI01).
3.4. Length of the luteal phase
In all 12 volunteers the luteal phase was significantly
shortened following treatment with LNG as compared with
the placebo cycles (mean length 11.5 days [SD ± 1.8] vs.
12.9 days [SD ± 2.5] p - 0.005, Table 3).
3.5. The effect on total LH during the luteal phase
Daily urinary LH concentrations were summated from the
first day of the LH peak (LH+0) up to the day before the first
day of the next menses to give a value for total LH concen¬
trations. The 8 women in whom pre-ovulatory LNG did not
affect the cycle length, showed a significant (p = 0.01) de¬
crease in total LH in the treatment cycles (18.7 U/mmoL,
a Placebo
35 42 49
Vaginal bleeding H ! Menses
Day of the cycle
Fig. 1. Daily levels ofLH (•) oestrone-3-glucuronide (E3G) (A), and pregnanediol (O), in urine relative to the cycle day. (a) Placebo cycle of a woman (SI 10)
(b) Treatment cycle of the same woman (S110) showing significantly prolonged cycle following pre-ovulatory LNG. j, Day of taking LNG or placebo tablet;
, day of the LH surge




















Fig. 2. Daily levels of LH (•), oestrone-3-glucuronide (E3G) (A), and pregnanediol (O), in urine during the treatment cycles, (a) Of the woman (S105) with
no significant rise in pregnanediol following LNG. (b) Of a women (S101) with apparently normal cycle length. J,, Day of taking LNG; 4k, day of the LH
surge in the placebo cycle; , day of the LH surge.
SD ± 8.9) as compared with the placebo cycles (27.1
U/mmoL, SD ± 13.6). In contrast, among the 4 women with
significantly longer cycles after taking LNG, there was no
difference in the total LH secretion in the luteal phase (mean
total LH = 18.8 mlU/mL, SD ± 8.3; versus mean total LH for
placebo cycles of 17.8 U/mmoL, SD ± 2.8; p = 0.81).
3.6. Effect on pregnanediol in the luteal phase
The sum of daily pregnanediol concentrations in the
luteal phase (from LH+1 onwards up to the day before the
first day of next menses) was compared during the treatment
and placebo cycles was employed to indirectly assess the
function of the corpus luteum.
In one woman (SI05) after taking LNG, there was no
significant rise in urinary pregnanediol levels (>0.5 mmol/
mol creatinine as expected in the mid-luteal phase) despite
an apparently normal LH peak. The mid-luteal semm pro¬
gesterone level during this treatment cycle was consistent
with an anovulation (<5 nmol/L) (Fig. 2a). In the remaining
11 subjects, the total values of pregnanediol did not show a
significant difference between placebo or treatment cycles.
4. Discussion
Evaluation of daily hormone concentrations confirmed
that all 12 women in our study took LNG before the LH
peak, and presumably ovulation. Seven women had appar¬
ently normal ovulatory cycles after taking LNG. Five of
them took LNG on the day before the LH surge and one on
the day of the surge. It is possible that the timing of LNG in
these women was "too late" to influence an event already
well underway. However, in the four women in whom the
LH peak and ovulation was delayed, the LNG was taken
within 3 days of the predicted LH peak. One woman did not
ovulate at all despite having an LH surge 2 days after taking
LNG.
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Table 3
Length of the luteal phase (n = 12)













"Women who had a delay of the LH peak by >5 days
bThe time from the LH surge to the next menses in the woman with an
anovulatory cycle, but a normal LH peak after LNG (Fig 2a)
It is apparent that different women respond differently to
the administration of LNG. The effects observed may be
related to administering LNG at a specific stage in follicular
development. Even though the timing of the LNG in rela¬
tionship to the onset of the LH surge did not appear to be
different between women in whom ovulation was affected
and those in whom it was not, it would be naive to accept
that our predicted day of the LH peak based on information
gathered in two cycles was always accurate. A more de¬
tailed study employing daily serum levels of gonadotro-
phins and steroid hormones and ultrasound scans to corre¬
late follicular size and maturity to the timing of the
administration of LNG might provide an explanation.
The 7 women, who apparently ovulated normally, had a
reduced total luteal LH and a shortened luteal phase. Basal
levels of LH are essential for the normal secretory function
of the corpus luteum [14], In the mid-luteal phase, LH
inhibition by the administration of GnRH antagonists con¬
sistently results in luteolysis in women as well as in non-
human primates [15-17], There are no direct ways of mea¬
suring whether the function of the corpus luteum is
compatible with the establishment of pregnancy. Although
there was no significant difference in the urinary preg¬
nandiol levels after LNG, it is possible that the shortened
luteal phase observed was a consequence of reduced total
LH and may have a contragestive effect.
If LNG acts as an emergency contraceptive only by
interfering with ovulation, the expected efficacy should fall
below 42% (5 of 12 women). Ho and colleagues [1] re¬
ported that LNG reduced approximately 60% of the ex¬
pected number of pregnancies (estimates were based on the
table ofprobabilities of pregnancy at different cycle days by
Dixon et al. [18]). LNG fared better in the WHO study [2]
with overall 85% reduction of expected number of pregnan¬
cies (the analysis of the prevented fraction was based on the
modified Wilcox estimates of conception probabilities
[19]).
Both studies reported effectiveness against estimates
based on historical data. The fertile period was determined
on the assumption that ovulation occurred 14 days before
the next expected menses. The validity of using these esti¬
mates directly relies on the accuracy of reported menstrual
cycle data. Women do not regularly keep records of their
menses, and by and large the sexual intercourse responsible
for requesting emergency contraception is unpremeditated.
Reporting errors are common and the estimates can be
inaccurate. In addition, other factors such as biologic vari¬
ability of the day of the ovulation and the length of the luteal
phase, factors affecting the probability of pregnancy unre¬
lated to the timing of intercourse, and heterogeneity among
couples in fecundability can distort the estimated number of
pregnancies. In a study comparing the efficacy of the Yuzpe
regimen of EC with a single dose ofmifepristone [20], there
were frequent discrepancies among subjects between the
stage of the cycle as estimated from the date of the LMP and
that suggested by circulating concentrations of progester¬
one. There has never been a placebo-controlled trial of EC.
Thus, it is possible that the genuine effectiveness of LNG as
an emergency contraceptive is less than 42%.
One woman (SI03) in our study showed a delayed LH
peak (on day 27) during a placebo cycle and subsequently
the length of that cycle was prolonged to 41 days (her usual
cycle length was 25 days). In contrast to the four women
who experienced similar prolongation of the cycles after
taking LNG, this woman did not report any intermenstrual
vaginal bleeding. Although we excluded this cycle from our
analysis, similar spontaneously occurring prolonged cycles
(with delayed ovulation), can influence the results of studies
into emergency contraception.
The discrepancy noted in the estimated effectiveness of
LNG and the prevalence of ovulation delay or inhibition in
our study may be due to mechanisms of action other than
interference with ovulation. Our study was not designed to
investigate the other possible mechanisms by which LNG
works. However, one woman in our study reported slight
vaginal bleeding after taking LNG with an apparently nor¬
mal LH peak, cycle length and hormone profile. This may
suggest an additional effect of LNG on the endometrium
[21-24]. Nevertheless, the question remains as to whether
similar alterations occur in the endometrium after taking the
emergency contraceptive regimen of LNG, and whether
these changes are sufficient to prevent implantation and
account for the observed contraceptive efficacy of LNG.
The effect of progestogens on cervical mucus and on the
cervix is well documented and this is thought to be the main
mechanism by which the progestogen-only pill exerts its
antifertility action [25-27], However, even if LNG has an
effect on cervical mucus, which interferes with sperm pen¬
etration, that action is unlikely to prevent pregnancy when
taken some 12-72 h after coitus.
The reason for using the monitor to time the administra¬
tion of LNG or placebo was to avoid having to subject the
volunteers to regular blood samples and ultrasound scans.
However, due to the variability in the number of high
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fertile days declared prior to the LH surge, greater reliance
had to be placed on calendar calculations to predict the LH
surge.
In conclusion, we suggest that LNG taken immediately
before ovulation acts as an emergency contraceptive by
delaying or preventing ovulation. Other plausible actions of
LNG including the retardation of the endometrium, inter¬
fering with sperm motility and altering cervical mucus may
be important, and need to be explored further.
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Feasibility of administering mifepristone as a once a month
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Many women find the idea of a once-a-month contraceptive pill an attractive concept. Mifepristone has been shown
to be effective as a contraceptive if administered in the early luteal phase. We tested the contraceptive efficacy of
200 mg of mifepristone on day luteinizing hormone (LH) + 2 in a group of 32 women who used a fertility monitor
to identify the LH surge. We also recruited a control group, comprising 20 women who were trying to conceive. In
this group, 12 women conceived during a total of 50 control cycles (probability of pregnancy 0.25-0.32). Women in
the treatment group contributed to a total of 178 cycles and there were two pregnancies (probability of pregnancy
0.01). An LH surge was not detected in 34 cycles (19.1%). In 20 cycles (11.2%) this was due to imperfect use while
14 were monitor method failures (7.9%). Treatment with mifepristone in the early luteal phase did not disrupt the
cycle length but women reported slight vaginal bleeding in 15% of the cycles. The combination of a home-use
fertility monitor with once-a-month administration ofmifepristone (especially ifmifepristone is administered at the
early luteal phase) is an acceptable contraceptive option with minimal side effects. Unfortunately, it is difficult to
envisage how an easier way of defining the correct timing, which required less compliance, could be devised.
Key words: contraceptive/home use fertility monitor/LH surge/Mifepristone/once-a-month pill
Introduction
Hormonal contraception is used by almost 100 million women
world-wide. However, many women are deterred from using
it because of perceived risks to health such as breast cancer
or side effects such as weight gain. Most of the risks and the
side effects are the results of prolonged exposure to steroids
and many women, in a variety of cultural settings, find the
idea of a pill which they need take only once each month, an
attractive concept (Rimmer et al., 1992; Glasier et al., 1999).
Progesterone is essential for the establishment and mainten¬
ance of human pregnancy. The anti-progesterone mifepristone
is a synthetic 19-norsteroid, which acts by blocking the action
of progesterone at the receptor level (Spitz and Bardin, 1993),
and thus, has multiple potential anti-fertility actions. When
administered in the early luteal phase mifepristone retards
endometrial development, without disturbing the timing of
menses (Swahn et al., 1988; Berthois et al., 1991; Maentausta
et al., 1993). It also alters uterine contractility to a pattern
more usually seen in the late luteal phase (Gemzell-Danielsson
et al., 1990). In 1993 Gemzell-Danielsson and colleagues
conducted a pilot study in which a single dose of 200 mg of
mifepristone was given in the early luteal phase [2 days
following the surge of the lutenizing hormone (LH) in urine].
Out of 124 cycles in which coitus took place during the fertile
period, only one pregnancy was observed (Gemzell-Danielsson
et al., 1993). There was no disruption of the timing of the
subsequent menstrual bleed, although in 35% of the cycles
slight vaginal bleeding was reported 2-3 days after treatment.
The main problem in developing a once-a-month contra¬
ceptive is finding a means that, both reliably and easily,
identifies the start of the LH surge. Gemzell-Danielsson tried
to solve this problem by using the LH sticks for home urine
testing (Ovu-quick; Organon). In their study 12 out of 169
cycles were deemed to be anovulatory. However, it is not
possible to determine if the LH surge truly was absent, or if
the method failed to detect a surge. The woman may have
read the test result wrongly or even failed to perform a test
on the appropriate day.
Unipath (Bedford, UK) have developed a technology that
can be used in the home to monitor changes in urinary
hormones. This system comprises disposable test sticks and a
hand held monitor, which together are used to detect changes
in the levels of oestrone-3-glucuronide (E3G), a urinary
metabolite of oestradiol, and LH, to indicate the potentially
fertile days leading up to ovulation. The time from the first
significant rise of LH in the urine to ovulation is reported to
be around 24-48 h (Collins, 1996). The monitor thus should
provide a convenient method of identifying the early luteal
phase. Summary data for up to six consecutive cycles can be
stored in the monitor memory and these data can be retrieved.
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We investigated the contraceptive efficacy of 200 mg of
mifepristone on day LH + 2 in a group of women who used
this monitor to identify the LH surge.
Materials and methods
This was a single centre study in healthy female volunteers,
approved by the Lothian Research Ethics Committee. All subjects
gave written informed consent to participation. Fifty-two sexually
active women, with regular (25-32 day) menstrual cycles were
recruited from a large Family Planning Clinic in Edinburgh. If the
women had a significant medical condition or if they or their partners
had a history of fertility problems, they were excluded from the study.
Treatment group
Thirty-two women were recruited to the treatment group. None had
been taking hormonal preparations within the 2 months prior to the
start of the study and all had had at least two spontaneous menstrual
periods since stopping hormonal contraception. All women underwent
screening at the time of recruitment including a routine physical and
gynaecological examination. A venous blood sample was taken for
full blood count, serum biochemistry and liver function. The study
started on day 1 of the menstrual period following screening, and
lasted for up to seven consecutive menstrual cycles in which subjects
took 200 mg mifepristone once per month.
Control group
The control group consisted of 20 healthy women with regular
menstrual cycles who were trying to become pregnant (for less than
6 months prior to the enrolment in to the study) and hence, were not
using contraception. They were provided with a monitor, which they
used according to the manufacturer's instructions. Women were
advised that their chance of conception would be higher if they were
to have sexual intercourse during the fertile period, identified by the
monitor. The controls took part in the study until pregnancy occurred
or for a maximum of six cycles if they did not conceive.
Procedure
All subjects and controls were provided with a home use hormone
monitoring system (Unipath, Bedford, UK). The system comprises a
hand-held monitor and disposable dual-assay urine test sticks, and is
used to simultaneously detect LH and E3G levels in early morning
urine. The monitor optically measures the intensity of the lines that
form on the test sticks after sampling, and the system will delineate
three levels of fertility (Low, High and Peak Fertility) according to
the optical signal changes detected. Low fertility will be displayed
from day 1 of the cycle, until the hormone levels rise above the
baseline levels. A change from low to high fertility is triggered by
detection of elevated E3G levels, to concentrations typically
between 20 and 30 ng/ml. The change from high to peak fertility is
triggered by the detection of an LH surge, typically with a concentra¬
tion >30 IU/1.
Peak fertility is displayed on the day of the LH surge and on the
following day. Subsequently high fertility is displayed for 1 day prior
to a return to low fertility. At the start of each menses, the subjects
pressed the'm' button on their monitor to initiate that cycle of use,
at a time suitable for testing the first urine of the day. For the rest of
the month, the subjects were required to consult the monitor display
each morning (3 h either side of the time when'm' button was set)
to determine whether they needed to perform a test that day. Beyond
this 6 h time window the monitor would not accept a test. The system
requests one test every day for up to a total of 10 or 20 tests,
depending on the length of the woman's cycle, and the timing of her
LH surge. Embedded software within the monitor collects and analyses
data from each cycle to identify and display fertility status to the
user, and stores data for several months.
Mifepristone (Laboratories Exelgyn, Paris, France) was taken 2
days after the day of the first day of peak fertility (LH surge). With
each cycle, subjects followed the same protocol, and were reviewed
by the investigator monthly, on day LH + 2. Just before taking the
200 mg tablet of mifepristone, a venous blood sample was taken,
and later assayed for progesterone. At the beginning of the study, if
the LH surge was not identified by day 21 of the cycle, the subject
was instructed to continue testing, but mifepristone was not given in
that cycle. The subject was also advised to use barrier contraception
from day 21 until the onset of the next menses. After the second
pregnancy (which occurred due to a failure in detecting an LH surge),
we changed this practice. We calculated the estimated day of LH
surge for each month based on information from the previous cycles.
If the women did not detect an LH surge either within 3 days after
the anticipated day of LH surge or by day 19, a blood sample was
taken for rapid serum progesterone assay. If the progesterone level
was >5nmol/l and if the woman was at risk of pregnancy, mifepristone
was administered.
All subjects and controls kept a menstrual record card, recording
all vaginal bleeding experienced during the study and the days on
which they had sexual intercourse. Subjects also marked the first day
of the peak fertility as identified by the monitor and the day of taking
the study medication.
If menstruation was overdue by more than one week the investigator
performed a pregnancy test. Provided this was negative, the subject
continued in the study and the next cycle was deemed to start with
the onset of menses. Since the effect of mifepristone taken in very
early pregnancy is unknown, and teratogenic effects could not be
ruled out, women who would not consider terminating any pregnancy
were not recruited to the treatment group.
At the end of the study, the subjects attended for a final visit, when
a routine physical and gynaecological examination was performed.
Full blood count, serum biochemistry and liver function were
reassessed.
The following definitions were created for the purpose of the study.
Imperfect use: was defined as failure to detect an LH surge
through performing the test incorrectly (e.g. dipping a test stick in
urine 30 or more min before it being read by the monitor), or failing
to perform tests as requested by the monitor.
Monitor method failures: were defined as failure to detect an LH
surge despite performing all tests as requested.
High fertile days: days preceding the urinary LH surge as indicated
by the monitor to be potentially fertile.
Peak fertile days: The first day of a significant rise in urinary LH
detected by the monitor, and the following day.
The fertile period: of the cycle was defined as 3 days before until
2 days after the urinary LH surge (LH-3 to LH+2).
Exposure cycles: were cycles in which women reported having
sexual intercourse at least once during the fertile period.
Statistical analysis
Cycle lengths and serum progesterone concentrations were compared
by two-sample r-tests. Confidence limits for efficacy were derived
from confidence limits for relative risk calculated by the Greenland
and Robins method (Greenland and Robins, 1985).
Results
Table I shows the demographic characteristics of the women
who took part in the study.
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Table I. Demographic data.
Treatment group Control group
(n = 32) (n = 20)
Age
Range 18-39 26-40
Mean (± SD) 30 (± 5.4) 32.9 (±
BMI
Range 19-38 21-29
Mean (± SD) 23.6 (± 4.3) 23.8 (±
Smokers (%) 7 (21.9) 1 (5)
Non-smokers (%) 21 (65.6) 16 (80)
Ex-smokers (%) 4 (12.5) 3 (15)
Previous pregnancies
1+ (%) 19 (59.4) 14 (70)
Never been pregnant (%) 13 (40.6) 6(30)
Ever abortion (%) 15 (46.9) 5(25)
Married/Co-habiting (%) 28 (87.5) 20 (100)
Single (with a regular boy friend) (:%) 4(12.5) 0(0)
The women in treatment group were slightly younger (mean
age 30 years) than those in the control group (mean age 32.9
years). Otherwise there were no differences between subjects
and controls.
The probability ofpregnancy in the control group
Twenty women were recruited to the control group and three
withdrew before completing the study. Two withdrew from
the study as they found using the system 'too stressful' and
one withdrew because she no longer wished to plan a pregnancy.
Data were collected from 50 control cycles during which 12
pregnancies occurred. Average frequency of intercourse was
1.7 episodes per week in the 39 control cycles in which the
women kept a record of their sexual activity. In 37 cycles
women had intercourse at least once during the fertile period
(FP). In two cycles intercourse did not occur during the FP,
while in 11 cycles the exposure status was unknown, as women
failed to keep a record of sexual activity. Eight pregnancies
occurred in the first exposure cycle.
If we assume that all 11 cycles from which information
on sexual activity was lacking were exposure cycles, the
probability of pregnancy was 0.25. However if those cycles
were all non-exposure cycles, the probability of conception
would be 0.32. Therefore among the control group the overall
probability of pregnancy if sexual intercourse took place at
least once during the fertile period lies between 0.25-0.32.
Contraceptive efficacy of the method
Thirty-two volunteers were treated with a single dose of
200 mg of mifepristone administered in the luteal phase
of the cycle as their sole method of contraception between
one and seven cycles. They contributed a total of 178 cycles,
and in 167 cycles mifepristone was administered. Eight women
withdrew from the study before completion; two women
moved out of the area, three ended their relationship, two
conceived during the study and one lost confidence in the
method.
Two clinical pregnancies occurred in the 178 cycles
studied. The first pregnancy was a true treatment failure,
which occurred in a woman (para 1) who took mifepristone
on day 14 (LH + 2) of her first treatment cycle. She opted
for a surgical termination of pregnancy, which was performed
at 8 weeks of gestation (confirmed by ultrasound scanning).
In the second woman (para 3), an LH surge was not identified
in her third study cycle hence she did not receive treatment
with mifepristone, menses did not occur and on day 37 after
her last menstrual period an ectopic pregnancy was diagnosed
and treated surgically. In a third woman a biochemical preg¬
nancy was diagnosed (serum (3HCG only rising to 34 IU/l),
which was spontaneously and completely aborted by day 34 of
the third study cycle after taking mifepristone on day 14 (LH
+ 2). This woman continued in the study and completed six
treatment cycles.
The mean frequency of sexual intercourse was 1.8 episodes
per week in 167 treatment cycles in which sexual activity was
recorded. If we assume the probability of pregnancy in the
treatment group is similar to the control group (0.25-0.32),
the expected number of clinical pregnancies during the 178
cycles (in which 140 were exposure cycles) studied should be
between 35-48.3. The observed number was two. Therefore,
the efficacy of the method is 94.3% (95% confidence interval
75.4-98.7) - 95.9% (95% CI 82.5-99.0).
When calculating the efficacy of the method, we excluded
the 29 cycles during which women were not exposed to a risk
of pregnancy, and the three cycles in which mifepristone was
taken in the follicular phase.
Contraceptive efficacy of luteal phase administration of
mifepristone
In 145 cycles in which mifepristone was taken in the early
luteal phase (within 2 days of the urinary LH surge) 117 were
exposure cycles (Table II). Exposure status was unknown in
eight cycles and in 20 cycles women were not at risk of
pregnancy. In the 117 exposure cycles, there was only one
clinical pregnancy.
In 19 (10.7%) cycles, no LH surge was declared by the
monitor but mifepristone was given as coitus had taken
place during the fertile period of the cycle (calculated according
to the usual cycle length and usual day of LH surge).
Occurrence of ovulation was confirmed by serum progesterone
of >5 nmol/1 in all 19 cycles and treatment was administered
prior to day 21 of the cycle in each case [between day 13-21
of the cycle, mean 16.9 (SD ± 2.1) days]. There were no
pregnancies in these cycles.
If the probability of pregnancy in all exposure cycles in
the study is 0.25-0.32 (the same as that of the control group),
between 34-46 clinical pregnancies would be expected in
the 136 ovulatory cycles in which mifepristone was taken in
the luteal phase. The observed number was one. Hence, the
contraceptive efficacy of luteal phase mifepristone is between
97.1% (95% CI 78.00-99.6) - 97.8% (95% CI 83.9-99.7).
Performance of the home use hormone monitor
In 140 treatment cycles an LH surge was identified by the
monitor, which equates to 90.9% LH surge detection when
calculated for perfect use cycles; and 80.5% when imperfect
use cycles are also included in the total. In 127 cycles this
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Table II. Treatment cycle details.
Total no. Exposure Unknown No
cycles cycles exposure Exposure
Mifepristone administered 167 136 8 23
In follicular phase 3 0 0 3
In luteal phase 164 136 8 20
Early luteal phase 145 117 8 20
LH + 2 127 100 7 20
LH + 1 17 16 1 0
LH + 0 1 1 0 0
In luteal phase (unknown LH status) 19 19 0 0
Mifepristone not given 11 5a 0 6b
Total 178 140 8 29
aLH surge missed, at risk of pregnancy but after day 21.
bAnovulatory cycle n = 1, LH surge missed and no risk of pregnancy n = 5).
was confirmed by a subsequent rise in serum progesterone of
>5 nmol/1 in the early luteal phase. This information was
not available from nine cycles (blood samples lost or not
collected). In the remaining four cycles serum progesterone
was between 2-5 nmol/1, 1 or 2 days following the urinary
LH surge as detected by the monitor. This may have been due
to an early detection of the first significant rise in urinary
LH. None of these five cycles were prolonged after taking
mifepristone, hence it is unlikely that they were anovulatory.
There was a total of 38 (21.3%) cycles in which an LH
surge was not detected. Among them, one (0.6%) was an
anovulatory cycle, defined by serum progesterone not rising
above 5 nmol/1 in the mid-luteal phase. In three (1.7%) other
cycles we administered mifepristone on day 19, before the
monitor had identified an LH surge. Serum levels of progester¬
one (taken on the day of administering mifepristone) confirmed
that in these cycles mifepristone was administered in the
follicular phase. All three cycles were prolonged (43-52 days).
In the remaining 34 cycles an LH surge probably occurred
(as suggested by a rise in serum progesterone of >5 nmol/1)
but was not identified by the monitor. Fourteen were missed due
to monitor method failure (7.9%) and 20 were a consequence of
imperfect use of the system (11.2%).
Cycle length
Mifepristone when given in early luteal phase did not signi¬
ficantly affect the cycle length (P = 0.35). The mean of
the usual cycle length was 28.3 days (SD ± 1.3) and during
the treatment cycles it was 28.0 days (SD ± 1.9).
Side effects
Women kept a record of vaginal bleeding in 139 out of the
total 144 cycles where mifepristone was taken on LH + 2.
Mifepristone induced vaginal bleeding within 72 h in 21 cycles
(15%). In a further 19 cycles, our volunteers took mifepristone
in the luteal phase but the LH status was not known. In 17 of
those cycles (>89%), mifepristone induced a vaginal bleed.
Serum progesterone values in blood samples taken just
prior to mifepristone administration were available for 136
cycles. The mean serum progesterone value was significantly
(P < 0.0001) higher in those cycles where mifepristone
induced bleeding when compared to the mean value for the
cycles without bleeding [21.72 (SD ± 9.04) nmol/1 versus
13.33 (SD ± 6.23) nmol/1].
Two women spontaneously reported improvement of their
pre-menstrual symptoms during cycles in which mifepristone
was administered, while one reported worsening. In one woman
hepatic alanine aminotransferase (ALT) was elevated at 103
IU/1 (normal range 10-40 IU/1) at the end of the study but
returned to normal within 2 months. One woman complained
of diarrhoea 12 h post mifepristone in one cycle, three reported
menstrual cramping within 72 h of taking mifepristone; two
women reported a reduction in menstrual blood loss.
Discussion
A single dose of 200 mg of mifepristone administered
once a month is an effective contraceptive method with an
overall efficacy of 95% increasing to 97% if administered
at the correct time (i.e. the early luteal phase). Thus our
results are in agreement with the findings of a previous study
(Gemzell-Danielsson et al., 1993).
One criticism of previous work in this field has been
the lack of a suitable control group for the subjects studied.
Unlike the Gemzell-Danielsson study, we were able to compare
the results with a contemporaneous control group using the
same methodology in the same cultural setting. In this control
group, if sexual intercourse took place on a fertile day the
probability of a pregnancy was 0.25-0.32. The calculated
probability of pregnancy in a cohort of couples monitored
during a study of natural family planning (WHO, 1983) was
0.486 if intercourse took place 3 days prior to and a day after
the peak day of mucus discharge. The difference in the
probability of pregnancy between our study and a variety of
other published series (Table III) may be explained by the fact
that we have extended our definition of the fertile period to 6
days (3 days prior to the urinary LH surge until 2 days after).
Other authors (Wilcox et al., 1995) have calculated that the
likelihood of conceiving during an ovulatory cycle to be 0.37
(95% confidence interval 0.31-0.48) if daily sexual intercourse
took place during a 6 day fertile period (four days before and
a day after ovulation). The lower frequency of intercourse in
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Table III. Probability of clinical pregnancy.
No. of No. of Probability of
exposure pregnancies pregnancy
cycles
Wilcox et al., 1995b 129 34 0.26
Our control group6 37-48 12 0.25-0.32
Our treatment group6 140-151 2 0.01
(monitor + mifepristone)
Our treatment group6 136-143 1 0.007
(mifepristone in luteal phase)
Gemzell-Daniellson et al., 1990" 124 1 0.008
WHO study3 72 35 0.48
"The length of the fertile period defined as 4 days.
**1116 length of the fertile period defined as 6 days.
our group (untimed intercourse averaging 1.7 per week) may
also explain the lower probability of pregnancy.
The limiting factor in this once-a-month approach to
administering anti-progesterone is the accurate detection of
the LH surge. Clearly, the failure to detect accurately the
LH surge has a big impact on the overall effectiveness of
the method. Using laboratory assay of LH in blood or urine
to identify ovulation is neither practical nor convenient for
long term use in the general population. The monitor
provided us with an opportunity to overcome these problems.
Gemzell-Danielsson et al. (1993) reported 49% accuracy using
home LH detection sticks (Gemzell-Danielsson et al., 1993).
Although the monitor performed better (over 80.5% accuracy),
both of these methods remain below the required standard.
We studied 32 women over a total of 178 cycles. Imperfect
use of the system accounted for failure to identify an LH surge
in 11.8% cycles while 7.9% were due to monitor method
failure. Compliance difficulties are associated with all contra¬
ceptives and non-compliance in -12% of cycles is probably
no worse than with any other method which demands action
from the user, for example, compliance rates reported from
oral contraceptive pill users range from 3.4-100% (Wheble
et al., 1981; Molloy et al., 1985; Hamilton and Hoogland,
1989). Although our study population consisted of women
who were motivated and committed and some of them already
had experience in using natural family planning methods, they
found the short, inflexible testing window set on day 1 of the
cycle to be particularly demanding. This is inconsistent with
couples using the monitor in order to get pregnant (Bonnar
et al., 1999). The prevalence of imperfect use is likely to rise
in the general population compared with that typical of a
research study.
During the course of the study we developed an algorithm
(Figure 1) for the administration of mifepristone if an LH
surge was not identified. In 19 exposure cycles (out of 28
cycles in which an LH surge was not identified) mifepristone
was administered using this algorithm and there were no
pregnancies. Given that the methods available to be used in
real life to time the administration of mifepristone cannot be
100% accurate, such an algorithm will be essential to deal
with a missed LH surge.
In our study, mis-timed administration of mifepristone
LH surge not identified by the monitor
a) within 3 days of the expected day of the surge
or
b) by day 19 of the cycle
Figure 1. Algorithm for administering mifepristone when the LH
surge is not identified
led to predictable effects. When administered during the
proliferative phase of the menstrual cycle, mifepristone
inhibited follicular development, and delayed the mid cycle
LH surge, leading to a delay in ovulation and subsequent
prolongation of the menstrual cycle (Liu et al., 1987;
Luukkainen et al., 1988; Swahn et al., 1988). Ovulation
may occur later in that cycle, leaving women at risk of
conception. In our study, when administered in the late
follicular phase (in error) in three cycles, mifepristone pro¬
longed the cycle length (43-52 days). The women were advised
to use condoms for the remainder of that cycle and none of
the three cycles resulted in pregnancy.
Administration of mifepristone in the mid or late luteal
phase induces a bleed within a few days of treatment, which
may or may not be followed by a second bleed at the time of
expected menstruation (Shoupe et al., 1987; Swahn et al.,
1988). In our study, in 17 out of the 19 cycles where
mifepristone was taken after ovulation (the LH status
unavailable and probably later than on LH + 2), inter¬
menstrual vaginal bleeding occurred (89.5%). Moreover, there
was an increased risk of bleeding seen in those women who
may have taken mifepristone slightly later in the LH + 2
window. The mean serum progesterone concentration was
significantly higher in those women who had bleeding after
taking mifepristone within LH + 2, when compared with those
who did not. The higher serum progesterone value in some on
LH + 2, could be due to a delayed identification of the first
significant rise in urinary LH, or because of a more rapid
increase in serum progesterone due to early ovulation. Never¬
theless, in our group ofwomen, in all cycles where mifepristone
induced a vaginal bleed, a second bleed occurred at the time
of the expected menses. Therefore, while the bleeding may
have been inconvenient, it did not jeopardise efficacy or
continued use of the method. There was less inter-menstrual
bleeding (15% of the cycles) reported in our study when
mifepristone was taken within LH + 2, less than half of
that reported by Gemzell-Danielsson et al. (32%) (Gemzell-
Danielsson et al., 1993). This is possibly due to the fact that
the majority of women in our study received mifepristone at
the correct time. In their study, in 51 % of the cycles, mifepri¬
stone was taken between 3 and 5 days after the LH surge.
In conclusion, the use of the combination of home use
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fertility monitor with once-a-month administration of
mifepristone (especially if mifepristone is administered at the
early luteal phase) is an attractive contraceptive option with
minimal side effects. However, to be an effective contraceptive
method, the women have to be committed to using a device,
which identifies the LH surge, in order that the pill can be
taken at the correct time in the cycle. Whilst this regimen may
be acceptable to motivated women, it may be regarded as too
complicated for others to adopt on a routine basis. There was
evidence of such non-compliance in this study, with 11.2% of
LH surges being missed as a consequence of imperfect use of
the monitor. Unfortunately, it is difficult to envisage how an
easier way of defining the correct timing, which obligated less
compliance, could be devised.
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Noncompliance among a group of women
using a novel method of contraception
Dharani K. Hapangama, M.B., Anna F. Glasier, M.D., and David T. Baird, D.Sc.
Contraceptive Development Network, Department of Reproductive and Development Sciences, The University
of Edinburgh, Centre for Reproductive Biology, Edinburgh, United Kingdom
Objective: To compare the incidence of noncompliance measured objectively by a home use fertility monitor
with the traditional self-reported incidence of compliance in a study of a new method of contraception.
Design: Prospective cohort study.
Setting: A large family planning clinic in Edinburgh.
Patient(s): Thirty-two healthy women who took part in a trial assessing the efficacy of a novel method of
contraception involving accurately timed administration of a single dose of mifepristone.
Intervention(s): Mifepristone was administered orally and a blood sample was collected on the same day.
Main Outcome Measure(s): Percentage of missed tests detected by the monitor against the self-reported
percentage during the critical period.
Result(s): Women failed to perform 24.2% (95% confidence interval, 16.5-31.5) of the tests in the 162 cycles
analyzed. They missed tests at an absolutely vital time for contraceptive efficacy in 42% of cycles according
to the monitor while admitting to missing tests in 14.8%. Poor compliance was associated with younger
women, those who discontinued the study before completion, and cycles in which women were not relying on
the contraceptive method.
Conclusion(s): The use of microelectronic monitoring systems may improve our understanding of the extent
of patient noncompliance, providing objective information that no other monitoring technique can produce.
This understanding provides the opportunity to make the optimum use ofpotentially effective treatments while
validating research evidence. (Fertil Steril® 2001 ;76:1196-1201. ©2001 by American Society for Reproduc¬
tive Medicine.)
Key Words: Compliance, contraceptive research, home-use fertility monitor, mifepristone
Received March 1, 2001;
revised and accepted June
22, 2001.







Baird, D.Sc., The University









Since the first woman on earth chose to
contradict the instructions of her Provider in
the Garden of Eden, expecting her descendants
to comply perfectly with a contraceptive regi¬
men may seem rather unrealistic. However,
noncompliance with a particular contraceptive
method is linked with an increased risk of
unintended pregnancy (1). Conventionally, it
has been assumed that the users of contracep¬
tion are highly motivated because the conse¬
quence of noncompliance —pregnancy—is so
obvious, and so significant. Studies involving
organ transplant recipients have shown, how¬
ever, that no consequence of poor compliance
is severe enough—not even the rejection of a
transplanted kidney—for all patients to reliably
follow their prescribed regimen (2).
Poor compliance—in both clinical practice
and research—is associated with a number of
factors. Though several patient characteristics
(e.g., age, education, socioeconomic back¬
ground) (3-5), characteristics of the treatment
regimen (e.g., frequency of dosing, side ef¬
fects) (6-8), and outcome characteristics (e.g.,
treatment of incurable or terminal illnesses) (9)
have been associated with nonadherent behav¬
ior, there are no reliable and universally appli¬
cable predictors of noncompliance. In addition,
there is no gold-standard measurement for pa¬
tient compliance (10).
Prevalence of noncompliance ranges from
0-96.6% in oral contraceptive pill users (11-
13). Although extremely common, there is a
dearth of information available on patient non¬
compliance with the use of different contracep¬
tive methods. What data exist commonly come
from self-reporting. When undetected, poor
compliance can invalidate results of efficacy
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studies (14, 15), yet it is commonly overlooked in clinical
research (16).
We observed behavior of 32 women who took part in a
trial assessing the efficacy of a novel method of contracep¬
tion (17). The women took 200 mg of mifepristone 2 days
after the midcycle LH surge (measured in urine) as a once-
a-month contraceptive pill. Mistimed administration ofmife¬
pristone can disrupt the menstrual cycle and can also leave
the women at risk of conception. A home use fertility mon¬
itor that could store data on daily testing events was used to
time the administration of mifepristone. Although it made
minimal demands on the users, the method provided objec¬
tive, long-term data on their routines. Because investigators
saw participants once each cycle throughout the study, we
were able to compare the results of this method with the
traditional self-reported incidence of compliance.
MATERIALS AND METHODS
Data were collected during a study assessing the feasibil¬
ity of administering mifepristone as a once-a-month contra¬
ceptive pill, and detailed study methodology has been re¬
ported elsewhere (17). Thirty-two sexually active women
(age range, 18-39 years) were enrolled from a large family-
planning clinic in Edinburgh. (The mean body mass index
was 24 ± 4.3, and 66% were nonsmokers.) All subjects gave
written informed consent to participate, and the Lothian
Research Ethics Committee approved the study. Data were
collected from a total of 178 cycles, with each subject
contributing between one and eight cycles. It was not pos¬
sible to retrieve compliance data from the monitors in 28 of
the study cycles because of infrequent downloading from the
monitor and lost or broken devices.
The study started on day 1 of the menstrual period after
screening and lasted for up to eight consecutive menstrual
cycles. The subjects were relying on once-a-month treatment
with mifepristone as their sole method of contraception
during 150 of the cycles analyzed. In addition, it was pos¬
sible to retrieve data from a further 12 cycles during the
study suspension period, during which women did not rely
on our method for contraception but only used the monitor.
During the cycles in which mifepristone was administered,
the timing of mifepristone depended on detection of the LH
surge, which in turn depended on compliance with daily
urine testing.
Procedure
All subjects were provided with a home use fertility
monitor (Unipath, Bedford, UK). The system comprises a
hand-held monitor and disposable dual-assay urine test
sticks and is used to detect simultaneously LH and estrone-
3-glucuronide levels in early-morning urine. The system
delineates three levels of fertility (low, high, and peak fer¬
tility) according to the optical signal changes detected. At the
start of each menses, the subjects pressed the m button on
their monitors to initiate that cycle of use at a time suitable
for testing the first urine of the day.
For the rest of the month, the subjects were required to
consult the monitor display each morning (3 hours on either
side of the time when the m button was set) to determine
whether they needed to perform a test that day. Without this
6-hour time window, the system would not accept a test. The
monitor requests one test every day for up to a total of 10 or
20 tests, depending on the length of the woman's cycle and
the timing of her LH surge. Embedded software within the
monitor collects, analyzes, and stores data for several
months.
The correct way to use the monitor (including the impor¬
tance of the testing window) was demonstrated to all sub¬
jects at the time of recruitment, and written information was
given. Subjects were advised to contact the investigator
immediately if they were not able to perform a test during a
critical period. The investigator was available by telephone 7
days a week.
In each cycle, subjects were reviewed by the investigator
monthly, on day LH+2. A sample of venous blood was
collected before taking the tablet of 200 mg mifepristone and
was later used for the analysis of progesterone. The infor¬
mation collected by the monitor was later analyzed using
special computer software. The estimated day of LH peak for
each month was calculated based on information from all the
previous cycles monitored. If an LH surge was not detected
either within 3 days after the anticipated day of LH peak or
by day 19 of the cycle, a blood sample was taken for rapid
serum progesterone assay, and the information from the
monitor was downloaded. Mifepristone was administered
only if the woman was at risk of pregnancy (i.e., had been
sexually active) and if the progesterone level was >5nmol/L.
All subjects kept a menstrual record card, recording all
vaginal bleeding experienced during the study and the days
on which they had sexual intercourse. They also marked the
day of the LH surge as identified by the device and the day
of taking the study medication.
The following definitions were created for the purpose of
the study. The period of time between the calculated earliest
day an LH peak was likely to occur (based on the usual cycle
length and the day of the LH surge in previous cycles) and
the day of the actual LH surge in each cycle was defined as
the critical period for each patient. The fertile period of the
cycle was defined as 3 days before until 2 days after the
urinary LH surge (LH—3 to LH+2). Exposure cycles were
cycles in which women reported having sexual intercourse at
least once during the fertile period. Noncompliance was
defined as a urine test that was requested by the monitor but
missed.
Statistical Methods
Some of the compliance data were summarized for de¬
scriptive purposes using numbers of cycles or tests as de-
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nominators. However, statistical inference was carried out
on data aggregated to patient level, to take account of pos¬
sible heterogeneity in behavior among patients that might
have invalidated analyses using data from individual cycles
or tests. Thus, percentages of tests missed were calculated
for each patient, and these were tested for association with
demographic data using Pearson correlations. Testing was
done on data aggregated to patient level. Thus, for example,
correlating each patient's age with the percentage compli¬
ance over all her cycles tested the association between age
and compliance. Similarly, percentages of tests missed at
different stages of the cycle, and when on and off the
treatment regime, were compared by paired /-tests. A two-
sample /-test was also used to compare the percentage of
tests missed in patients who dropped out and those who did
not.
RESULTS
One hundred sixty-two cycles were analyzed, of which
150 were study cycles. Data collected during the 12 cycles
during which subjects were using a barrier method through¬
out the cycle and did not receive mifepristone were analyzed
separately.
In total, 2,013 tests were requested by the monitor during
the 162 cycles analyzed (12.4 tests per cycle, 95% confi¬
dence interval [CI], 11.8-13.0), and 494 were missed
(24.2%; 95% CI, 16.5-31.5). On average, three tests (95%
CI, 2.4-3.6) per cycle were missed.
Compliance During the Intention-to-Treat
Cycles
During the 150 cycles in which women were relying on
the study method as their only contraception, a total of 1,816
tests was requested by the monitor, and 411 tests were
missed (22.6%; 95% CI, 15.2-30.1).
Compliance Before and After Identifying the
Peak
In the days before the women knew an LH surge had
occurred, 23% of the requested tests were missed (95% CI,
16-30; 260 of 1,160). Women were not more likely to miss
tests before the LH surge than after it (/ = 0.57, NS).
Concordance of Monitor Data With the Self-
Reported Data
In 68 cycles (42%), women failed to test at all on a day of
the cycle, which was critical to the accurate detection of an
LH surge. In 27 of these cycles, the monitor did not detect an
LH peak. In the remaining 41 cycles, despite critical tests
being missed, the monitor did detect an LH peak. Women
admitted to not performing tests in 24 cycles (14.8%). In the
other 44 cycles, women did not report missed tests and only
admitted to it once the investigator showed the downloaded
monitor data to them.
Some women actively fabricated the information that they
reported to the investigator. In one of these cycles, when
contacted, a woman declared detecting an LH peak on a day
(day 13 of the cycle) when she had not performed a test at
all. Another woman performed the tests correctly and iden¬
tified an LH peak on day 13 but forgot to inform the
investigator and failed to obtain the mifepristone tablet as
per protocol. When contacted on day 19 of the same cycle,
she claimed that the monitor had not detected an LH peak.
Compliance During the Critical Days
Noncompliance with urine testing as monitored by the
system was significantly lower during the critical period
(15.6%; 95% CI, 9.5-21.7) when compared with during the
noncritical days (27.5%; 95% CI, 17.9-37; paired /-test, / =
3.64, P<.01). The self-reported percentage of missed tests
during the critical period was 2.7% (95% CI, 1.0-4.3),
which was significantly lower than that detected by the
monitor (/ = 4.48, PC.001).
Compliance During the Study Suspension
Interval
After a pregnancy that occurred because of a failure in
detecting a LH peak, the study was suspended for a month.
However, some women continued to use the monitor only,
while using a barrier method for contraception. Therefore, it
was possible to retrieve data from the monitors for 12 cycles
in which the women were not using our method as their
contraceptive.
In six of these 12 cycles, the monitor was not able to
identity an LH peak because of its imperfect use. During this
period, a significantly high percentage of tests (41.2%; 95%
CI, 22.4-60.0) were missed when compared with the study
cycles (22.6%; 95% CI, 15.2-30.1; / = 2.9, P=.015).
Compliance and Sexual Activity
There was no correlation between the frequency of sexual
intercourse per cycle and the number of missed tests per
cycle (correlation coefficient was 0.01). The percentage of
missed tests were compared between the exposure and non-
exposure cycles in 12 women who had at least one exposed
and one unexposed cycle. There was no significant differ¬
ence (paired /-test, / = 0.06, NS; 95% C.I for differences
between exposed and unexposed, —8.3 to +7.8) in compli¬
ance during exposed and nonexposed cycles.
Demographic Features and Compliance
Age was negatively correlated with the percentage of
missed tests—younger women missed more tests (r =
-0.36, PC.05). There was no apparent relationship between
compliance with the method and the number of pregnancies,
number of previous abortions, or number of living children.
Compliance Among Dropouts
We analyzed cycle data from the seven women who
discontinued the study before completion. They missed a
significantly higher percentage of tests (44.4%) when com¬
pared with the other 25 women who completed the study
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Information collected from the monitor and the diary card from a woman with a 31-day cycle in which the LH surge was
identified. Mifepristone was administered on day 20 (LH+2). (A), Information downloaded from the monitor. Level of fertility
displayed to the woman on each day of the cycle: open block, low fertility; partially closed block, high fertility; closed block with
circle, peak fertility. Data on testing events appears as a narrower bar underneath: open block, test performed; closed block,
test missed. (B), Data recorded on the diary card by the woman (self-report). B, days of vaginal bleeding; check mark, tests
done during the critical period; X, days in which sexual intercourse occurred; T, day when mifepristone was taken. (C),
Downloaded information on signal levels of LH and estrone-3-glucuronide (E3G) levels. Closed circle, LH; open square, E3G;
M, missed tests. Note that on several days (comparing panels A and B), the woman reported performing the test (check mark)
when the monitor showed that she did not (M).
A Panel I
H~r
10 15 20 25 30
B Panel II B B B B B B B s/ V V V V V V T
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(17.4%; 95% CI of the differences between the two percent¬
ages, 10.6-43.3; t = 3.39, />=.002). The dropouts missed
tests on a critical day in 16 of the 22 cycles, although they
admitted to missing tests in only four. Therefore, the self-
reported incidence of noncompliance during the critical pe¬
riod was 18.1%, whereas the monitor-detected incidence was
72.7%.
DISCUSSION
The home use fertility monitor offered us an important
methodological advance in providing reliable data on the
incidence and the magnitude of noncompliance with the
contraceptive method studied and on information about ex¬
actly when the imperfect use occurred. We sought to achieve
significantly high compliance rates with employing this
monitoring system in a contraceptive regimen, which ap¬
peared to be acceptable to women (18, 19). Women were
counseled at the start of the study regarding the importance
of performing urine tests accurately to identify the time to
administer mifepristone. They were aware that if mifepris¬
tone was not taken, they would be at risk of pregnancy.
Because the teratogenic effects of mifepristone are not
known, women considering participation in the study were
advised that if pregnancy occurred, they should consider
termination. Despite this, the information collected from the
monitor demonstrates that women failed to perform 24.2%
of the tests in the 162 cycles analyzed. Moreover, in 42% of
the cycles, women missed tests during a day that an LH
surge was likely to have occurred, in other words, at an
absolutely vital time for contraceptive efficacy.
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Information collected from the monitor and the diary card from a 35-day cycle in the same woman as illustrated in Figure 1.
As a consequence of missed tests, the monitor did not identify the LH surge, and mifepristone was not administered. (A),
Information downloaded from the monitor. Level of fertility displayed to the woman on each day of the cycle: open block, low
fertility; closed block, high fertility. Data on testing events appears as a narrower bar underneath: open block, test performed;
closed block, test missed. (B), Data recorded on the diary card by the woman (self-report). B, days of vaginal bleeding; check
mark, tests done during the critical period; X, days in which sexual intercourse occurred. (C), Downloaded information on signal
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Although noncompliance is common, by inviting only a
selected group ofwomen who appeared to be motivated and
committed, we sought to exclude those who might be poor
compliers. Interestingly, the medical profession is reportedly
poor in identifying noncompliers (20). Users of our method
were reasonably young (mean age, 30 years) and were healthy.
The serious outcome of noncompliance (pregnancy) was rare.
Women may have found the daily requirement for urine testing,
using the monitor on a long-term basis, to be complicated or
inconvenient. Side effects of the method (although fewer than
in most other methods available) may not have been acceptable
to them, or they may not have had faith in the effectiveness
of the method although this seems unlikely because they did
not revert to condoms. Considering these odds, it is not
difficult to infer why compliance problems were frequent.
Common sense suggests that with increasing experience,
the women may trivialize the need for testing on days during
which an LH surge was unlikely to have occurred. All women
were made aware of the critical period for testing urine at the
start of the study, and as expected, women missed fewer tests
during this period. Incomplete understanding of how to be
compliant with a regimen has been suggested as a common
reason for poor compliance (21). Women in our study were
given detailed verbal and written information on using the
monitor at the start of the study. The importance of accurate use
of the device according to manufacturer's guidelines was
stressed at each monthly visit. Because there was no significant
difference in the percentage of missed tests between the first
study cycle and the last study cycle, it is difficult to support
the suggestion that in the earlier cycles, women were less
confident about how to use the method or more confident in
their ability to guess the correct time for testing (22).
There was a highly significant difference between the patient
self-reported percentage of missed tests (2.7%) and that de¬
tected by the monitor (15.6%) during the critical period. Figures
1 and 2 illustrate this discrepancy during two cycles contributed
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by one woman. This discrepancy was even greater among the
seven women who discontinued the study before completion
and is consistent with results of previous studies that reported
significant overestimation of compliant behavior with self-
regulation (23). Patients tend to tell doctors what they think
the doctors wish to hear. If they assume that doctors perceive
patient nonadherence as a judgmental disappointment, they
may feel guilty and fail to report noncompliance.
Although older women tended to miss fewer tests, the other
demographic characteristics such as parity, previous abortions,
number of living children, and educational background did not
correlate with the number ofmissed tests. Neither did frequency
of sexual activity or exposure to the risk of pregnancy
correlate with the missed tests. However, because the infor¬
mation about sexual activity was only collected by self-
reporting, this association should be accepted with caution.
Most investigators work on the assumption that a patient
who complies with one aspect of a clinical protocol (e.g.,
attending the clinic as directed) also adheres to all other aspects
of the study, though this might not always be the case. The
monitor supplied data on daily testing ofurine, which was only
one part of the contraceptive method. We cannot infer from
those data how well the women in our study complied with the
rest of the protocol, such as recording daily events (sexual
intercourse, vaginal bleeding). With no means of testing this,
for validity of our results, we had to depend on our volunteers
being truthful. Therefore, in the future, we have no other option
but to work toward forming a true therapeutic alliance with our
volunteers and to come to an agreement with our patients rather
than to impose a prescription or a protocol upon them.
In conclusion, the use of microelectronics monitoring
systems such as the home use fertility monitor may improve
our understanding of the extent of the problem of patient
noncompliance, providing precise objective information that
no other monitoring technique can produce. This understand¬
ing will empower us as health care providers to adopt a
no-fault approach to behavior relating to noncompliance and
establish "a tailored consensual regimen" with the user that
she is able to adhere to (24). This provides the opportunity to
make the optimum use of potentially effective treatments
and legitimate research evidence. Perhaps a small price to
pay for such a return!
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Mifepristone-Induced Vaginal Bleeding Is Associated
with Increased Immunostaining for Cyclooxygenase-2
and Decrease in Prostaglandin Dehydrogenase in Luteal
Phase Endometrium
DHARANI K. HAPANGAMA, HILARY O. D. CRITCHLEY, TERESA A. HENDERSON, and
DAVID T. BAIRD
Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, Edinburgh EH3 9ET,
United Kingdom
The mechanism ofmifepristone-induced vaginal bleeding and
endometrial sheddingwas investigated in 13 womenwho took
200 mg mifepristone in the midluteal phase on d 8 after the
onset of the urinary LH surge (LH+8). Endometrial biopsies
were collected, 6-24 h after mifepristone (group 1, n = 7) or
36-48 h aftermifepristone (group 2, n = 6), and compared with
those from a control group in the midluteal phase (n = 7). All
women reported vaginal bleeding commencing 36-48 h after
taking mifepristone. Treatment with mifepristone signifi¬
cantly reduced serum progesterone levels in all women, when
compared with the controls (13.2 nM vs. 34.8 nM, P = 0.001).
Aftermifepristone, a significant increase in cyclooxygenase-2
immunoreactivity was apparent at 36-48 h (P = 0.0018),
whereas prostaglandin 15 dehydrogenase enzyme-positive
immunostaining declined, to be virtually absent by 36-48 h in
both glands and in stroma (P < 0.05). There was no change in
intensity or distribution of staining for steroid receptors after
mifepristone. The changes in immunostaining for cyclooxy-
genase-2 and prostaglandin 15 dehydrogenase strongly sup¬
port the hypothesis that an increase in the local concentration
ofprostaglandins in the endometrium is involved in the mech¬
anism ofbleeding induced by mifepristone in the luteal phase.
(J Clin Endocrinol Metab 87: 5229-5234, 2002)
HUMAN ENDOMETRIUM is a target organ for theovarian steroid hormones estradiol and progester¬
one. One of the fundamental roles of progesterone is the
differentiation of an estrogen-primed endometrium (1). The
endometrial receptivity that permits successful implantation
depends on timed and regulated synthesis and secretion of
a specific set of progesterone-induced proteins in an estro¬
gen-primed endometrium. If a pregnancy fails to occur, the
corpus luteum regresses, with a subsequent fall in proges¬
terone levels. There is now compelling evidence that a period
of exposure of the estrogen-primed endometrium to proges¬
terone followed by a withdrawal of progesterone are the
hormonal prerequisites for menstruation (2). The character¬
istics of the endometrial changes (including the extensive
changes observed in the endometrial vasculature) associated
with the withdrawal of progesterone and menstrual bleeding
suggest an involvement of vasoactive local mediators. The
evidence that prostaglandin (PG) activity in the endome¬
trium is modulated by progesterone, and the widely recog¬
nized vasoactive properties of PGs, make them prime can¬
didates for mediators of progesterone action on the
endometrium (3).
PGs are synthesized from arachidonic acid (AA); thus, the
liberation of AA from precursors (present as membrane-
Abbreviations: AA, Arachidonic acid; AR, androgen receptor; COX,
cyclooxygenase; ER, estrogen receptor; LH+8, d 8 after the onset of the
urinary LH surge; PG, prostaglandin; PGDH, prostaglandin 15 dehy¬
drogenase; PLA2, phospholipase A2; PR, progesterone receptor; RT,
room temperature.
bound phospholipids) by the action of phospholipase A2
(PLA2) is one of the first steps (and a rate-limiting step) in PG
synthesis. AA is then converted to prostanoides (including
PGE2 PGF2„ and PGI2) by the actions of cyclooxygenase
(COX). In the endometrium, PGs are not stored but are im¬
mediately synthesized and released and metabolized to in¬
activemetabolites by PG 15 dehydrogenase (PGDH) enzyme.
The antiprogesterone compound mifepristone (RU 486;
Roussel Uclaf, Paris, France) is a synthetic 19-norsteroid with
a specific high affinity for binding to the progesterone re¬
ceptor (PR). It blocks the biological effects of progesterone by
binding with high affinity to the PR (4). In the midluteal
phase, mifepristone, at a single dose of 50-800 mg, induces
menstrual bleeding within 72 h (5, 6). Luteolysis was incom¬
plete in two thirds of the subjects, and they experienced a
further episode of vaginal bleeding at the expected time of
menses. In the remainder, there was complete luteolysis,
with only one episode of bleeding. Thus, the vaginal bleeding
observed after mifepristone, without a decrease in the cir¬
culating progesterone values, seems to be attributable to a
direct effect on the endometrium. It has been suggested that
themenstrual bleeding induced bymifepristone inmidluteal
phase is attributable to a direct effect on endometrial vessels
(7). After treatment with 50 mgmifepristone in themidluteal
phase (d 20-23), there is a significant reduction in the cap¬
illary luminal area and diameter associated with degenera¬
tive changes in the endothelial cells, which preceded the
menstrual shedding. These changes do not always accom¬
pany regressive changes in the adjacent stroma. This effect of
mifepristone on the endometrium (at a time when the en-
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dometrial PR level is relatively low) is poorly understood
and has been hardly investigated.
The endometrial effects of antigestogens given in the early-
luteal phase have been extensively investigated (8-11). In the
early-luteal phase, mifepristone inhibits progesterone-
induced down-regulation of PR and estrogen receptors
(ERs), while antagonizing the progesterone action on endo¬
metrial markers such as PGDH, which are known to be
progesterone-dependent (12,13). Moreover, PGDH has been
postulated as a useful marker of the closure of the implan¬
tation window, and the effect of midluteal administration on
such markers might add to our current understanding of
potential contraceptive actions of mifepristone.
Our study investigated the mechanism of mifepristone-
induced vaginal bleeding in the endometrium from 16
healthy women with regular cycles. The endometrial biop¬
sies were performed between 0 (control) and 6-48 h after
midluteal phase administration of a single dose of 200 mg
mifepristone. We examined the expression and the distribu¬
tion of sex steroid receptors in the endometrium and the
expression of PGDH, and inducible PG synthesizing enzyme
COX-2. Alterations in the expression of such progesterone-
dependent proteins may widen our understanding of the
mechanism by which mifepristone induces endometrial
bleeding in the midluteal phase.
Subjects and Methods
Subjects
Twenty healthy women with regular cycles (25- to 30-d duration;
mean age, 34 yr; range, 26-45 yr) were recruited into a randomized,
single center study with mifepristone. Women were either using a re¬
liable nonhormonal method of contraception or were abstinent. All
women underwent a comprehensive screening procedure before com¬
mencing the study. This consisted of a full medical history and routine
physical and gynecological examination, together with measurement of
blood pressure, pulse, height, and weight. In addition, a venous blood
sample was taken for full blood count, serum biochemistry, and liver
function. These blood tests were repeated at the end of the study. All
women kept a menstrual diary card and recorded all vaginal bleeding
experienced during the study period and in the following cycle, and the
day in which they identified an LH surge using urinary dipsticks.
We also studied the endometrial samples from four women taking
part in a separate study, which evaluated the secretory endometrium.
Those women also used the same type of urinary dipsticks to identify
the urinary LH surge, and the biopsies were collected 7 or 8 d after the
first day of the urinary LH surge. Because these women did not receive
any treatment, the four biopsies were included in our control group.
Therefore, the total number of biopsies analyzed in the control group
was seven.
Lothian Research Ethics Committee (Institutional Review Board) ap¬
proved the study, and informed written consent was obtained from each
woman.
Study design
The women were monitored over two consecutive cycles: a treatment
cycle, and a follow-up cycle. The women were allocated, at random, to
1 of 5 groups, depending on the timing of the biopsy, i.e. 6,24,36, or 48 h
after a 200-mg mifepristone treatment on d 8 after onset of urinary LH
peak (LH + 8). The control group had a biopsy but no treatment. Each
of the 20 women in the study were allocated to the next consecutive
study number in the randomization list before commencing the study.
The randomization list was produced using the Statistical Package for
Social Scientists (SPSS, Inc., Chicago, IL), such that each study number
was randomly assigned to 1 of 5 groups in the study. The list was
balanced after each block of 5.
Women used detection kits to detect the LH surge in a first sample
of urine. On the occasion when the endometrial biopsy was taken, a
blood sample was also collected for serum progesterone measurement
by RIA.
Fourwomen were subsequently withdrawn from the study: 1 because
of previously undiagnosed cervical stenosis, which made endometrial
biopsy difficult; in 1 woman, RIA could not confirm the self-detected LH
peak; and the endometrial samples were inadequate for analysis in 2
other women. Therefore, we analyzed the endometrial samples in 13
women after taking mifepristone in the midluteal phase (n = 3, at 6 h;
n = 4, at 24 h; n = 3, at 36 h; n = 3, at 48 h after mifepristone). Three
samples from our original control group plus the above mentioned 4
additional samples from a separate study made a total number of 7 in
the control group.
Detection of the urinary LH peak
The timing of the urinary LH surge were detected by the subjects
themselves, using a commercially available LH detection kit (Oviquick;
Unipath, Bedford, UK),which they used according to themanufacturer's
instructions. The self-detected urinary LH peak was subsequently con¬
firmed by RIA (MAI Aclone Kit; Biostat-Diagnostics, Stockport,
Cheshire, UK).
Serum progesterone
A blood sample was collected immediately before the endometrial
biopsy in all women, stored, and later assayed for progesterone. Serum
progesterone measurements were done by using the Coat-A-Count pro¬
gesterone procedure [solid-phase RIA; Diagnostic Products (UK) Ltd.,
Glyn Rhomwy, Llanbersi, Caernarfon, Gwwyedd, North Wales, UK.
Endometrial biopsies
Endometrial biopsies were obtained using a Pipelle endometrial sam¬
pling device (Prodimed, Neuilly-en-Thelle, France) and were fixed im¬
mediately in 4% paraformaldehyde for 24 h, routinely processed, and
embedded in paraffin, and sections were cut to 5-p.m thickness. All tissue
samples were labeled with a code number for anonymity; and, except
for this number, the mounted sections did not contain any other
information.
Immunohistochemistry
Immunohistochemical staining was performed for immunolocaliza-
tion of: 1) PR, with a 1:40 dilution of mouse monoclonal antihuman PR
antibody (0.88 ^g/rnl protein; Novocastra Laboratories, Newcastle
upon Tyne, UK); 2) ER, with a 1:400 dilution of mouse monoclonal
antihuman ER antibody ER1D5 (0.58 jug/ml protein; DAKO Corp. Lab¬
oratories, High Wycombe, UK); 3) androgen receptor (AR), with a 1:480
dilution of monoclonal mouse antihuman AR antibody (F-39; BioGenex
Laboratories, Inc. antibody, A Merarini Diagnostics, Berkshire, UK); 4)
PGDH, with a 1:3000 dilution of rabbit polyclonal antibody (Dr. H. H.
Tai, University of Kentucky, Lexington, KY); and 5) COX-2, with a 1:600
dilution of goat polyclonal antihuman COX-2 antibody (0.3 ju.g/ml pro¬
tein; Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Immunohistochemistry procedures
All protocols were optimized to determine the correct conditions for
maximum specific staining, and all sections used as negative controls
(where the primary antibody was replaced with nonimmune IgG of the
same species and concentration) did not show immunostaining. Each
immunostaining procedure was performed in a single run. The immu¬
nohistochemical technique used was as follows:
Five-micrometer paraffin sections were dewaxed in Histoclear (Na¬
tional Diagnostics, Yorkshire, UK) and rehydrated in descending con¬
centrations of ethanol to dH20. After a 10-min wash in 0.01 M PBS (pH
7.4-7.6; PBS tablets, Sigma, Dorset, UK), antigen retrieval was carried
out as follows: Sections to be stained for PgR and ER were microwaved
for 10 min in 0.01 M sodium citrate buffer (pH 6) while those for AR and
COX-2 were pressure-cooked in 0.01 M sodium citrate (pH 6) for 5 min
and 2 min, respectively (Tefal, Nottingham, UK). An antigen retrieval
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step was not required to expose the PGDH epitope. Sections were
washed in PBS, and endogenous peroxide activity was blocked by in¬
cubation in 3% hydrogen peroxide in distilled water for 10 min (PR, ER,
AR, PGDH) or 3% hydrogen peroxide in methanol for 30 min (COX-2).
After a 10-min wash in PBS, an endogenous biotin blocking step was
carried out for AR and COX-2, where sections were incubated sequen¬
tially in avidin then biotin for 15 min each at room temperature (RT)
(Vector Laboratories, Inc., Peterborough, UK). After a further 10-min
wash, sections were incubated in normal horse serum (Vector Labora¬
tories, Inc.) for PR, ER, and AR or in 20% normal goat serum for PGDH,
and in 20% normal rabbit serum for COX-2 (Diagnostics Scotland, Ed¬
inburgh, UK), all for 20 min at RT. The primary antibodywas then added
at the dilutions stated above. Sections were incubated for 60 min at 37
C for PR, ER, and COX-2 and overnight at 4 C for AR and PGDH. After
washing in PBS with Tween 20, biotinylated horse antimouse antibody,
followed by an avidin biotin horseradish peroxidase complex (ABC,
Vectastain Elite; Vector Laboratories, Inc.) was added for 60 min for ER
and AR, and 30 min for PR at RT. Biotinylated goat antirabbit and horse
antigoat (Vector Laboratories, Inc.) were added for PGDH and COX-2,
respectively, for 30 min, followed by the ABC complex for 60 min
(PGDH) and 20 min (COX-2) at RT. Staining was visualized by incu¬
bation in 3,3' Diaminobenzidine (DAB; DAKO Corp. Laboratories). Sec¬
tions were then counterstained using Harris' Hematoxylin (Pioneer Re¬
search Chemicals Ltd., Essex, UK), dehydrated, and mounted in Pertex
(Cellpath, Hemel Hempstead, UK).
Scoring and immunohistochemistry analysis
We employed a semiquantitative subjective scoring system to eval¬
uate the intensity and the localization of immunoreactivity in entire
tissue sections. Previously, we have reported that the immunostaining
patterns in endometrial sections measured by the subjective semiquan¬
titative scoring showed an almost perfect correlation with that measured
objectively by computerized image analysis (14). Therefore, the less-
time-consuming, semiquantitative scoring system provides a valid score
suitable for graphical presentation.
Two independent observers, using light microscopy, visually as¬
sessed all coded sections. The two separate scores were then compared
to obtain a more objective final score for each section. Once the final score
had been agreed for all sections in the five-immunostaining runs, the
code was broken. Afterwards, the final immunostaining scores were
analyzed by the respective groups.
The immunostaining intensity of the steroid receptors (PR, ER, and
AR) were scored using a four-point scoring scale, where the intensity of
stainingwas assigned as 0 = none, 1 = weak, 2 = distinct, and 3 = strong.
However, the staining intensity of PGDH and COX-2 showed a narrow
range; and therefore, we adapted a three-point scoring scale, where the
score of zero = an absence of immunoreactivity, 1 = faint immunore¬
activity; and 2 = strong immunoreactivity.
Statistical analysis
Originally, the sample size was determined to include 5 women in
each of 4 groups at 6, 24, 36, and 48 h after mifepristone. However,
because of a number of reasons listed above, only 13 biopsies after
treatment were available. Because mifepristone induced bleeding by
36-48 h in all women, a preliminary analysis was performed to deter¬
mine the appropriate statistical test for analysis of the data. The mean
staining intensity scores between 6-h and 24-h groups and between 36-h
and 48-h groups showed no significant difference; hence, the 13 samples
after treatment with mifepristone were analyzed in 2 groups: group 1
(6-24 h after mifepristone, n = 7), and group 2 (36-48 h after mife¬
pristone, n = 6). Comparisons between these 2 groups were tested by
nonparametric Kruskal-Wallis ANOVA test and the Dunn's multiple-
comparisons test because they were discontinuous data sets.
Results
All women reported vaginal bleeding commencing 36-48
h after taking mifepristone. Four women in group 2 (one
woman after 36 h, and three women after 48 h) had already
started to bleed at the time the endometrial biopsy was taken;
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the others started bleeding after the biopsy. The bleeding
lasted for 12-72 h, and all but three women reported a second
bleed at the time of the expected menses. In these three
women, a second episode of bleeding occurred approxi¬
mately 4 wk later.
The concentration of progesterone was significantly lower
at the time of biopsy in the women treated with mifepristone
than in the control women (13.2 nM vs. 34.8 nM, P = 0.001).
However, the levels were still significantly higher than those
found during the follicular phase.
Intense PGDH immunoreactivity was observed in the cy¬
toplasm of predominantly glandular epithelium (with a
lesser degree of staining in the stromal cells) in all midluteal-
phase control sections (Fig. 1A). The abundance of PGDH-
positive immunostaining clearly declined, to be virtually
absent by 36-48 h in both glands and in stroma (Fig. IB). The
difference in PGDH-staining scores between the control
group and 36- to 48-h group were statistically significant (P <
0.05) (Fig. 2A).
In all samples (treated and untreated), COX-2 staining was
localized predominantly in the endometrial glands, with no
(or barely detectable) staining in the stroma (Figs. 1C and 2B).
Untreated endometria in the midluteal phase showed min¬
imal staining for COX-2 in the glandular cellular compart¬
ments. After mifepristone, a significant increase in immu¬
noreactivity was apparent at 36-48 h (Figs. ID and 2B) (P =
0.0018).
Steroid receptor immunostaining
As expected, there was weak staining for PR in the nuclei
of stromal cells in the control samples, with minimal ER
staining. AR staining was confined to stroma. There was no
change in intensity or distribution of staining for steroid
receptors after mifepristone (data not shown).
Discussion
Endometrial shedding and vaginal bleeding are observed
after withdrawal of progesterone (for example at luteal re¬
gression) from an estrogen-primed endometrium that is sub¬
sequently exposed to progesterone (2). Similar bleeding is
also seen after the pharmacological withdrawal of proges¬
terone after administering the antiprogesterone, mifepris¬
tone, in the luteal phase of the cycle. While the endometrial
morphology exhibits a marked sensitivity to mifepristone,
with a 0.5-mg daily dose being the threshold dose for delay
in endometrial maturation (15-17), in general, higher doses
(in excess of 10 mg) are required to produce endometrial
shedding and menstrual bleeding.
All women in our study reported vaginal bleeding com¬
mencing at 24-48 h after taking 200 mg mifepristone in the
midluteal phase. In 13 out of the 16 subjects, this was fol¬
lowed by a second bleed of normal character at the expected
time of the next menses. Althoughmifepristone significantly
depressed the serum progesterone value in all women, the
occurrence of a second bleed in the majority suggests only a
partial luteolysis and a direct effect of mifepristone on the
endometrium (18).
The current understanding advocates a central role for PGs
as a trigger mechanism for menstruation (2, 3, 19, 20). The
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Fig. 1. A, PGDH immunostaining in midluteal-phase endometrium, demonstrating positive immunoreactivity in the glands and stroma. B,
Endometrium, biopsied 36 h after administration ofmifepristone, on d LH+8 of cycle. Note the decrease in immunoreactivity in the glandular
and stromal compartments. C, COX-2 immunostaining in an endometrial biopsy collected in the midluteal phase. Negligible immunostaining
in glands and stroma. D, COX-2 immunostaining in endometrium, collected 36 h after administration of mifepristone, on d LH+8. Note the
increase in immunoreactivity in the glandular cytoplasm. Scale bar, 50 p.m.
concentration of PG in any tissue is related to its rate of
synthesis and metabolism, and the variation in the endome¬
trial release of PGs at different stages of the menstrual cycle
suggests an ovarian hormonal influence. The two key en¬
zymes that control the endometrial PG synthesis (PLA2 and
COX) seem to be under the influence of progesterone. COX
enzyme exists as two isoforms produced by two different
genes (COX-1 and COX-2). COX-1 is constitutively ex¬
pressed, whereas COX-2 expression is modulated by a va¬
riety of stimuli and may be inhibited by progesterone in the
endometrium (21). PLA2 also seems to be present in the
endometrium in two different isoforms: the calcium-depen¬
dent and inducible PLA2(i), which is localized in the endo¬
metrial glands; and the calcium-independent PLA2(ll), which
is predominantly confined to the stroma (22). Conversely,
PGDH metabolizes PGs to inactive metabolites, and this
enzyme is induced by progesterone (12,13, 23). The increase
in PGDH activity in a secretory endometrium that occurs in
response to the rising levels of progesterone in the luteal
phase (12) can be prevented by administration of antigesta-
gens shortly after ovulation (11). Thus, progesterone is re¬
sponsible for stimulating PGDH and suppressing COX-2.
In our study, treatment with mifepristone in the midluteal
phase resulted in a decreased PGDH and an increased COX-2
expression in the endometrial glands, which was apparent at
36 h after mifepristone. This effect would be expected to be
synergistic in increasing endometrial PGs (because of a syn¬
chronized suppression ofmetabolism, with an augmentation
in the synthesis) and would lead to increased uterine activity
and menstrual bleeding (2). In addition, progesterone with¬
drawal mediates the degradation of the endometrial extra¬
cellular matrix by inducing matrix metalloproteinases (24).
Attempts have been made to demonstrate the effects of
progesterone on the endometrial PGs activity both in vitro
and in vivo studies. Progesterone seems to enhance the PG
biosynthetic capacity of the secretory endometrium. This is
demonstrated by the in vitro studies employing cell culture
techniques and by maintaining endometrial explants in cul¬
ture (25, 26). Conversely, progesterone has shown to sup¬
press the release of PGs from the endometrium (26, 27).
Studies in vitro have reported a reduction of both the estra-
diol-stimulated and the basal PG production by progester¬
one (26, 28). Furthermore, during pregnancy, when proges¬
terone levels are high, basal endometrial PG production is
also reduced (29). It had been suggested that this effect might
involve the inhibitory effect of progesterone on the PLA2
activity (22).
The withdrawal of progesterone from an endometrium
that has been primed with progesterone and estradiol results
in an increased COX-2 expression, whereas continuing ex¬
posure to progesterone is associated with low levels of
COX-2 expression (30). Evidence for increased PG activity by
antagonizing progesterone also comes from in vitro data,
which showed a dose-dependent induction of PGF2a release












Fig. 2. Intensity of staining for PGDH (A) and COX-2 (B) in endo¬
metrial glands (■) and stroma (□) in the midluteal phase of the cycle
before (control) and at times after administration of 200 mg mife¬
pristone. Bar, Median and range.
from endometrial stromal cells (23) and also from the in vivo
observation of increased uterine contractility after mifepris¬
tone, possibly attributable to increased PGs (31-33). This is
further supported by the inhibition of glandular PGDH
expression seen after administration of antiprogesterones
in the early-luteal phase (10, 11) and during the early
pregnancy (34).
A decrease in the uterine PGF2o; release (33) and in the
luminal expression of COX-2 had been reported after mife¬
pristone in the early-luteal phase (35). However, in the early-
luteal phase, progesterone values are relatively low; and, as
a consequence, the PR and ER expression is maximal,
whereas the converse is true for the midluteal phase of the
cycle. Therefore, in the early-luteal phase, mifepristone may
prevent the effects that are to be exerted by progesterone;
whereas in the midluteal phase, itmay antagonize the actions
of progesterone, which, at that time, seems to be the sup¬
pression of PGs release.
Our results: are consistent with previous reports (10, 21)
that demonstrated localization of PGDH and COX-2 in the
glandular epithelium, and also support the in vitro evidence
that glands are the main site for PG synthesis (36, 37).
There was no significant change in the level of immuno-
reactivity of AR, ER, or PR after mifepristone. When given
immediately after ovulation, mifepristone and onapristone
prevent the progesterone-induced down-regulation of PR
and ER, which normally occurs during the luteal phase (10,
38, 39). In the midluteal phase, the levels of ER and PR are
already low and were unchanged at 48 h after mifepristone
administration. AR staining was mainly confined to the stro¬
mal compartment and remained unchanged after mifepris¬
tone (40). In contrast, when mifepristone was given in the
early-luteal phase, there was strong immunostaining for AR
in the glands (41). The factors regulating the spatial and
temporal expression of AR in the endometrium and its phys¬
iological role are not fully understood.
The distinct endometrial effects seen after the midluteal
administration of mifepristone add to our understanding of
the mechanism of menstruation. There is overwhelming
evidence that PGs are involved in the process of normal
menstruation (Reviewed in Ref. 3). Our results show a down-
regulation of PGDH expression and a simultaneous up-
regulation of COX-2 expression after administering mife¬
pristone in the midluteal phase. Therefore, we conclude that
mifepristone induces endometrial bleeding, in the midluteal
phase, by a mechanism involving both PGDH and COX-2 to
increase local PG levels in the endometrium.
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